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Chapter 1 
General introduction 
Part of this chapter has been published as a review: 
Rho GTPase signaling at the synapse: implications for intellectual disability. 
Experimental Cell Research. 2013 319:2368-74. 
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The human brain is one of the most complex and fascinating organs, which governs 
fundamental processes including learning and memory. The brain is not a passive recording 
machine of existing facts. Instead, it can dynamically encode, retain, edit and retrieve 
information based on experiences. Human memories are associated with emotion, episodes 
of experiences and acquired knowledge/skills in lives, allowing us to comprehend, define and 
adapt to the world with our personal tags. Unraveling the mechanisms underlying learning 
and memory has become a central issue in neuroscience in the last decades. It is now widely 
believed that synaptic plasticity, the ability of the brain to modify the efficacy of neuronal 
communication in response to experience, is the cellular basis of learning and memory 1,2. The 
dynamic modification of neuronal communication can be achieved by the structural 
regulation of spines, small actin enriched protrusions on dendrites, as well as the functional 
regulation via remodeling neurotransmitter receptors such as glutamate ionotropic alpha-
amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPArs). The number of 
AMPArs and the geometry of dendritic spines have been found to be tightly correlated 3–5. 
Rho subfamily of GTP-binding proteins, key regulators of actin cytoskeleton dynamics, play 
critical roles in synapse formation, maturation and maintenance, directly affecting both 
synapse structure and function 6–8. It is therefore not surprising that genetic mutations 
involving Rho GTPase signaling have been implicated in several neurodevelopmental disorders 
such as autism spectrum disorders (ASD) and intellectual disability (ID). 
 The aim of the research described in this thesis is to elucidate the role of Rho GTPase 
signaling pathways in regulating synaptic structure and function in normal brain, and 
therefore to enrich our understanding of cellular and molecular mechanisms underlying 
learning and memory, and to shed light on novel and effective therapies for neurological 
disorders including ID. 
 
1. The Synapse 
Neurons communicate with each other through specialized sites called synapses, which were 
first documented by Ramón y Cajal more than 100 years ago and which is derived from the 
Greek word συνάπσις (Synapsis), meaning “to clasp”. Most synapses in the central nervous 
system (CNS) are chemical synapses, which utilize neurotransmitters to convey signals. 
Synapses consist of a presynaptic axonal terminal (or bouton) and a postsynaptic 
compartment, which are separated by a synaptic cleft (Figure 1). Synaptic vesicles containing 
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neurotransmitters are docked and primed for release in the active zone, a specialized region 
on the presynaptic membrane. After crossing the narrow cleft (~20 nm), released 
neurotransmitters act on their corresponding receptors on the postsynaptic side. Two major 
categories of synapses have been identified based on their appearance under electron 
microscopy (EM): type I (asymmetric, shown to be excitatory), and type II (symmetric, shown 
to be inhibitory) 9,10. The most prominent postsynaptic component of excitatory synapses is 
the postsynaptic density (PSD), an electron-dense structure with a thickness of 35-50 nm on 
the postsynaptic membrane. The PSD contains a variety of scaffolding proteins, receptors and 
signaling complexes involved in synaptic transmission and plasticity, such as PSD95, Shank and 
Homer family proteins, glutamate receptors, CaMKII, and small GTPases 11. Intensive studies 
have established that the strength of a synapse is fundamentally dependent on two main 
factors: presynaptic factors such as the number, content and release probability of synaptic 
vesicles, and postsynaptic factors including the amount and properties of receptors 12,13.   
 
 
Figure 1 Schematic diagram of the basic structure of synapses. 
Left, a piece of dendrite containing spines with diverse shapes. Purple and green highlight the 
excitatory and inhibitory synaptic sites, respectively. Right, a zoomed in picture showing the basic 
composition of pre- and post- synaptic compartments.  
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 In the mammalian brain, most excitatory synapses are formed on dendritic spines, small 
protrusions on the dendrite. Spines come in a wide range of sizes and shapes and they are 
typically categorized into three groups based on the anatomical studies: thin spines (long neck 
and small heads, <0.6 μm in diameter); mushroom spines (constricted neck and large bulbous 
head, >0.6 μm in diameter) and stubby spines (similar head and neck widths). The shapes of 
the spines represent their maturation status. Mushroom and stubby spines are mature and 
relative stable while thin spines, which are extremely motile, are considered as the precursors 
of mature spine 14. One remarkable feature of synapses is their structural variability. Dynamic 
alterations in the shape and density of spines are occurring in response to activity and/or 
during development, which largely rely on the primary cytoskeletal element within the spine, 
actin. The actin cytoskeleton undergoes dynamic turnover with a total protein replacement 
every 2-3 min 15. Both monomers of globular actin (G-actin) and polymers of filamentous actin 
(F-actin) are present in the spines and they dynamically cycle through a process known as 
treadmilling. The amount of actin assembly is determined by the available pool of G-actin since 
F-actin is formed by the polymerization of ATP-bound G-actin. A large group of actin-binding 
proteins (ABPs) that cooperate actin-mediated cellular events have been found enriched in 
the spines, such as the Arp2/3 complex, which orchestrates de novo actin polymerization, and 
its activators cortactin, Abp1, N-WASP and WAVE-1, as well as ADF/cofilin and gelsolin which 
participate in F-actin severing. Deficiencies of these ABPs have been shown to lead to 
abnormal dendritic spines 16–18. By transmitting and integrating signals to ABPs, Rho GTPases 
are able to regulate actin dynamics, and therefore control spine morphology and stability 19. 
 In rat hippocampus, nascent synapses appear as early as postnatal day 1 20. The density 
of synapses doubles from postnatal day 7 to day 15 and then gradually increases until 
adulthood 21. In general terms, excitatory synapse development directly relates with 
spinogenesis. The balance between spine formation and elimination determines spine density. 
In the early development, abundant highly motile, thin spines are detected. Upon an adhesive 
contact with the presynaptic axon, these thin spines gradually transform into more stable 
mushroom spines. In accordance, rapid conversion from immature “silent synapses” which 
are characterized by the presence of postsynaptic N-methyl-D-aspartic acid receptor (NMDArs) 
but not AMPArs 22 into mature AMPArs containing synapses happens during the first two 
weeks of postnatal development. In adult animals, spine formation and elimination reach a 
plateau and the overall spine density remains roughly constant 23–25. In spite of this relative 
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stability throughout adulthood, dynamic remodeling of synaptic structure and transmission in 
the brain is still continuously occurring. This plastic nature of synapses is termed synaptic 
plasticity. 
 
2. Synaptic plasticity 
Synaptic plasticity refers to the capacity of synapses to strengthen or weaken in response to 
activity and/or experience and it is considered to underlie the ability of the brain to encode 
and store information. The hypothesis of learning resulting from changes in synaptic strength 
was first proposed by Ramón y Cajal in 1904, based on his anatomical studies: “the future will 
prove the great physiological role played by the dendritic spines". This idea was later refined 
by Donald Hebb in the 1940s, stating as “neurons that fire together wire together”. This axiom 
reminds us that our experience, feelings and thoughts are embedded in thousands of neurons 
that form a network. The long-lasting increase and decrease in synaptic strength, known as 
long-term potentiation (LTP) and long-term depression (LTD), respectively, are two most well-
studied forms of Hebbian synaptic plasticity. LTP and LTD occur in an input-/synapse-specific 
manner and have been observed in many brain regions 26–28. To date, they are well accepted 
as the cellular mechanisms of learning and memory and are considered essential for normal 
cognitive function 29,30. Experimentally, LTP and LTD can be induced by 
electrophysiological/pharmacological paradigms or by introducing several learning tasks in 
animal models 30–33. Diverse molecules and signaling pathways have been reported to be 
involved in distinct forms of LTP/LTD, depending on the brain region, induction paradigm as 
well as synapse type. Most studies have focused on hippocampal Schaffer collateral synapses 
on CA1 pyramidal neurons (CA3-CA1) where high frequency stimulation (HFS, typically 100 Hz) 
induces classical NMDAr-dependent LTP 34,35. The same stimulus paradigm, however at the 
dentate gyrus (DG) mossy fiber synapse (DG-CA3) induces LTP by increasing presynaptic 
release probability, independently of postsynaptic NMDAr 36, indicating that the cellular 
mechanisms of Hebbian plasticity are synapse specific.  
Interestingly, intimate association between LTP/LTD and enlargement/shrinkage of 
dendritic spines have been observed 37,38, which leads to the concepts of functional plasticity 
and structural plasticity. At the single synapse level, NMDArs activation increases spine Ca2+ 
concentrations and activates Ca2+-calmodulin-dependent kinase (CaMKII), which further 
phosphorylates and activates several critical proteins including Ras and Rho GTPases. By acting 
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on their downstream effectors, activated Rho GTPases trigger remodeling of actin 
cytoskeleton and eventually enlarge spine size. In the meanwhile, AMPArs exocytosis occurs 
upon Ras GTPases activation and results in elevated synaptic efficacy. Previous studies have 
shown that inhibition of spine enlargement by blocking actin polymerization prevents normal 
LTP expression 39,40. Of note, increasing spine size alone, through actin polymerization, is not 
sufficient to express LTP 41–43. 
Although many mechanisms can regulate the onset or magnitude of synaptic plasticity, 
one common mechanism has appeared to control long-lasting changes of synaptic strength: 
insertion or removal of AMPArs at synapses 44–48.  
 
2.1 AMPAr trafficking in synaptic plasticity 
Glutamate receptors mediate most excitatory transmission in the CNS. In particular, AMPArs 
play a key role in synaptic transmission and plasticity. AMPArs consist of four subunits, GluA1-
GluA4. The extracellular and transmembrane regions of AMPArs subunits are very similar, but 
their intracellular regions which contain regulatory domains involved in multiple signaling 
pathways are variable. GluA1, GluA4 and GluA2L (a long splice form of GluA2) have long 
cytoplasmic carboxy-terminal tail (C-tail) while GluA2, GluA3 and GluA4c (a short splice form 
of GluA4) contain short C-tails. AMPArs are usually assembled as heteromers and the 
composition of subunits varies depending on the age and the brain region. In mature 
hippocampal excitatory synapses, GluA1/GluA2 and GluA2/GluA3 are the two major 
heterodimers of AMPArs 49. GluA2 subunit is also subject to RNA editing, the glutamine codon 
is replaced by an arginine codon (Q/R editing) 50,51. This editing largely regulates the property 
of AMPArs, such as the calcium permeability, channel conductance and kinetics 52,53. 
Intracellular polyamines strongly interact with GluA2 lacking AMPArs and result in a voltage-
dependent block, namely rectification, in these receptors 54,55.  
Compared to NMDArs, AMPArs are highly mobile proteins, which are subject to controlled 
exo-/endocytosis, recycling and/or degradation. It is still controversial how AMPArs are 
targeted to the synapse after being generated in endoplasmic reticulum (ER) and Golgi 
apparatus in the soma. Most evidence suggests that AMPArs are first transported by motor 
proteins such as kinesin, dynein, as well as myosins in dendrites and then directly inserted at 
synaptic sites 56–60, although some other studies showed that most AMPArs are first inserted 
into the plasma membrane at the soma at extrasynaptic sites, and then travel to synapses via 
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lateral diffusion61–63. In addition, several studies reported that AMPArs can also be synthesized 
in dendrites and then directly inserted into synapse 64,65. It is likely that a combination of these 
three processes mediates AMPAr insertion in the synapse.  
AMPAr endocytosis is regulated by conserved clathrin-mediated endocytic machinery, 
which also plays a role in presynaptic vesicle recycling 66,67. Previous studies have shown that 
clathrin-mediated AMPAr endocytosis mainly occurs at endocytic zones (EZs), stably 
positioned sites adjacent to the PSD 68. Methods that block clathrin-dependent endocytosis 
including high concentrations of sucrose or dominant-negative forms of key components of 
clathrin complex have been found to block AMPArs endocytosis 69. After endocytosis, AMPArs 
are sorted to early endosomes for recycling or to late endosomes and lysosomes that allow 
degradation 70,71. The amount of AMPArs at synapses is determined by the relative rate of 
exocytosis and endocytosis 13.  
AMPAr subunits undergo constitutive (the constitutive pathway) or activity-dependent 
(the regulated pathway) exchanges at synapses 72,73. Under basal conditions, short C-tailed 
subunits like GluA2 continuously cycles in and out of synapses, whereas the trafficking of long 
C-tailed subunits GluA1 and GluA4 is activity and NMDAr activation dependent 72,74,75. When 
GluA1/2 heteromeric channels are expressed, the activity-dependent trafficking of GluA1 
dominates, whereas GluA2/3 heteromeric channels behave more like GluA2 homomeric 
channels and traffic constitutively in and out of synapses 67. The different trafficking 
preferences are mainly due to various interacting proteins via the C-terminus of AMPAr 
subunits. For example, GluA2 interactors such as N-ethylmaleimide-sensitive fusion protein 
(NSF), protein interacting with C kinases 1 (PICK1) and glutamate receptor interacting protein 
(GRIP) are largely involved in controlling GluA2/3 subunit trafficking. The interaction of 
GluA2/3 and GRIP promotes synaptic targeting while NSF binding dissociates the GluA2-PICK1 
complex and allows insertion. It is believed that the constitutive pathway maintains the basal 
synaptic strength and the regulated pathway acts upon the induction of synaptic plasticity 67. 
Enhanced AMPAr exocytosis and recycling have been observed during LTP, regardless of the 
exact sites of AMPAr delivered into synapses, enhanced AMPAr exocytosis and recycling have 
been observed during LTP. Conversely, increased endocytosis rate occurs during LTD 48,67.  
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2.2 Rho GTPase signaling in synaptic plasticity 
The pivotal role of actin in the regulation of synaptic structure and function pointed to Rho 
GTPase family members as key contributors, since they directly regulate the actin dynamics 
and organization76. Rho GTPases belong to the Ras superfamily of small (~21 kDa) GTPases, 
which function as molecular switches cycling between an active GTP-bound form and an 
inactive GDP-bound form. So far, 22 human members of the Rho family have been identified 
and they can be divided in eight different subgroups: Rho (RhoA-RhoC); Rac (Rac1-Rac3, RhoG) 
Cdc42 (Cdc42, TC10, and TCL, Chp, Wrch-1); RhoD (RhoD and Rif); Rnd ( Rnd1, Rnd2, 
RhoE/Rnd3); RhoH/TTF; RhoBTB (RhoBTB1 and RhoBTB2); and Miro (Miro-1 and Miro-2) 77. 
The activity of Rho GTPases is mainly regulated by guanine nucleotide exchange factors (GEFs), 
which are positive regulators, by GTPases activating proteins (GAPs) and guanine nucleotide 
dissociated inhibitors (GDIs), which are negative regulators 76. 
 
2.2.1 Synaptic function of RhoA, Rac1 and Cdc42 
The best-characterized Rho family members are RhoA, Rac1 and Cdc42. In the first study 
addressing the role of Rho GTPase signaling in spine morphogenesis, Luo et al. found a 
decrease in spine size and an increase in spine density, as well as a corresponding increase in 
number of synapses in cerebellar Purkinje cells of transgenic mice expressing a constitutive 
active form of Rac1 (CA Rac1) 78. Subsequent studies in neuronal cultures and brain slices 
expressing CA and dominant-negative (DN) mutant forms of Rac1 confirmed the importance 
of proper Rac1 signaling in dendritic spine morphology. Expression of CA Rac1 in hippocampal 
brain slices resulted in the formation of multiple small spines79–81. Conversely, expression of a 
DN Rac1 mutant in mouse and rat hippocampal slices caused a reduction in spine density and 
a corresponding reduction in synapse formation80,82. Notably, the spines of DN Rac transfected 
neurons were in general significantly longer than control spines, and detailed analysis 
revealed that blocking Rac1 transforms a subset of existing spines into long, thin filopodia-like 
protrusions. Furthermore, inhibition of Rac1 reduces spine head growth (particularly in 
mature neurons), morphological changes, and spine stability 82. Beside the critical role of Rac1 
in controlling spine morphology and motility, Rac1 is also directly implicated in controlling 
synaptic function. Overexpression of wild type (WT) Rac1 or CA Rac1 induces clustering of 
AMPArs, resulting in an enhancement of excitatory synaptic transmission 83. All of these 
studies overwhelmingly show that Rac1 is a significant modulator of spine morphology and 
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synaptic function. The role for Cdc42 in spine morphogenesis was initially less well defined. In 
hippocampal pyramidal neurons in organotypic slices, expression of a CA- or DN-Cdc42 mutant 
did not have a significant effect on spine density or length 80. However, Cdc42 has been 
demonstrated to affect spine formation in other systems. Loss of function of Cdc42 in vertical 
system neurons in the Drosophila visual system leads to a reduction in the density of spine-
like structures 84. Another study identified two different variants of Cdc42, an isoprenylated 
and a palmitoylated variant in the brain. Both are present in dendrites, but only the 
palmitoylated variant was found in dendritic spines. Using elegant experiments in which they 
selectively down regulated one of the two variants, they found a specific role for the 
palmitoylated form in spine formation 85. Furthermore they showed that changes in 
palmitoylation of Cdc42 could quickly decrease in response to glutamate, a condition that 
causes rapid spine contraction and removal. Thus regulated palmitoylation of Cdc42 
potentially underlies the changes in spine morphology in response to synaptic activity. 
Effects of Rac1 and Cdc42 on spine number and morphology were shown to be mediated 
by the well-characterized downstream pathway, PAK/LIM kinase/actin depolymerization 
factor (ADF)/cofilin. Activation of Rac/p21-activated kinase (PAK) leads to phosphorylation of 
LIMK and subsequently to the inhibition of ADF/cofilin mediated actin-filament disassembly. 
This leads to an increase in the number of actin filaments. In addition PAK has been shown to 
also directly phosphorylate myosin IIB, which is present in the postsynaptic density, where it 
regulates spine morphology 86. Furthermore, the PAK signaling pathway regulates spine 
morphogenesis in both intact animals and cultured neurons 87. Rac1 has also been reported 
to affect the actin cytoskeleton in spines by the activation of the Arp2/3 complex through 
WAVE complex, which is localized to dendritic spines in hippocampal neurons. Similarly, Cdc42 
has been shown to promote actin polymerization via the neural Wiskott-Aldrich syndrome 
protein (N-WASP) and the Arp2/3 complex. Upon activation by Cdc42 in dissociated 
hippocampal neurons, N-WASP regulates actin polymerization by stimulating the actin-
nucleating activity of the Arp2/3 complex. Activation of the Arp2/3 complex results in the 
assembly of branched actin networks, leading to the cytoskeletal reorganization of spines. 
Besides N-Wasp, also the insulin receptor substrate 53 (IRSp53) and PAK3 have been shown 
to mediate the effects of Cdc42 on spine morphogenesis. Of note, whereas IRSp53 seems to 
bind equally to Cdc42 and Rac1, Pak3 preferentially binds to Cdc42 88.  
15
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In contrast to Rac1, RhoA appears to inhibit the growth and/or stability of dendritic spines 
82. In general, increased RhoA activity has been coupled to reduced spine length, size, and 
density 80,89,90, whereas, low levels of RhoA have been associated with the maintenance of 
dendritic spine structures 79,91,92. Interestingly, a few groups reported a decrease in 
endogenous RhoA activity upon ionotropic and metabotropic glutamate receptor activation 
91,93, suggesting a link between synaptic input and regulation of endogenous RhoA activity. 
Rho-kinase (also called ROK or ROCK) has been well documented to play a key role in RhoA-
induced actin reorganization and to mediate at least in part RhoA’s effects on spine 
morphogenesis 82,94. Rho-kinases appear to influence the actin cytoskeleton by acting on LIM 
Kinase (LIMK), myosin light chain (MLC) and/or MLC phosphatase. Rho-kinase phosphorylates 
and activates LIMK, which in turn phosphorylates and inactivates the actin depolymerization 
factor ADF/cofilin 95–97. Phosphorylation of MLC by Rho-kinase results in the stimulation of 
myosin-actin interactions 98. Rho-kinase can also regulate the amount of phosphorylated MLC 
by phosphorylating and inactivating MLC phosphatase 99. Finally, ROCK has been shown to 
directly phosphorylate myosin IIB and it was shown that myosin IIB, which binds and contracts 
actin filaments, is essential for spine morphology and dynamics, as well as synaptic function 
86.  
Importantly, emerging evidence has shown that the formation of both stable LTP and LTD 
at glutamatergic synapses are accompanied with enduring structural changes in spine heads 
that are dependent on actin dynamics. Inhibition of actin polymerization attenuates LTP 
maintenance, whereas LTD is associated with actin filament disassembly 42. Therefore, it is not 
surprising that Rho GTPases have been found to play important roles in synaptic plasticity 100–
102. Rapid activation of Cdc42 and RhoA has been observed in a single spine where LTP is 
induced by local glutamate uncaging. Inhibition of Cdc42-PAK and RhoA-ROCK pathways block 
initiation and maintenance, respectively, of spine growth during LTP 103. It has demonstrated 
that postnatal disruption of Cdc42 leads to impairments of transient and sustained spine 
enlargement induced by glutamate uncaging, as well as a pronounced deficit of remote 
memory 104. Moreover, ADF/cofilin has been shown as a pivotal downstream Rho GTPase 
effector protein involved in spine shrinkage (LTD) and enlargement (LTP). ADF/cofilin, whose 
activity depends on its phosphorylation state, can be regulated by various Ca2+-dependent 
kinases (CamKII), phosphatases (calcineurin and PP1) and Rho GTPase activity (LIMK). When 
ADF/cofilin is phosphorylated on Ser-3, and thus inactivated, it facilitates actin polymerization. 
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Dephosphorylation of ADF/cofilin has been associated with spine shrinkage upon low-
frequency induced LTD in hippocampal brain slices that was dependent on NMDAr activation 
37. Conversely, ADF/cofilin was found to be phosphorylated, upon LTP signaling synapses 105. 
Since ADF/cofilin can be phosphorylated by either the RhoA/ROCK/LIMK or Rac/PAK/LIMK 
pathway the question arises as to which GTPase signaling pathway might be involved in LTP. 
One study addressed this question by investigating the role of RhoA and Rac signaling cascade 
in LTP. They found that NMDAr-dependent LTP sets in motion two distinct signaling cascades: 
a RhoA/Rock/LIMK/cofilin pathway, which is required for the initial induction of LTP, and a 
Rac/PAK pathway that is required for the later LTP consolidation phase 106. The distinct 
functional roles of the RhoA and Rac cascade in LTP therefore suggest the sequential activity 
dependent remodeling of actin involving first RhoA and then Rac1 signaling. One possibility is 
that RhoA and Rac1 target a distinct pool of actin in dendritic spines and as such contribute to 
different aspects of LTP-induced actin remodeling 15. In addition, Brain-derived neurotrophic 
factor (BDNF) also induces LTP in hippocampus, which is associated with cofilin 
phosphorylation. Up-regulation of RhoA was observed upon BDNF stimulation, suggesting 
that RhoA could also be implicated in BDNF-induced LTP 107. 
 
2.2.2 Synaptic function of GEFs and GAPs 
Although the precise roles of all Rho GTPase regulatory proteins in CNS are far from complete, 
the synaptic functions of a number of important GEFs and GAPs have been well described. 
Accumulating evidence indicates that an individual Rho GTPase regulator displays unique 
structure, expression pattern and synaptic function. Here I describe two key Rho regulators, 
Kalirin7 and Tiam1.  
The extensively studied Rho GEF Kalirin7 (Kal7) has been found to be highly expressed in 
the mature hippocampus and cortex. It is exclusively localized to the postsynaptic 
compartment of excitatory synapses in hippocampus. Kal7 contains two GEF domains, and 
GEF1 targets Rac1/RhoG while GEF2 activates RhoA. It has been shown that elevated Kal7 
levels increase spine density and size, whereas downregulation of endogenous Kal7 leads to a 
decrease in spine and synapse density both in vitro and in vivo 108,109. Kal7 interacts with 
multiple proteins at synapse including NR2B subunit of NMDArs 110. Loss of Kal7 results in a 
decrease of NR2B containing NMDAr in PSDs and specifically impairs NMDAr-dependent LTP 
and LTD 111. A recent study suggests that a loss of Kal7 in spinal neurons impairs the induction 
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of synaptic potentiation without affecting basal transmission, due to a direct disruption of Kal7 
interacting with proteins in PSD 112. Additionally, Kal7 has been reported to mediate cocaine 
induced plasticity in the nucleus accumbens (NAc) via its downstream effectors Rac1 and PAK 
113,114. In contrast, another GEF Tiam1 is highly expressed in the cortex and hippocampus early 
in development, with an established role in axon extension and neuronal migration both in 
vitro and in vivo 115–117. Inhibition of neuronal migration and axon formation have been 
observed in the condition of decreased Tiam1. Also, knocking down Tiam1 significantly 
reduces dendritic arborization and spine density, as well as frequency of miniature excitatory 
postsynaptic current (mEPSC) in cultured hippocampal neurons 118–120. Tiam1 overexpression 
induces multiple axon-like neurites 116,117 and increases spine density 119, implying its 
importance in axon formation. Unlike Kalirin7, Tiam1 directly interacts to the NR1 subunit of 
NMDAr and is phosphorylated by CaMKII upon NMDAr stimuli. Phosphorylation of Tiam1 
enhances its GEF activity, resulting in activation of Rac1. Selectively blocking Tiam1 function 
with either RNAi knockdown or dominant negative Tiam1 mutants reduces spine density and 
inhibits NMDA receptor-dependent spine formation as well as dendritic arbor growth 119. 
Furthermore Tiam1 is required for NMDAr phosphorylation of AKT and EIF4E factor suggesting 
that Tiam1 plays a role in regulating NMDAr-dependent mRNA translation. Recently, Um et al. 
have demonstrated that Tiam1 forms a GEF/GAP complex with Rac GAP Bcr which is essential 
for Rac1 signaling and synaptogenesis, controlling excitatory synapse formation and loss in an 
optimal range 121.  
 These studies suggest that Rho regulators, through controlling specific Rho GTPase 
signaling in time and space, are potent manipulators of synaptic efficacy via regulating actin 
cytoskeleton dynamics and/or via interacting with molecular partners to control postsynaptic 
receptors, particularly AMPArs and NMDArs.  
 
3. Rho GTPase signaling in ID  
ID is defined by an intelligence quotient (IQ) lower than 70, associated with deficits in 
conceptual, social and adaptive skills 122. The severity of ID can be divided into mild (IQ 
between 50 and 69), moderate (IQ between 35 and 49), severe (IQ between 20 and 34) and 
profound ID (IQ lower than 20) 122. Clinically, ID has been grouped into non-syndromic ID, 
which is characterized by impaired cognitive function without any other clinical features, and 
syndromic ID in which patients additionally present multiple biological or metabolic defects. 
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The causes of ID are highly heterogeneous and include environmental factors that influence 
the development of nervous system, and/or genetic factors, such as chromosomal 
aneuploidies and single gene mutations 123. Over the past two decades, great efforts have 
been made to identify ID genes, resulting in a list of approximately 700 ID causing genes 122. 
Several of these genes are associated with severe brain abnormalities, such as neuronal 
heterotopia, lissencephaly, and microcephaly. A vast number of other genes however have 
been associated with ID disorders with no apparent gross abnormalities in brain structure and 
architecture. Because learning deficits are a constant feature of ID patients, it is tempting to 
attribute some of ID traits to alterations in synaptic function. Several lines of evidences point 
into this direction. First, many of the ID-related proteins are enriched at pre- and/or post-
synaptic compartments 124. Second, alterations in dendritic spines, actin-rich structures on 
which most excitatory synapses in the brain are located, are observed in patients with ID. Such 
alterations are recapitulated in mouse models of ID, including Fragile X, which is the most 
common form of ID. Third, recent studies have provided functional evidence for alterations in 
synaptic strength in models of ID. These observations support the notion that many forms of 
ID, may share a common synaptic component 125.  
For most of the ID genes identified, little information is available as to how mutations in 
these genes result in cognitive impairment. The functions of these genes vary largely including 
regulating cell adhesion, Rho and Ras signaling, gene transcription and chromatin remodeling. 
Given the actin-rich nature of dendritic spines, the Rho GTPase family, as key regulator of actin 
dynamics and organization, has recently received much attention in ID research 8,126 (Figure 2) 
Indeed, mutations in regulators and effectors of the Rho GTPases have been found to underlie 
various forms of ID. Here, we describe some of the Rho GTPase signaling pathways involved 
in ID. 
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Figure 2 Overview of the ID genes discussed in this chapter and their functions in Rho-GTPase 
signaling at the synapse.  
On the left an excitatory synapse and on the right an inhibitory synapse. Rho-GTPases are depicted as 
yellow squares, GAP proteins as red ovals, GEF proteins as green ovals and ID gene names are 
highlighted in red. When activated, Rac1, Cdc42 and RhoA interact with downstream effector proteins, 
which eventually results in actin remodeling. At the postsynaptic compartment of excitatory synapses, 
ARHGEF6 positively regulates Rac1 and Cdc42 activity, MEGAP negatively regulates Cdc42 activity and 
OPHN1 negatively regulates RhoA activity. PAK is a downstream effector of Rac1 and Cdc42. OPHN1 is 
furthermore involved in AMPAr-mediated synaptic transmission, which is dependent of the interaction 
with Homer, and OPHN1 expression increases upon mGluR1 stimulation. The Cin85, Amphiphysin, 
Endophilin A2/3, OPHN1 complex mediates AMPAr endocytosis. At the presynaptic compartment of 
excitatory synapses, OPHN1 regulates RhoA activity and the Endophilin A1 OPHN1 complex is involved 
in endocytosis. At the postsynaptic compartment of inhibitory synapses, OPHN1 is present and 
ARHGEF9 regulates Cdc42 activity. ARHGEF9 furthermore binds to Gephyrin, Neuroligin2 and PI3P. 
OPHN1 is also present at the presynaptic compartment of inhibitory synapses.  
 
Oligophrenin-1 
Oligophrenin-1 (OPHN1), the first identified Rho-linked ID gene, encodes a Rho-GAP protein 
that negatively regulates RhoA in neurons 127. Besides RhoA, OPHN1 also interacts with Homer 
1b/c 127, endophilin A1 and A2/3 (EndoA1, A2/3) 128, amphiphysins, and CIN85 129. The protein 
is abundantly expressed in the brain, where it is found in neurons of all major regions, 
including hippocampus and cortex, and is present in axons, dendrites and spines 127. Families 
with mutations in the OPHN1 gene have syndromic ID with cerebellar abnormalities, of which 
cerebellar hypoplasia is the most recurring phenotype 130–133.  
All OPHN1 mutations identified to date appear to result in a loss of protein function. 
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Several studies have provided insight as to how mutations in OPHN1 may impact neuronal 
function. Knockdown of Ophn1 in CA1 pyramidal neurons in hippocampal slices resulted in a 
significant decrease in dendritic spine length. This phenotype was mimicked by using a 
constitutive active RhoA mutant and was rescued by inhibiting a key effector of RhoA, Rho-
kinase (ROCK) 127. In accordance, Nadif Kasri and colleagues demonstrated that knocking down 
Ophn1 in hippocampal neurons inhibited AMPAr- and NMDAr-mediated currents and 
impeded synaptic maturation and both structural and functional LTP 89. These defects were 
dependent on Rho-GAP activity, and the interaction of OPHN1 with Homer 1b/c 89,134. 
Conversely, overexpressing OPHN1 selectively enhanced AMPAr-mediated synaptic 
transmission and increased spine density 89. Using a peptide derived from the C-terminus of 
the AMPAr GluA2 subunit that blocks AMPAr endocytosis 135, they have further demonstrated 
that OPHN1 can regulate synaptic function and structure by stabilizing synaptic AMPArs. A 
model was therefore proposed in which OPHN1 during early development contributes to 
excitatory synapse maturation at the CA3-CA1 synapse by stabilizing AMPArs. OPHN1 was also 
found to play an important role in metabotropic glutamate receptor-induced LTD (mGluR-LTD). 
OPHN1 expression was rapidly increased at the synapse upon mGluR1 stimulation, an increase 
in OPHN1 that was required for the proper expression of mGluR-LTD. Interestingly, the role of 
OPHN1 in mediating mGluR-LTD could molecularly be dissociated from its role in basal AMPAr-
mediated synaptic transmission 134. Whereas the former required OPHN1’s interaction with 
EndoA2/3, the latter requires OPHN1’s Rho-GAP activity and interaction with the Homer 1b/c 
proteins. Studies in Ophn1 KO mice provided further evidence for the importance of OPHN1 
in spine morphology and the regulation of AMPAr trafficking 129,136. Disruption of OPHN1 in 
mice was shown to increase the number of filopodia-like spines and impaired NMDA receptor-
dependent LTD. Interestingly, the deficits in AMPAr endocytosis and LTD could be reversed 
completely using a Rho kinase inhibitor. A recent study unveiled that the interaction of OPHN1 
and Homer is critical for the positioning of endocytic zones (EZs) near the PSD and disruption 
of the OPHN1-Homer interaction results in impaired receptor recycling/exocytosis along with 
a decrease in synaptic AMPAr expression 137. At the pre-synaptic compartment, a reduction in 
endocytosis of synaptic vesicles was observed in cortical neurons of Ophn1 KO mice. 
Additionally, Nakano-Kobayashi and colleagues demonstrated that OPHN1 controls pre-
synaptic vesicle cycling in CA3 neurons by forming a complex with EndoA1 128. Besides 
controlling excitatory synaptic transmission, OPHN1 is also important for inhibitory synaptic 
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transmission 138. Impairments in presynaptic vesicle recycling and a reduction in the readily 
releasable pool were recently observed in inhibitory synapses in the dentate gyrus of Ophn1 
KO mice 138. Interestingly, pharmacologic treatment with Rho kinase inhibitors rescued these 
deficits 139. Finally, OPHN1 has been implicated in circadian clock regulation through its 
interaction with the nuclear receptor Rev-erbD in the hippocampus 140. Accordingly, they 
observed circadian rhythm deficits in Ophn1 KO mice. This is particularly interesting since 
sleep disturbances are common in children and adults with ID 140. Together, these studies 
clearly illustrate the multifaceted function of OPHN1 in spine morphology, synaptic plasticity 
and vesicle recycling at the pre- and post-synaptic terminals. 
 
ARHGEF6 
Mutations in ARHGEF6, also known as alphaPIX or Cool-2, have been found in patients with 
non-syndromic ID. The first mutation was identified in a male ID patient carrying a reciprocal 
X;21 translocation breakpoint located between exons 10 and 11 of the ARHGEF6 gene. 
Additionally, mutations were detected in the first intron of this gene 141. ARHGEF6 codes for a 
Cdc42/Rac1 exchange factor, which was initially isolated as a PAK-interacting protein. Previous 
studies have unraveled the complex nature of its GEF activity towards Rac1 and Cdc42. In its 
dimeric form, ARHGEF6 functions as a Rac1-specific GEF, whereas in its monomeric form, 
ARHGEF6 can act as a GEF for Rac1 and Cdc42, but only upon binding of PAK to its SH3 domain 
142. In the brain, ARHGEF6 is highly expressed in hippocampus compared to cortex and 
cerebellum. Previous studies showed that, in cultured neurons, overexpressed ARHGEF6 
localizes specifically at the post-synaptic compartment of excitatory synapses, suggesting an 
important synaptic function of ARHGEF6 143. Subsequently, several lines of evidence have 
demonstrated a crucial role of ARHGEF6 in regulating spine morphology, synaptogenesis and 
synaptic plasticity. Knocking down Arhgef6 by RNAi in cultured neurons resulted in a decrease 
of large mushroom spines as well as an increase of elongated spines and filopodia–like 
protrusions. This phenotype could be rescued by a constitutively active form of PAK3 143. 
Moreover, Arhgef6 KO mice showed longer and more branched dendrites and an increase in 
the density of spines in CA1 pyramidal neurons. Surprisingly, the increase in dendritic spines 
on apical dendrites was accompanied by a reduction in excitatory synapses. In addition, 
Arhgef6 KO mice showed a significant impairment in early-phase LTP (E-LTP) and an increase 
in NMDAr-dependent LTD. These changes in synaptic plasticity were attributed to a dramatic 
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reduction in the levels of the active form of Rac1 and Cdc42 in the hippocampus, in accordance 
with the Rho-GEF function of ARHGEF6. Furthermore, behavioral characterization showed 
impairments in complex spatial learning, associated with deficits in coping with altered 
learning tasks or sensory stimuli 144. These deficits caused by the loss of ARHGEF6 may mimic, 
at least in part, the human ID phenotype.  
 
PAK3 
PAK3 encodes p21-activated kinase 3, a member of the PAK family of serine/threonine protein 
kinases which are downstream effectors for Rac/Cdc42 Rho GTPases. Different mutations of 
PAK3 have been found in non-syndromic X-linked ID patients 145–147. PAK3 is prominently 
expressed in different regions of the brain 148. Activation of PAK by Rac1 or Cdc42 leads to the 
phosphorylation of LIM Kinase (LIMK). In turn, activated LIMK phosphorylates and inactivates 
cofilin, resulting in actin depolymerization 149,150.  
Several studies, using knockdown and overexpression approaches in neuronal cell 
cultures and transgenic animal models, have elucidated the role of PAK3 in spine 
morphogenesis and synaptic plasticity in vitro and in vivo. In rat hippocampal organotypic slice 
cultures, antisense- and RNAi-mediated suppression of PAK3 levels, or expression of a 
dominant negative PAK3 (dnPAK3) mutant carrying the human (MRX30) mutation, decreased 
the number of mature spines and promoted thin, immature spines. These changes in dendritic 
spines were accompanied by impaired AMPAr transmission and LTP 151. These spine 
phenotypes were largely recapitulated in transgenic mice expressing dnPAK3 (dnPAK). At the 
functional level, these mice also displayed enhanced LTP and reduced LTD in the cortex. 
Furthermore, behavioral tests showed impaired memory consolidation 87. Mice lacking the 
PAK3 gene, showed no obvious deficits in neuronal structures. Functionally however, these 
mice were selectively impaired in late-phase hippocampal LTP (L-LTP) and showed a dramatic 
decrease in the levels of the active form of cAMP-responsive element-binding protein (CREB) 
in the hippocampus 152. The reduction of active CREB, which is required for activity-dependent 
transcription, may therefore contribute to the L-LTP phenotype. A more recent investigation 
indicated a dual role of PAK3 in regulating activity-dependent and learning-associated 
structural plasticity. Dubos et al. found that PAK3 negatively regulated spine growth, as loss 
of PAK3 function caused uncontrolled and excessive growth of new spines. This suggests that 
PAK3 may be involved in homeostatic regulation of spine morphology upon synaptic activity. 
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On the other hand, they showed that PAK3 was activated in spines during LTP induction and 
was specifically recruited to dendritic spines by synaptic activity. PAK3 inhibition prevented 
stimulated spines to maintain in a stable state. This indicates that PAK3 is involved in 
regulating activity-mediated rearrangement of synaptic connectivity 153.  
 Interestingly, in Fmr1 KO mice, a model for Fragile X syndrome, inhibition of PAK3 activity 
by dnPak or PAK inhibitor could reverse the abnormalities in dendritic spines, synaptic 
plasticity and behavior 154,155. This indicates that Rac/Cdc42-PAK pathway may have 
therapeutic potential for ID. In addition, PAK signaling has also been found to play an 
important role in Alzheimer disease (AD) and Huntington disease (HD), which has recently 
been reviewed in detail 156.  
As mentioned above, PAK and Rho-kinases both stimulate LIMK. It is therefore interesting 
that LIMK1 is one of the genes heterozygously deleted in Williams-syndrome, a rare (1 in 
25,000) genetic disorder 157. Patients with this syndrome suffer from a variety of abnormalities, 
including mild ID. Of particular interest is the fact that Limk1 knockout mice show abnormal 
spine morphology, abnormal synaptic plasticity, and impaired spatial learning. Together these 
studies indicate that regulation of the actin cytoskeleton by Rho GTPases through 
ARHGEF6/Rac-Cdc42/PAK3/LIMK1 pathway plays a crucial role in controlling local spine 
growth and stability, which subsequently contribute to learning and memory processes. 
 
MEGAP   
The MEGAP gene was identified as a gene that is disrupted in patients suffering from 3p- 
syndrome. These patients exhibit microcephaly, growth failure, heart and renal defects, 
hypotonia, facial abnormalities and ID 158. Due to the finding of heterozygous MEGAP-
truncating mutations in three healthy families, the implication of MEGAP in ID is currently 
under debate 159.  
The MEGAP (mental-disorder-associated GAP) gene product was initially identified as a 
WAVE-associated protein (WRP) and as a SLIT-ROBO interacting protein (srGAP3) 160,161. The 
MEGAP mRNA transcript is predominantly expressed in fetal and adult brain, and is enriched 
in the neurons of the hippocampus, cortex and amygdala 158. The RhoGAP domain of MEGAP 
strongly enhances intrinsic Rac1 GTPase activity and to a lower extent Cdc42 158. Besides the 
RhoGAP domain, MEGAP contains two other conserved domains, a WAVE1 binding SH3 
domain and a lipid membrane binding IF-BAR domain. MEGAP was also shown to regulate key 
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aspects of synapse development and function 162. Using a MEGAP conditional KO mouse they 
showed that, in hippocampal cultured neurons, only removing MEGAP in early development 
decreases filopodia and spine formation. This phenotype could be rescued by overexpressing 
either the IF-BAR truncation or full-length MEGAP. Knockout of Megap at later stages did not 
result in any spine phenotype. These results were confirmed in vivo, strongly supporting the 
idea that MEGAP is required during the early (filopodial) stages of spine development and that 
the IF-BAR domain is important in this function. In addition, loss of Megap led to significant 
impairments in long-term memory as measured in multiple behavioral tests such as novel 
object recognition, water maze, and passive avoidance 162. Interestingly, mice expressing a 
WRP binding impaired mutant form of WAVE-1, were also deficient in long-term memory 19. 
Together these findings suggest that signaling through MEGAP and WAVE-1 to the actin 
cytoskeleton is important for normal neuronal function. 
 
ARHGEF9/Collybistin 
Although much of the ID research has been directed towards the formation of excitatory 
synapses, Rho GTPase regulatory proteins also function in the formation inhibitory synapses. 
ARHGEF9 is the best-characterized Rho-family GEF involved in the formation of inhibitory 
synapses.  
 ARHGEF9 is located on the X chromosome and the first mutation, located in exon2, was 
detected in a patient with severe ID and clinical symptoms of hyperekplexia and epilepsy 163. 
Subsequent studies have shown that loss of function mutations in the ARHGEF9 gene cause 
ID associated epilepsy 164–167. ARHGEF9 encodes a Cdc42 GEF protein collybistin (Cb), which is 
highly expressed throughout the adult brain and is specifically enriched in neuronal dendrites 
168,169. In rodents, four distinct splice variants (Cb1-Cb3) have been described. Three of them 
differ in their C-termini (Cb1-3). Cb2 exists with (Cb2SH3+) and without a SH3 domain (Cb2SH3-). 
In the human brain, only a single isoform (hPEM2, human homolog of Posterior End Mark-2) 
corresponding to Cb3, was found to be expressed 163,170,171. All Cb isoforms contain a Dbl-
homology (DH) domain, which is known to be responsible for the GDP/GTP exchange activity, 
and a pleckstrin-homology (PH) domain. Cb is required for formation and maintenance of 
postsynaptic gephyrin scaffolds and the synaptic localization of gephyrin-dependent GABAAR 
subtypes163,172. The PH domain of Cb was shown to selectively bind with phosphatidylinositol-
3-phosphate (PI3P) and overexpressed Cb2SH3- mutant lacking the PH-domain interfered with 
25
23 
 
gephyrin clustering at inhibitory postsynaptic sites165. Interestingly, the GEF activity of Cb 
seems not to be essential for gephyrin clustering 163,173,174. It has been proposed that the 
interaction of the Cb PH domain and the plasma membrane may be sufficient for establishing 
and maintaining gephyrin clustering-dependent GABAergic synapses, since any of the Cb 
isoforms can rescue the impairment in GABAergic neurotransmission induced by Cb 
knockdown 175. Studies comparing Cb isoforms with or without SH3 domain further revealed 
that the SH3 domain exerts an autoinhibitory function, as Cb2SH3- was constitutively active and 
promoted the clustering of gephyrin while CbSH3+ isoforms did not. Interestingly, SH3 domain 
containing Cb isoforms were found to be activated by neuroligin 2 (NL2), as the binding of NL2 
and GABAARα2 released the autoinhibition of Cb by its SH3 domain 176,177.  A recent study 
further demonstrated that Cb can adopt open/active and closed/inactive conformations and 
act as a switchable adaptor that links gephyrin to plasma membrane phosphoinositides. This 
function is regulated by binding of NL-2 178. Arhgef9 KO mice displayed deficits in spatial 
learning and increased anxiety-like behavior. These mice showed a reduced density of both 
synaptic gephyrin clusters and GABAAR in hippocampus, amygdala and cerebellum. 
Consequently, GABAergic transmission in the hippocampus was significantly impaired, as both 
the frequency and the amplitude of GABAergic miniature inhibitory post synaptic currents 
(mIPSC) from CA1 pyramidal neurons were dramatically reduced in Arhgef9 KO mice. In 
addition, in Arhgef9 knockout mice, theta-burst induced LTP was increased. Blocking GABAR 
by applying picrotoxin eliminated the difference between Arhgef9 KO and control mice, 
indicating that the reduction of GABAergic inhibition contributed to the changes in LTP 179.     
 
Conclusion 
Spine abnormalities are associated with numerous neurodevelopmental, neuropsychiatric, 
and neurodegenerative disorders 180–182. It is therefore not surprising that Rho GTPase 
signaling, as a critical controller of the actin cytoskeleton pathway, has emerged as a major 
signaling pathway affected in these disorders. More specifically, Rho GTPase signaling plays 
an important role as a key signaling integrator regulating both synaptic structure and function 
through the control of AMPAr trafficking.  
The knowledge gained from the identification and characterization of Rho-linked genes 
associated with different forms of ID has now opened new avenues for the development of 
therapeutic strategies for cognitive disorders. Indeed, in some cases targeting Rho GTPase 
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signaling has recently proven to be successful to rescue cellular and behavioral phenotypes 
139.  
 Finally, these are exciting times for ID research because many more genes in ID will be 
discovered. Since many more GEFs and GAPs, with unknown function, are expressed in the 
brain, it is to be anticipated that more Rho regulators will be identified that play critical roles 
in spine morphology and synaptic function.  
 
Scope and outline of this thesis 
Functional analysis of uncharacterized genes that are vital for neuronal function during 
development will largely enhance our understanding of how the healthy brain governs 
cognitive processes and will further provide insight into the mechanisms underlying 
neurological diseases such as ID and ASD. The aim of the research described in this thesis is to 
enrich our knowledge of the cellular and molecular mechanisms of learning and memory in 
health and disease, by elucidating the roles of novel genes implicated in ID and ASD in 
modulating synaptic function and neuronal development. I particularly focus on the role of 
Rho GTPase signaling in regulating synaptic structure and function. 
In order to achieve these goals, I initiated my research by screening 22 genes encoding 
Rho GTPases and their regulators for their spatial and temporal expression patterns, as is 
described in chapter 2. Based on the developmental expression profile in the hippocampus, a 
well-studied brain region responsible for spatial memory and navigation, as well as the 
implication in neurological disorders of these genes, I selected several genes that are 
potentially important for hippocampal synaptic function and development for subsequent in- 
depth studies. Chapters 3, 4 and 5 of this thesis describe in detail the functions of three genes 
encoding Rho regulators at the synaptic level. A previously unstudied gene, Arhgap12, has 
drawn particular attention due to its highly specific expression in the hippocampal CA1 region 
during early development. The novel function of ARHGAP12 in maintaining proper spine 
formation, synaptic transmission and plasticity is described in chapter 3. We identified 
ARHGAP12 as a “structure-function coordinator” during hippocampal development. The 
underlying mechanism is attributed to its ability of regulating both Rac1 GTPase signaling 
mediated modification of spine structure via its GAP activity, and clathrin-mediated AMPArs 
trafficking via its interaction with CIP4. Chapter 4 reports on an intragenic de novo deletion 
and three truncating mutations of TRIO, a gene encoding a Rho GEF, in patients with ID and 
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the neurophysiological basis of mild to borderline ID caused by mutations of this gene. 
Chapter 5 reports on the functional characterization of Ocrl1, a gene associated with Lowe 
Syndrome and Dent Disease. I showed that OCRL1 bidirectionally controls dendritic spine 
density, miniature excitatory synaptic transmission and LTP. In addition, OCRL1 regulates 
AMPAr endocytosis and the homeostasis of cellular AMPAr amount in primary hippocampal 
neurons. In chapter 6, we report on a disruptive mutation in the X-linked KIF4A and a de novo 
missense mutation in KIF5C in patients with ID and epilepsy. I further describe emerging roles 
of KIF4A and KIF5C in maintaining the balance between excitation and inhibition. In chapter 
7, a discussion of all the collected data is provided, and prospects for future work and the 
potential therapeutic implications for neurological disorders are discussed. 
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Abstract 
As key regulators of cytoskeletal dynamics, Rho GTPases contribute to a wide variety of actin-
based cellular processes. The ability of Rho GTPases to control diverse cellular events largely 
relies on the tight spatial-temporal regulation mediated by their regulators, namely GEFs, 
GAPs and GDIs. It has been proposed that the developmental-specific expression of Rho 
regulatory proteins is one of the critical features that enable them to control Rho GTPase 
signaling in time and space. However, the expression patterns, as well as the function of most 
Rho regulators in the brain are unknown. In this study, we analysed mRNA levels of 22 genes 
encoding Rho GTPases and their regulators during rat hippocampal and cortical development 
by performing qPCR experiments. Our results reveal unique developmental expression 
patterns of previously unstudied Rho proteins and provide an important indication for the 
direction of future investigation regarding the novel roles of Rho GTPase signaling pathways 
in controlling neuronal function. 
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Introduction 
Rho GTPases are key regulators of cytoskeletal dynamics in a wide variety of actin-based 
cellular events, such as spine morphogenesis, cell migration, axonal guidance and cytokinesis 
1–4. Rho GTPases cycle between an active GTP-loaded and an inactive GDP-loaded state, which 
is highly regulated by their interaction with several regulators. Guanine nucleotide exchange 
factors (GEFs) are positive regulators which turn on signaling by promoting the replacement 
of GDP by GTP, and GTPase-activating proteins (GAPs) are negative regulators that terminate 
signaling by providing an essential catalytic group for GTP hydrolysis. A third class of regulator, 
the GDP dissociated inhibitors (GDIs), have also been found to be involved in regulating the 
activity of Rho GTPase by inhibiting the dissociation of bound GDP from their partner GTPases 
5. In the active form, they are able to bind to numerous effector proteins and activate 
downstream signaling pathways.   
 The ability of Rho GTPases to control diverse cellular processes largely relies on the tight 
spatial-temporal regulation mediated by their regulators. So far, 22 human members of the 
Rho family have been identified 6. Surprisingly, approximately 80 Rho GEFs and 70 GAPs have 
been found in the human genome, leading to a ratio of GEFs/GAPs to Rho proteins roughly 
4:1. In addition, Rho GAPs and GEFs exhibit a wide variety of subcellular distribution and their 
expression is developmentally regulated. Importantly, most Rho GAPs and GEFs possess 
multiple conserved domains, which enable them to receive diverse upstream cues as well as 
interact with their targeting Rho proteins and multiple downstream effectors 7. Despite the 
fact that the biological function of most Rho GEFs/GAPs remains elusive, all the features of 
Rho GTPases regulators indicate their ability of controlling specific Rho GTPases signaling in 
time and space.  
In order to identify and characterize critical Rho GTPase regulators involved in synaptic 
function and development, we performed expression profiling of several candidate genes 
encoding Rho GTPase regulators at various stages of hippocampal and cortical development 
by using quantitative polymerase chain reaction (qPCR). Our data showed that most Rho 
proteins we analyzed display unique developmental-specific expression patterns in both 
hippocampus and cortex, which provides novel indications of directions for future 
investigations on potentially critical Rho GTPase proteins in neuronal development. 
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Results 
We selected candidate genes based on four criteria: 1) previously reported to be enriched in 
PSD in both human and mouse brains 8; 2) present in hippocampus and cortex, two important 
brain regions for learning and memory (©2014 Allen Institute for Brain Science; Allen Mouse 
Brain Atlas from: http://mouse.brain-map.org/); 3) associated with neurological disorders, 
particularly reported targets of Fragile X mental retardation protein (FMRP), whose loss of 
function leads to Fragile X syndrome 9; 4) functions in the brain are unknown.  
In total, 22 genes including 10 GAPs, 1 GDI, 10 GEFs and 1 Rho GTPase were selected 
(Table 1). We then collected rat hippocampi and cortices at embryonic day 17 (E17), postnatal 
day (P) 3, P10, P17, P24 and P90 (adult), corresponding to different critical stages of neuronal 
development. We subsequently performed qPCR experiments on mRNAs isolated from these 
tissue and analyzed expression patterns of all the genes. Our results showed that most genes 
exhibit developmental expression patterns in both hippocampus and cortex (Table 2 and Table 
3). The levels of most Rho GEFs genes increase during development. Among these genes, 
Dock2 and Dock10 display remarkable steep increasing curves, reaching peaks at P24, 
indicating their importance in both developing and mature brains. Conversely, we found that 
the expression of most genes encoding Rho GAPs are constant or decreasing with age. Of note, 
some genes showed opposite expression patterns in hippocampus and cortex. For example, 
the level of Arhgap6 significantly decreases after birth in the hippocampus whereas its 
expression increases during cortical development, suggesting that Arhgap6 might contribute 
to different developmental events in hippocampus and in cortex.  
 
GEFs GAPs GDI  Rho GTPase 
Arhgef2 Arhgap1 Arhgdia Rho B 
Arhgef7 Arhgap6     
Dock1 Arhgap11     
Dock2 Arhgap12     
Dock3 Arhgap15     
Dock4 Arhgap21     
Dock5 Arhgap23     
Dock9 Arhgap26     
Dock10 Bcr     
Trio Ocrl1     
 
Table 1 Summary of selected genes of Rho protein and regulators 
22 genes encoding 10 GAPs, 1 GDI, 10 GEFs and 1 Rho GTPase were selected for qPCR experiments. 
38 
 
40
C
h
a
p
te
r 
2
37 
 
 
 
 
 
38 
 
 
 
Genes E17 P3 P10 P17 P24 Adult 
Arhgef2 1.00 0.75 1.02 1.26 1.29 1.55 
Arhgef7 1.00 1.98 2.34 1.63 1.49 1.04 
Dock1 1.00 1.10 1.40 1.40 1.65 2.39 
Dock2 1.00 2.86 6.35 7.39 25.41 12.02 
Dock3 1.00 1.99 2.87 2.18 1.78 3.36 
Dock4 1.00 2.07 3.58 6.82 7.61 3.82 
Dock5 1.00 1.10 0.99 1.72 3.41 20.85 
Dock9 1.00 6.23 7.59 7.30 7.03 4.28 
Dock10 1.00 3.04 7.34 21.78 41.93 21.28 
Trio 1.00 0.31 0.16 0.17 0.13 0.20 
Arhgap1 1.00 1.61 1.50 1.35 1.06 1.00 
Arhgap6 1.00 0.33 0.35 0.39 0.48 0.50 
Arhgap11 1.00 0.25 0.16 0.13 0.13 0.25 
Arhgap12 1.00 0.93 0.82 0.51 0.50 0.32 
Arhgap15 1.00 6.03 8.45 6.21 6.04 10.95 
Arhgap21 1.00 1.13 1.09 1.20 1.44 1.53 
Arhgap23 1.00 1.61 1.69 1.56 1.93 2.91 
Arhgap26 1.00 3.86 7.48 8.57 8.88 12.97 
Bcr 1.00 0.88 0.90 0.65 0.58 1.14 
Ocrl1 1.00 1.20 1.14 1.00 1.29 1.16 
Arhgdia 1.00 1.34 2.20 1.87 1.63 1.67 
Rho B 1.00 1.92 2.68 2.21 2.46 2.01 
 
    < 0.20     < 0.40     < 0.60      < 0.80      1.00        > 1.50     > 2.50      > 5.00      > 7.50    >10.00     >20.00 
           
 
Table 2 Expression of Rho protein and regulators during hippocampal development 
Relative expression levels of selected genes at different hippocampal developmental stages. 
Expression of individual genes at each time point are normalized to the expression of E17. The 
expression changes of each gene are colour-coded by a green to red colour gradient, corresponding to 
decreased (green) or increased (red) expression. 
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Genes E17 P3 P10 P17 P24 ADULT 
Arhgef2 1.00 1.67 0.96 1.14 1.70 1.12 
Arhgef7 1.00 2.58 2.51 1.76 2.00 1.07 
Dock1 1.00 0.78 0.75 0.82 1.31 1.18 
Dock2 1.00 2.39 6.50 5.78 10.68 9.35 
Dock3 1.00 4.26 4.81 2.27 2.07 2.79 
Dock4 1.00 1.80 1.92 2.34 3.14 4.26 
Dock5 1.00 1.27 4.45 2.70 6.93 7.82 
Dock9 1.00 6.40 7.90 4.62 4.53 4.39 
Dock10 1.00 2.27 2.84 7.26 11.60 13.06 
Arhgap1 1.00 1.38 1.10 0.78 0.95 0.93 
Arhgap6 1.00 2.93 4.84 8.73 9.38 24.70 
Arhgap11 1.00 0.22 0.08 0.03 0.03 0.04 
Arhgap12 1.00 0.934 0.821 0.511 0.503 0.840 
Arhgap15 1.00 3.32 5.87 6.65 10.13 10.67 
Arhgap21 1.00 0.99 0.72 0.62 1.00 1.22 
Arhgap23 1.00 4.99 2.18 1.09 2.04 1.79 
Arhgap26 1.00 2.58 6.67 10.49 11.47 12.70 
Bcr 1.00 0.91 0.78 0.51 0.54 0.73 
Ocrl1 1.00 2.01 1.69 1.47 1.72 1.35 
Arhgdia 1.00 1.38 1.45 1.48 1.45 1.31 
Rho B 1.00 1.86 1.87 1.71 1.65 2.14 
 
    < 0.20    < 0.40       < 0.60    < 0.80       1.00       > 1.50      > 2.50      > 5.00     > 7.50     >10.00     >20.00 
           
 
Table 3 Expression of Rho protein and regulators during cortical development 
Relative expression levels of selected genes at different cortical developmental stages. Expression of 
individual genes at each time point are normalized to the expression of E17. The expression changes 
of each gene are colour-coded by a green to red colour gradient, corresponding to decreased (green) 
or increased (red) expression. 
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Discussion 
It has been proposed that the developmental-specific expression of Rho regulatory proteins 
is one of the critical features that enable them to control Rho GTPase signaling pathways in 
time and space 10. By performing transcriptional expression profiling, one could gain better 
insights on when and where the genes that encode Rho proteins play a role in modulating 
neuronal function, since the physical distribution of Rho GTPases and their regulators is 
instructive for their function 11.  
 In order to identify and characterize critical Rho GTPase proteins that are involved in 
synaptic function and development, in the present study, we generated a transcriptional map 
of 22 genes encoding Rho GTPases and their regulators. We observed diverse expression 
patterns of individual Rho proteins during hippocampal and cortical development. For 
instance, Arhgap12 and Arhgap15, two closely related members of RhoGAP subfamily 12, 
exhibit complimentary expression pattern. Arhgap12 is highly expressed in early development 
whereas the level of Arhgap15 rapidly increases after birth and reaches a peak level in 
adulthood. So far, detailed functional analysis of Arhgap12 and Arhgap15 in neurons have not 
been reported, although Arhgap15 has been implicated in ASD 13. Our results indicate that it 
is likely that these two homologous proteins play roles at different stages of hippocampal and 
cortical development. Of note, the mRNA of Arhgap12 has been shown to be prominently 
expressed in hippocampal CA1 region in mice (©2014 Allen Institute for Brain Science; Allen 
Mouse Brain Atlas from: http://mouse.brain-map.org/), suggesting that Arhgap12 plays vital 
roles in sculpting specific hippocampal circuits and function.  
Ocrl1, a gene mutated in patients with Lowe syndrome and type 2 Dent Disease, displays 
relative constant expression in both hippocampal and cortical development. Most studies 
have focused on non-neuronal cells whereas the function of Ocrl1 in the brain remains elusive. 
Experiments illustrating the role of Ocrl1 in normal neuronal function are needed to reveal 
how mutations in this gene lead to ID. 
 Our data also showed that the mRNA level of Trio is the highest at embryonic stage and 
gradually decreases with age in the hippocampus, which is consistent with the previous report 
of the expression pattern of Trio 14. Compared to its homolog Kalirin, the neuronal function of 
TRIO is much less understood, partially due to the lethality of global Trio-/- knockout in rodents 
15. Analysis of Drosophila Trio (dTrio) mutants highlighted its role in axon formation and path 
finding 16–18. Importantly, we recently identified mutations in TRIO in patients with ID 
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(described in chapter 4). Therefore functional analysis of Trio will significantly advance our 
understanding of pathogenesis of ID.  
 Furthermore, our data showed that the mRNA levels of most members of DOCK-family 
RhoGEFs increase during development and sustain high in adulthood, implying their 
contribution in both juvenile and mature hippocampus and cortex. Interestingly, a recent 
study has reported distinct patterns of the DOCK-family members in cerebellum Purkinje cells 
19. The mRNAs of Dock1, Dock2 and Dock3, could not be detected due to extremely low 
expression levels. Dock4 is stably expressed in the first two postnatal weeks followed by a 
significant drop at the third week, while Dock9 and Dock10 levels significantly increase during 
the second and third postnatal weeks. The different expression patterns between cerebellum 
and hippocampus/cortex further support the hypothesis that distinct spatial-temporal 
expressions of Rho regulators enhance the specificity of Rho GTPase signaling-mediated 
cellular events. Future experiments will reveal the roles and differences of individual RhoGEFs 
in neuronal function and brain development. 
Collectively, our data reveal developmental-specific expression patterns of novel Rho 
proteins and shed light on directions of future investigations. We further selected Arhgap12, 
Ocrl1 and Trio for detailed functional analysis, as described in chapters 3, 4 and 5.  
 
Material and Methods 
Animals  
Wistar rats were housed per 2 or 3 animals on a 12-h light cycle in a temperature-controlled 
(21 ± 1°C) environment with ad libitum access to food and water. Rats were sacrificed at E17, 
P3, P10, P17, P24 and P90 (adult). The hippocampus and cortex were dissected out and snap-
frozen in liquid nitrogen. All samples were stored at -80°C for further analysis. All experiments 
involving animals were evaluated and approved by the Committee for Animal Experiments of 
the Radboud university medical center, Nijmegen, the Netherlands. 
 
RNA isolation, reverse transcription and qPCR  
Total RNA from the tissue was isolated using RNeasy Lipid Tissue mini kit (Qiagen). cDNA was 
synthesized from 0.5–1 mg RNA using iScript™ cDNA Synthesis Kit. QPCR experiments were 
subsequently performed in 7900HT Fast Real-Time PCR System using GoTaq qPCR Master mix 
(Promega). 
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Primers used for qPCR 
DOCK1_RTqPCR_rat_F ttaccttccgccatagatcc 
DOCK1_RTqPCR_rat_R gggtggtcccatcatatctc 
DOCK10_RTqPCR_rat_F aagacttaccgggatgatgc 
DOCK10_RTqPCR_rat_R ctgtgctctgcttcttctgg 
DOCK2_RTqPCR_rat_F gaggacaggaggctctcaag 
DOCK2_RTqPCR_rat_R cctgtattcgaaccacatcg 
DOCK3_RTqPCR_rat_F gggaaatgatgttgctgttg 
DOCK3_RTqPCR_rat_R agggtcactgcagggtttac 
DOCK4_RTqPCR_rat_F caaaatcatggaccaacagc 
DOCK4_RTqPCR_rat_R catgccctcgacatacaaac 
DOCK5_RTqPCR_rat_F tcaggtcatctccaaagcag 
DOCK5_RTqPCR_rat_R aaccggtttgtccttgtagc 
DOCK9_RTqPCR_rat_F caagagcaccagagaagcag 
DOCK9_RTqPCR_rat_R tggcttcacttctggttcag 
ARHGAP1_RTqPCR_rat_F atgataagtacgggcggaag 
ARHGAP1_RTqPCR_rat_R ggtgcaggtacaggagtgtg 
ARHGAP21_RTqPCR_rat_F ccacacattggactggtctg 
ARHGAP21_RTqPCR_rat_R tcaccctgttcctttccatc 
ARHGAP23_RTqPCR_rat_F tccagcattctgactggttc 
ARHGAP23_RTqPCR_rat_R caggggttctctctcctttg 
ARHGAP26_RTqPCR_rat_F aacccccttgaacacaagac 
ARHGAP26_RTqPCR_rat_R gaaccatggtgatttgcttg 
ARHGDIA_RTqPCR_rat_F atctctttccgggtgaacag 
ARHGDIA_RTqPCR_rat_R tcccgaccatgtagtcagtc 
ARHGEF2_RTqPCR_rat_F tgatgacagatgtgctggtg 
ARHGEF2_RTqPCR_rat_R ataccactgagggcttgtcc 
ARHGEF7_RTqPCR_rat_F cctcagacctctcggaagac 
ARHGEF7_RTqPCR_rat_R aagcaacacttgtggagcag 
ARHGAP6_RTqPCR_rat_F cagcatctggaaaaacatgg 
ARHGAP6_RTqPCR_rat_R tgtgctcctcttccagacag 
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ARHGAP11a_RTqPCR_rat_F agctgttgccaagtcatctc 
ARHGAP11a_RTqPCR_rat_R tcgccttaggtctgtactgg 
ARHGAP15_RTqPCR_rat_F aagtctccctccaccaaatc 
ARHGAP15_RTqPCR_rat_R agaagggtgggtccaaatac 
ARHGAP12_RTqPCR_rat_F agcagttgtttcagccagtc 
ARHGAP12_RTqPCR_rat_R acatgcttgagccacttttc 
OCRL1_RTqPCR_rat_F agtccccaatcagactctcc 
OCRL1_RTqPCR_rat_R cttttcacctcattggcatc 
BCR_RTqPCR_rat_F cactacccaacatccctctg 
BCR_RTqPCR_rat_R agcttcttcctcagcctctc 
RhoB_RTqPCR_rat_F ttgaggttgagaggaagcag 
RhoB_RTqPCR_rat_R aggcacaaagttcgcttatg 
TRIO_RTqPCR_rat_F1 gtcacggaacatgttgaagg 
TRIO_RTqPCR_rat_R1 cctgtatcacctcacggatg 
TRIO_RTqPCR_rat_F2 tcgaggaagttgcacagaac 
TRIO_RTqPCR_rat_R2 actcttcggggtcacattc 
TRIO_RTqPCR_rat_F3 agttggagaacgggtacagg 
TRIO_RTqPCR_rat_R3 acctcgctcaatgggataac 
Hprt1_RTqPCR_rat_F tgctgaagatttggaaaagg 
Hprt1_RTqPCR_rat_R cccatctccttcatgacatc 
Tbp_RTqPCR_rat_F ctgggattgtaccacagctc 
Tbp_RTqPCR_rat_R cgcttgggattatattcagc 
 
Reference genes  
Two housekeeping genes were used: TBP, TATA-binding protein; PPIA, Peptidylprolyl 
isomerase A 20.  
 
Data processing and analysis  
Raw data was processed by SDS QR Manager 2.3. The relative levels of individual genes were 
normalized to the expression of E17 and calculated using 2-ΔΔCt (ΔCt = Ct candidate genes - Ct 
corresponding reference genes; ΔΔCt (different ages) = ΔCt (different ages) – ΔCt (E17)). The heat map 
44 
 
46
C
h
a
p
te
r 
2
43 
 
ΔΔ Δ
ΔΔ Δ Δ
44 
 
was generated to present relative expressions of individual genes during hippocampal and 
cortical development. 
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Abstract 
The molecular mechanisms that promote excitatory synapse development have 
been extensively studied. However, the molecular events preventing precocious excitatory 
synapse development so that synapses form at the correct time and place are less well 
understood. Here, we report the functional characterization of ARHGAP12, a previously 
uncharacterized Rho GTPase-activating protein (RhoGAP), in the rat brain. ARHGAP12 is 
specifically expressed in the CA1 region of the hippocampus where it localizes to the 
postsynaptic compartment of excitatory synapses. ARHGAP12 negatively controls spine 
size via its RhoGAP activity and promotes, by interacting with CIP4, postsynaptic 
AMPA receptor endocytosis. Notably, Arhgap12 knockdown results in precocious 
maturation of excitatory synapses, as indicated by a reduction in the proportion of silent 
synapses. Collectively, our data show that ARHGAP12 is a synaptic RhoGAP that 
regulates excitatory synaptic structure and function during development.  
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Highlights 
x ARHGAP12 functions at excitatory synapses of CA1 hippocampal neurons 
x ARHGAP12 promotes postsynaptic AMPA receptor endocytosis  
x ARHGAP12 restricts synaptic maturation by limiting silent synapse unsilencing 
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Introduction  
The dynamic process of formation and fine-tuning of synaptic connections between neurons 
is critical for neuronal development and proper brain function 1,2. Most excitatory synapses 
are located on dendritic spines, small filamentous actin (F-actin) enriched protrusions on 
dendrites 3. Synaptic efficiency is rapidly modified during development or in response to 
changes in activity by the remodeling of spine structure and the trafficking of glutamate 
ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPArs) 4.  
 Several observations have shown that the number of AMPArs and the geometry of 
dendritic spines are tightly correlated 5–7. Actin remodeling, which occurs in dendritic spines, 
drives changes in spine morphology and is required, but not sufficient, for stable long-term 
potentiation (LTP), one of the core mechanisms of synaptic plasticity underlying learning and 
memory 8,9. Indeed, inhibition of spine enlargement by blocking actin polymerization prevents 
proper LTP expression 10,11, whereas increasing spine size alone, by promoting actin 
polymerization, is not sufficient to express LTP 8,12,13. Importantly, evidence suggests that 
impairments in spine structure and synaptic strength during development contribute to 
numerous neurological diseases including intellectual disability (ID), autism spectrum disorder 
(ASD) and schizophrenia 14–17.  
 How modifications in spine structure and synaptic strength are coordinated, however, 
remains largely unknown. As key regulators of the actin cytoskeleton, the Rho subfamily 
members of GTP-binding proteins play a critical role in synapse formation, maturation and 
maintenance, directly affecting both synapse structure and function 14,18,19. The Rho subfamily 
of GTP-binding proteins acts as molecular switches cycling between an active GTP-bound form 
and an inactive GDP-bound form. Their activity is mainly regulated by guanine nucleotide 
exchange factors (GEFs), which are positive regulators, and by GTPases activating proteins 
(GAPs) and guanine nucleotide dissociated inhibitors (GDIs), which are negative regulators 20. 
GEFs and GAPs are typically multi-domain proteins and their expression levels are tightly 
regulated during development. Their specific spatial and temporal expression patterns enable 
them to regulate synaptic function through the interaction with diverse upstream molecules 
and downstream effectors 18. Several Rho GEFs and GAPs have been shown to uniquely 
regulate synaptic development and plasticity 21–23. In addition, a number of Rho GTPase 
regulators and effectors have been directly associated with ID, including Oligophrenin-1 
(OPHN1) 24,25, OCRL1 26, ARHGEF6 27 and PAK3 28. However, remarkably little is known about 
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how individual GEFs or GAPs precisely coordinate synaptic morphology and function during 
development.   
 In this study, we focused on ARHGAP12, a RhoGAP that negatively regulates Rac1 signaling 
and whose function has not yet been described in the brain. We found that ARHGAP12 is 
almost exclusively expressed in rat hippocampal CA1 neurons during early stages of 
development. We investigated the postsynaptic function of ARHGAP12 by spatially and 
temporally manipulating the levels of ARHGAP12, specifically at hippocampal CA3-CA1 
synapses. We characterized ARHGAP12 as a "structure-function coordinator" of excitatory 
synapses during hippocampal development. Our results uncover a dual function for 
ARHGAP12 in coordinating synaptic structure and AMPAr trafficking in hippocampal CA3-CA1 
synapses during development.  
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Results 
Expression and distribution of ARHGAP12 in the rat hippocampus 
To identify Rho GTPase regulators that are critical for the development of cell type-specific 
synapses in the hippocampus, we made use of the mRNA expression data from the Allen Brain 
Atlas (©2014 Allen Institute for Brain Science; Allen Mouse Brain Atlas from: 
http://mouse.brain-map.org/). We focused on Rho GTPase regulators with a specific spatial 
expression pattern. We identified the Rac1 GAP protein, ARHGAP12 29, as an interesting 
candidate protein based on its very specific CA1 and to a lesser extent dentate gyrus (DG) 
expression (Figure 1A). We initiated the characterization of ARHGAP12 by determining its 
spatiotemporal distribution in the rat hippocampus. Immunostaining experiments revealed 
that ARHGAP12 was prominently expressed in the hippocampal CA1 region and to a lesser 
extent in the DG, confirming the mRNA expression data. ARHGAP12 was detected in all 
hippocampal CA1 pyramidal cell layers, in the somata and along the dendrites (Figure 1B). We 
next examined the expression of ARHGAP12 during different stages of hippocampal 
development by Western blot. ARHGAP12 was abundantly expressed in embryonic (E18) and 
early postnatal hippocampus (1-2 weeks), and thereafter its expression gradually declined into 
adulthood. In adult hippocampus, the expression of ARHGAP12 was still detectable but 
remarkably decreased compared to E18 hippocampus (Figure 1C). These results show that 
ARHGAP12 is expressed in a distinct spatiotemporal pattern within the hippocampus. 
 The subcellular distribution of Rho GEFs and GAPs is instructive for their function 30. We 
therefore assessed the subcellular distribution of ARHGAP12 in hippocampal CA1 pyramidal 
neurons. To this end, we tagged ARHGAP12 at its N-terminus with GFP and introduced GFP-
Arhgap12 together with a red fluorescent protein, dsRed, as a cellular marker, into CA1 cells 
in 12 DIV organotypic hippocampal slices by biolistic transfection. The partition of ARHGAP12 
between spines and dendrites was calculated from the ratio of the GFP/dsRed signal in the 
spine head versus the adjacent dendritic shaft 24. Interestingly, we found a strong enrichment 
of ARHGAP12 in the spines compared to the dendrites (Figure 1D). Consistently, we observed 
overlapping localization of endogenous ARHGAP12 with PSD95 in the stratum radiatum of the 
hippocampal CA1 region (Figure 1E). Finally, we showed that ectopically expressed GFP-
ARHGAP12 colocalized with PSD95 and was found juxtaposed to the pre-synaptic marker 
Synapsin-1 in hippocampal primary neurons (Figure S1). Together, these data reveal that 
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ARHGAP12 is located postsynaptically in excitatory synapses of hippocampal CA1 pyramidal 
neurons.   
Figure 1 Expression and distribution of ARHGAP12 in the hippocampus  
(A) In situ hybridization of Arhgap12 from the Allen Brain Atlas database. Scale bars, 50 μm. 
(B) Hippocampi sections from a P20 rat double-immunolabled with an anti-ARHGAP12 antibody (red) 
and an anti-NeuN antibody (green). Scale bars, 50 μm.  
(C1) Rat hippocampi were collected at indicated ages and probed with anti-ARHGAP12 antibody. 
Expression of Υ-TUBULIN was used as a loading control; equal amounts of protein (50 μg) were loaded.  
(C2) Quantification of ARHGAP12 proteins levels at indicated postnatal ages. ARHGAP12 expression 
was normalized to Υ-TUBULIN in the same sample. Data are shown as mean ± SEM; n = 3. 
(D1) Left, representative images of a dendritic branch of a hippocampal CA1 pyramidal neuron co-
transfected with GFP-Arhgap12 (green) and dsRed (red). Right, ratio image of the representative cell. 
Blue depicts low ARHGAP12 enrichment and red depicts high density. Scale bar, 5 μm.  
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(D2) Quantification of GFP-ARHGAP12 enrichment in spines. Data are shown as mean ± SEM; n = 8; 
**P<0.01, t-test. 
(E) Left, hippocampi sections from a P20 rat double-immunolabled with an anti-ARHGAP12 antibody 
(green) and an anti-PSD95 antibody (red). Right, higher magnification images of the area indicated in 
the white box on the left panel. White arrows indicate sites of co-localization of ARHGAP12 and PSD95. 
Scale bars, 10 μm. 
See also Figure S1. 
 
 
Negative regulation of spine morphology by ARHGAP12 
Given the presence of ARHGAP12 in spines, and the importance of Rho GTPases in controlling 
actin cytoskeleton remodeling, we first examined the role of ARHGAP12 in regulating dendritic 
spine morphology in CA1 pyramidal neurons. We biolistically introduced a GFP-expressing 
construct, as a cellular marker, with or without a second construct containing Arhgap12 into 
CA1 neurons in organotypic hippocampal slices. Immunostaining experiments revealed that 
neurons transfected with GFP alone showed similar ARHGAP12 levels compared to adjacent 
non-transfected neurons, whereas neurons expressing Arhgap12 exhibited a 10-fold increase 
in ARHGAP12 levels (Figure S2B). Compared to neurons expressing GFP alone, Arhgap12 
overexpressing CA1 pyramidal neurons displayed a significant decrease in both spine density 
and volume (spine density: GFP control: 5.02 r 0.22 spines/10 μm, Arhgap12: 1.87 r 0.44 
spines/10 μm; spine volume: GFP control: 270.56 r 49.22; Arhgap12: 153.03 r 52.68; Figure 
2A, B, C). In addition, we found that elevated ARHGAP12 levels significantly increased the 
percentage of immature spines in CA1 neurons (GFP control: 6.03 r 1.05%, Arhgap12: 15.90 
r 3.45%; Figure 2D). These observations are consistent with experiments in which reduced 
Rac1 activity has been coupled to reduced spine density and size 31. 
 We next examined the function of endogenous ARHGAP12 by probing the effects of 
reduced ARHGAP12 expression on dendritic spines. Constructs were generated to coexpress 
GFP and short hairpin RNA’s (shRNAs) targeting either the 3’-untranslated (3’-UTR, Arhgap12 
sh#1) or the translated region (Arhgap12 sh#2) of rat Arhgap12 mRNA. Arhgap12 shRNAs 
significantly reduced endogenous ARHGAP12 protein levels in hippocampal primary neurons 
(Figure S2A), as well as in organotypic hippocampal slices (Figure S2B). We found that neither 
shRNA (Arhgap12 sh#1 and #2) affected spine density (GFP control: 5.02 r 0.22 spines/10 μm, 
Arhgap12 sh#1: 5.06 r 0.62 spines/10 μm, Arhgap12 sh#2: 5.02 r 1.41 spines/10 μm), but 
both significantly increased spine volume (GFP control: 270.56 r 49.22; Arhgap12 sh#1: 
443.69 r 52.30; Arhgap12 sh#2: 416.79 r 116.03; Figure 2B, C). The percentage of immature 
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spines also significantly decreased in neurons expressing Arhgap12 shRNAs (GFP control: 6.03 
r 1.05%; Arhgap12 sh#1: 1.33 r 1.34%; Arhgap12 sh#2: 1.68 r 1.42%; Figure 2D). Importantly, 
we were able to rescue these phenotypes by coexpressing Arhgap12 sh#1 with an Arhgap12 
expressing vector that lacked the 3’-UTR and was therefore resistant to Arhgap12 sh#1-
mediated knockdown. This confirmed that the knockdown effects were mediated specifically 
by loss of ARHGAP12 (spine density: GFP control: 5.02 r 0.22 spines/10 μm, Arhgap12 sh#1 + 
Arhgap12: 4.77 r 1.02 spines/10 μm; spine volume: GFP control: 270.56 r 49.22; Arhgap12 
sh#1 + Arhgap12: 226.51 r 103.55; Fig 2B, C, D). Importantly, immunostaining experiments on 
biolistically transfected organotypic hippocampal slices confirmed that the levels of 
ARHGAP12 were restored to normal levels (Figure S2B).  
Next, we examined whether the regulation of ARHGAP12 on spine morphology was 
dependent on activity. To this end, we treated organotypic slices with high concentration of 
MgCl2 or the NMDAr antagonist 2-amino-5-phosphonovaleric acid (APV, 100 μM) on the same 
day of biolistic transfection. Both manipulations however did not prevent the enlargement of 
spine volume induced by Arhgap12 downregulation (Figure S3A), indicating that knocking 
down Arhgap12 is sufficient to increase spine size. Since the expression of ARHGAP12 declines 
during normal development, we wondered whether blocking NMDAr activity would affect this 
process. Interestingly, we found that the gradual decrease of ARHGAP12 levels did not occur 
in the presence of APV (Figure S3C), suggesting that the developmental elimination of 
ARHGAP12 is dependent on NMDAr activity.  
Together, our results support a model in which NMDAr activity during development drives 
the repression of ARHGAP12, resulting in the enlargement of spines.  
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Figure 2 ARHGAP12 negatively regulates spine morphology 
(A) Representative images of secondary apical dendrites from CA1 neurons transfected with indicated 
constructs. Scale bars, 10 μm.  
(B, C, D) Quantification of spine density (B), spine volume (C) and percentage of immature spines (D) 
for indicated experimental conditions. Data are shown as mean ± SEM; GFP: n = 15, Arhgap12: n = 9, 
Arhgap12 sh#1: n = 8, Arhgap12 sh#2: n = 7, Arhgap12 sh#1+ Arhgap12: n = 9 from three to four 
independent experiments. A minimum of 500 spines were analyzed per condition; *P<0.05, **P<0.01, 
one-way ANOVA. 
See also Figure S2 and S3. 
 
 
Selective modulation of synaptic AMPA receptor mediated transmission by ARHGAP12 
Due to the importance of dendritic spine structure for synaptic function and the effects of 
ARHGAP12 on spine morphology, we next assessed the role of ARHGAP12 in modulating 
excitatory synaptic function. We first examined the effects of ARHGAP12 overexpression on 
synaptic transmission. Simultaneous whole-cell recordings of evoked excitatory post-synaptic 
currents (EPSCs) were recorded at 7 DIV from CA1 pyramidal neurons expressing GFP-
Arhgap12 and from adjacent non-transfected neurons. Overexpression of Arhgap12 
significantly depressed AMPAr- and NMDAr-mediated synaptic transmission (AMPAr-EPSC: 
uninfected: 197.61 r 21.15 pA, infected: 45.33 r 4.67 pA; NMDAr-EPSC: uninfected: 193.71 r 
19.13 pA, infected: 157.84 r 18.71 pA, Figure 3A, D), suggesting that ectopically expressed 
Arhgap12 is sufficient to depress AMPAr- and NMDAr-mediated transmission. Importantly, 
overexpression of GFP alone did not alter AMPAr or NMDAr-mediated synaptic transmission 
(Figure S4A). These observations complement our finding that ectopic expression of Arhgap12 
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significantly reduced the number of mature spines and therefore could explain the changes in 
NMDAr-EPSCs, in addition to the changes in AMPAr-EPSCs. 
Next we examined the effects of ARHGAP12 downregulation in regulating synaptic 
transmission. We found that downregulation of ARHGAP12 levels resulted in potentiation of 
AMPAr-mediated transmission, but not NMDAr-mediated transmission (Arhgap12 sh#1: 
AMPAr-EPSC: uninfected: 40.03 r 8.98 pA, infected: 60.57 r 7.85 pA; NMDAr-EPSC: uninfected: 
67.28 r 7.40 pA, infected: 72.82 r 9.94 pA; Arhgap12 sh#2:  AMPAr-EPSC: uninfected: 51.32 r 
8.03 pA, infected: 70.91 r 5.43 pA; NMDAr-EPSC: uninfected: 62.13 r 8.85 pA, infected: 67.88 
r 10.62 pA; Figure 3B, C, D), indicating that downregulation of ARHGAP12 is sufficient to 
enhance AMPAr-mediated transmission. These results are consistent with our observation 
that reducing endogenous ARHGAP12 results in larger dendritic spines without affecting the 
spine density. Thus, bidirectional manipulation of ARHGAP12 levels is associated with 
opposing effects towards AMPAr-mediated synaptic transmission. 
To test whether the effect of ARHGAP12 on AMPArs is restricted to synaptic AMPArs, we 
recorded extrasynaptic responses evoked by bath application of AMPA (1 μM), which initiated 
inward currents in all neurons 32. Interestingly, no differences in AMPA-induced inward 
currents were observed between control uninfected neurons and Arhgap12 sh#1 infected 
neurons (Figure 3E), indicating that the modulation of glutamatergic receptors by ARHGAP12 
is specific for synaptic AMPArs. Since altered AMPAr-mediated EPSC may also result from an 
altered proportion of GluA2-lacking AMPArs, whose currents show unique inward rectification, 
we further measured the rectification index of AMPAr-EPSCs by measuring AMPAr-mediated 
EPSCs at -60 mV and at +40 mV holding potential, in the presence of intracellular spermine 33. 
We did not, however, observe a significant difference between uninfected neurons and 
Arhgap12 sh#1 infected neurons (Figure 3F), indicating that enhanced AMPAr-EPSCs were not 
a result of changes in AMPAr subunit composition. 
The changes in AMPAr-mediated transmission could result from either a change of 
synaptic AMPArs at individual synapses, a change in the number of functional synapses, or 
both. In order to determine the precise mechanism, we measured the effect of ARHGAP12 on 
the amplitudes and frequencies of miniature excitatory postsynaptic currents (mEPSCs). 
Arhgap12 sh#1 largely increased both frequency and amplitude of mEPSCs in CA1 pyramidal 
neurons (Figure 3G). The change in amplitude supports our previous findings showing that 
ARHGAP12 affects synaptic AMPAr function. A change in frequency usually reflects a change 
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in the number of active synapses or in presynaptic release probability. We further examined 
presynaptic release by measuring the paired-pulse ratio. We did not observe significant 
differences between uninfected and Arhgap12 sh#1 expressing neurons (Figure 3H), 
indicating that no retrograde signaling was involved to alter presynaptic release probability 
and the changes in frequency reflect a change in the amount of active synapses. 
Finally, we evaluated the impact of ARHGAP12 on inhibitory (GABAergic) synaptic function 
in CA1 pyramidal neurons. Evoked inhibitory postsynaptic currents (IPSCs) were measured on 
neurons expressing Arhgap12 sh#1 and adjacent control uninfected neurons on hippocampal 
slices at 7 DIV. We found that Arhgap12 knockdown did not affect evoked IPSCs (Figure S4B).  
Together, our findings indicate that ARHGAP12 is critical for modulating excitatory, but not 
inhibitory, synaptic transmission at the postsynaptic terminal in a cell autonomous way. 
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Figure 3 Post-synaptic ARHGAP12 modulates AMPA receptor mediated transmission 
(A-C) Amplitudes of AMPAr (left panel) and NMDAr (right panel) EPSCs of uninfected neurons are 
plotted against simultaneously recorded neighboring neurons expressing Arhgap12 (A), Arhgap12 
sh#1 (B), Arhgap12 sh#2 (C). Recordings were performed at 7 DIV. Black symbols represent single pairs 
of recordings; green or grey symbols show mean values. Inserts in each panel show sample average 
traces; black traces, uninfected neurons; grey traces, Arhgap12 overexpressed neurons; green traces, 
Arhgap12 shRNAs expressing neurons. Scale bars, 10 ms and 25 pA.  
(D) Summary of effects of Arhgap12 overexpression or knockdown. Data are shown as mean ± SEM; n 
= 9-15 from three independent experiments; *P<0.05, paired t-test. 
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(E) Time course of whole-cell currents recorded from CA1 pyramidal neurons infected with Arhgap12 
sh#1 or control uninfected neurons during the application of 1 μM AMPA. Uninfected: n = 9, Arhgap12 
sh#1: n = 8 from two independent experiments.  
(F) Synaptic responses were recorded at -60 mV and +40 mV from CA1 pyramidal neurons infected 
with Arhgap12 sh#1 or uninfected neurons in the presence of intracellular spermine. Rectification 
Index was calculated by dividing the amplitude at -60 mV by the amplitude at +40 mV. n = 8 for both 
conditions from two independent experiments.  
(G) Representative traces and quantifications of excitatory miniature events recorded from uninfected 
neurons and neurons expressing Arhgap12 sh#1 at 7 DIV. Scale bars, 1 s and 25 pA. Data are shown as 
mean ± SEM; n = 13-15 from three independent experiments; *P<0.05, t-test. 
(H) Paired-pulse facilitation (EPSC2/EPSC1) recorded from uninfected and Arhgap12 sh#1 expressing 
neurons at indicated inter-stimulus intervals. Data are shown as mean ± SEM; n = 7 for both groups 
from three independent experiments. 
See also Figure S4. 
 
 
Arhgap12 knockdown promotes hippocampal synaptic development by accelerating silent 
synapse unsilencing 
We next sought to further delineate the mechanism by which ARHGAP12 restricts synaptic 
function. We reasoned that a plausible mechanism could involve the regulation of silent 
synapse activation. Silent synapses refer to those synapses with NMDArs but no functional 
AMPArs 34, and they can convert to active synapses by AMPAr insertion (also termed 
“unsilencing”) during development and/or in response to neuronal activity 35,36. In the 
hippocampus, the proportion of these silent synapses rapidly decreases during the first two 
weeks of postnatal development 35. To detect silent synapses, we performed whole-cell patch-
clamp recordings on CA1 pyramidal neurons using minimum stimulation. In control uninfected 
4 DIV CA1 neurons, the failure rate was much larger at -60 mV than at +40 mV (Figure 4A, B), 
indicating that a substantial fraction of the synapses are still silent at this stage of development 
(Figure 4C). As expected, the proportion of silent synapses gradually decreased during 
development, with almost all synapses unsilenced at 14 DIV (Figure 4C). Interestingly, when 
the same experiments were performed on Arhgap12 sh#1 expressing hippocampal CA1 
neurons, we found that the proportion of silent synapses was significantly decreased at the 
earlier developmental time points (4 DIV and 7-8 DIV) but was comparable to control at 13-14 
DIV (Figure 4C), suggesting that Arhgap12 downregulation promotes synaptic maturation by 
accelerating synapse unsilencing.  
Robust synaptogenesis occurs during the first two weeks of postnatal development and a 
major mechanism underlying these critical events is synapse unsilencing. Since the 
developmental gradient of ARHGAP12 expression is inversely correlated to the trend of 
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synaptic maturation in hippocampus, we speculated that ARHGAP12 might act as an 
endogenous “brake” during development. Namely, decreasing levels of ARHGAP12 would 
release the repression and accelerate synaptogenesis and functional synapse maturation. If 
this is the case, the potentiation of CA3-CA1 synapses would be stronger when Arhgap12 is 
downregulated in the early developmental stages compared to that at the later stages. 
Conversely, keeping ARHGAP12 expression at a high level throughout the development would 
severely limit excitatory synapse development. We first tested this hypothesis by knocking 
down Arhgap12 in organotypic hippocampal slices and compared evoked AMPAr-EPSC on a 
CA1 pyramidal neuron expressing Arhgap12 sh#1 and an adjacent uninfected neuron at 
different stages of the development in vitro (4 DIV, 7-8 DIV and 13-14 DIV). Whole-cell patch-
clamp recordings revealed that neurons expressing Arhgap12 sh#1 indeed displayed the most 
profound potentiation of AMPAr-EPSC at 4 DIV and this effect gradually decreased when 
recording at later stages, with no changes observed at 13-14 DIV (Figure 4D). Conversely, when 
keeping elevated levels of ARHGAP12 throughout the development of hippocampal neurons, 
we observed significantly decreased AMPAr-mediated synaptic transmission, measured as a 
reduction in amplitude and frequency of mEPSCs (Figure S5A, B). The decreased AMPAr-
mediated transmission was also accompanied with a reduction in PSD95 density, further 
suggesting that ARHGAP12 can prevent excitatory synapse formation (Figure S5C).  
Together, our results indicate that endogenous ARHGAP12 dampens synaptic 
development by limiting the unsilencing of silent synapses and suggest that endogenous 
ARHGAP12 acts as a synaptic "brake" during hippocampal development.  
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Figure 4 Arhgap12 knockdown promotes hippocampal synaptic development by accelerating silent 
synapse unsilencing 
(A) Minimal stimulation assay. Representative plot of individual response at -60 mV and +40 mV with 
minimal stimulations in indicated conditions. 
(B) Failures of responses using minimal stimulation at -60 mV and +40 mV from uninfected neurons 
and Arhgap12 sh#1 infected neurons.  
(C) Percentage of silent synapses at different developmental stages of uninfected neurons and 
Arhgap12 sh#1 infected neurons. Data are shown as mean ± SEM; n = 11-14 from three independent 
experiments; *P<0.05, paired t-test. 
(D) Evoked AMPAr-mediated transmission recorded from CA1 pyramidal neurons infected with 
Arhgap12 sh#1 and uninfected neurons at different developmental stages. Data are shown as mean ± 
SEM; n = 11-15 for both groups at all time points, from three to four independent experiments; 
*P<0.05, paired t-test. 
See also Figure S5. 
 
 
Identification of Cdc42-interacting protein 4 (CIP4) as an ARHGAP12 interactor 
Next, to gain insights into the mechanisms by which ARHGAP12 modulates synapses, we 
sought to identify direct interactors of ARHGAP12 by performing a GAL4-based interaction 
trap screen in yeast (yeast two-hybrid system).  
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ARHGAP12 contains several protein motifs: a Src homology-3 (SH3) domain at its N-
terminus, two WW domains, and a Pleckstrin-homology (PH) domain, followed by a GAP 
domain shown to negatively regulate Rac1 GTPase 29. Full-length human ARHGAP12 and 
fragments containing different conserved domains were used as baits in the yeast two-hybrid 
screening (Figure 5A). Interestingly, four independent cDNAs matched the sequence of Cdc42-
interacting protein 4 (CIP4, also named thyroid hormone receptor 10 variant, TRIP10; Figure 
S7A) that harbors a highly conserved F-BAR (Fes-CIP4 homology-Bin/Amphyphysin/Rvsp) 
domain at the N-terminus and which has recently been implicated in neurite outgrowth 37, 
clathrin-mediated endocytosis, endosomal trafficking 38–40 and synaptic growth at the 
neuromuscular junction (NMJ) in Drosophila 41. We subsequently performed co-
immunopricipitation (co-IP) experiments to validate the interaction between ARHGAP12 and 
CIP4. Since none of the antibodies for CIP4 that we have tested to date were suitable for 
Western blot analysis and IP in vivo (data not shown, and 37), we coexpressed GFP-Arhgap12 
WT and Myc-Cip4 in HEK293T cells and carried out reciprocal co-IP experiments using an anti-
Myc and an anti-ARHGAP12 antibody. Indeed, ARHGAP12 specifically co-immunoprecipitated 
with CIP4 and vice versa (Figure 5B, C).  
 Next, we set out to identify the CIP4 binding region in ARHGAP12. Given that the positive 
clones from the yeast two-hybrid screening encompassed the first 156 amino acids (aa) of 
ARHGAP12 (Figure 5A), we reasoned that ARHGAP12 is likely to bind to CIP4 via its N-terminal 
domain. To test this hypothesis, we generated an ARHGAP12 deletion mutant lacking aa 1-
156 (Δ1-156aa) and repeated the co-IP experiment. We found that the Δ1-156aa mutant failed 
to bind CIP4. Since the first 156 aa of ARHGAP12 include an SH3 domain and this domain is 
known to be critical for protein-protein interactions, we reasoned that ARHGAP12 is likely to 
bind CIP4 via its SH3 domain. A deletion of the SH3 domain (ΔSH3) of ARHGAP12 was 
generated and tested for its ability to interact with full-length CIP4 in HEK293T cells using co-
IP. Surprisingly, the SH3 domain deletion mutant (ΔSH3) of ARHGAP12 was still able to bind 
CIP4, indicating that the SH3 domain of ARHGAP12 is not required for interacting with CIP4. 
Likewise, a point mutation leading to an inactivation of the GAP function of ARHGAP12 (R695Q) 
(Figure S6A; Nadif Kasri et al., 2009) did not affect the ARHGAP12-CIP4 interaction in vitro. 
Overall, these data indicate that ARHGAP12 can interact with CIP4 via its N-terminal domain 
(aa 1-156).  
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Figure 5 Interaction of ARHGAP12 with CIP4 
(A) Domain structure of ARHGAP12 and fragments used as “baits” in yeast two-hybrid screening. 
Presence of positive colonies using distinct baits was indicated with “+” or “-”.  
(B-C) Co-immunoprecipitation of ARHGAP12 and CIP4 in vitro. Protein extract from HEK293T cells co-
transfected with GFP-Arhgap12 and myc-Cip4 constructs for 24 hours was incubated with mouse IgG 
or an anti-Myc antibody (B) or an anti-ARHGAP12 antibody (C). The immunoprecipitates were analyzed 
by immunoblotting using indicated antibodies. n = 6. 
(D) Co-immunoprecipitation of ARHGAP12 mutants and CIP4 in vitro. Extract from HEK293T cells co-
transfected with myc-Cip4 and indicated mutants of Arhgap12 for 24 hours was incubated with an 
anti-CIP4 antibody. Immune complexes were immunoblotted with an anti-ARHGAP12 antibody. n = 3. 
 
 
Functional dissection of ARHGAP12 controlling synaptic structure and strength  
Previously ARHGAP12 has been shown to contain a GAP domain that negatively regulates the 
activity of Rac1 GTPase in non-neuronal cells 29. We confirmed that this is also the case in 
hippocampal neurons by performing Rac1 activity assay (Figure S6A).  
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Since ARHGAP12 also interacts with CIP4 via its N-terminal domain, which has been shown 
to play a role in clathrin-mediated endocytosis 38–40, we wondered whether these two distinct 
domains play separate roles affecting synaptic structure and function, respectively. As a first 
step toward addressing this question, we compared the effects of regulating dendritic spine 
morphology between ARHGAP12 WT and two mutants, Arhgap12_R596Q and Arhgap12_Δ1-
156aa. Spine structure analysis revealed that expression of the Arhgap12_R596Q mutant in 
CA1 pyramidal neurons failed to mimic the phenotype observed by expressing Arhgap12 WT, 
namely decreased spine density and volume compared to GFP control (spine density: GFP 
control: 4.62 r 0.51 spines/10 μm, Arhgap12 WT: 2.21 r 0.82 spines/10 μm, Arhgap12_R596Q: 
4.17 r 0.36 spines/10 μm; spine volume: GFP control: 273.72 r 57.27, Arhgap12 WT: 150.11 
r 52.73, Arhgap12_R596Q: 307.61 r 35.2, Figure 6A, B). Conversely, Arhgap12_Δ1-156aa 
expressing CA1 neurons displayed spine morphology similar to Arhgap12 WT expressing 
neurons (spine density: GFP control: 4.62 r 0.51 spines/10 μm, Arhgap12 WT: 2.21 r 0.82 
spines/10 μm, Arhgap12_ Δ1-156aa: 2.41 r 0.78 spines/10 μm; spine volume: GFP control: 
273.72 r 57.27, Arhgap12 WT:  150.11 r 52.73, Arhgap12_Δ1-156aa: 175.45 r 53.01; Figure 
6A, B). These data indicate that the GAP activity of ARHGAP12, but not its interaction with 
CIP4, is required to regulate dendritic spine morphology. To corroborate our data showing 
ARHGAP12 affects dendritic spine structure by acting on the Rac1 signaling pathway, we 
examined whether inhibiting Rac1 signaling could rescue the increased spine volume resulting 
from Arhgap12 knockdown by making use of the competitive inhibitor of Rac1 activation 
NSC23766 42. We found that NSC23766 (0.1 mM) treatment of Arhgap12 shRNA transfected 
hippocampal slices largely rescued the spine volume defects in Arhgap12 knockdown neurons. 
The mean spine volume did not significantly increase compared to control GFP expressed 
neurons (spine density: GFP control: 4.62 r 0.51 spines/10 μm, Arhgap12 sh#1: 5.06 r 0.62 
spines/10 μm, Arhgap12 sh#1 + Rac1 inhibitor: 4.34 r 0.75 spines/10 μm; spine volume: GFP 
control: 273.72 r 57.27, Arhgap12 sh#1: 443.69 r 52.30, Arhgap12 sh#1 + Rac1 inhibitor: 
251.54 r 73.82; Figure 6A, B). Moreover, we found that, as expected, treating neurons with 
NSC23766 resulted in decreased spine density and volume, and this treatment on Arhgap12 
overexpressed neurons did not cause additional effects on spine morphology (Figure S6B, C). 
Overall, these findings imply that the GAP activity of ARHGAP12, but not ARHGAP12-CIP4 
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interaction, is responsible for controlling dendritic spine morphology in CA1 pyramidal 
neurons via Rac1 GTPase signaling pathway. 
Given that CIP4 is involved in clathrin-dependent endocytosis, a mechanism that mediates 
internalization of most plasma membrane proteins including AMPArs 43, we speculated that 
the inhibitory effect of ARHGAP12 on AMPAr function could be due to involvement of the 
ARHGAP12-CIP4 complex in AMPAr endocytosis process. To directly evaluate the AMPAr 
endocytotic process, live-cell antibody feeding experiments were performed in 14 DIV primary 
hippocampal neurons transfected with GFP, Arhgap12 sh#1, Arhgap12 WT, Arhgap12_R695Q 
or Arhgap12_Δ1-156aa. We observed impaired GluA1 endocytosis in neurons expressing 
Arhgap12 sh#1. Both Arhgap12 WT and Arhgap12_R659Q significantly enhanced endocytosis 
of GluA1 compared to the GFP control condition, whereas Arhgap12_Δ1-156aa mutant, did 
not alter GluA1 endocytosis (Figure 6C). Functionally, overexpression of Arhgap12 WT 
decreased both mEPSC amplitude and frequency. Arhgap12_R695Q overexpression led to 
reduced mEPSC amplitude without affecting frequency, whereas Arhgap12_Δ1-156aa 
resulted in unaltered amplitude but reduced frequency (Figure 6D, E).  
66 
 
Δ
68
C
h
a
p
te
r 
3
65 
 
Δ
Δ
Δ
66 
 
 
Figure 6 ARHGAP12 regulates synaptic structure and function via distinct domains  
(A-B) Morphological analysis of dendritic spine density (A) and volume (B) of CA1 pyramidal neurons 
in indicated conditions. Data are shown as mean ± SEM; GFP: n = 15, Arhgap12: n = 9, 
Arhgap12_R695Q: n = 9, Arhgap12_Δ1-156aa: n = 8, Arhgap12 sh#1+NSC23766: n = 6, data pooled 
from three to four independent experiments; *P<0.05, **P<0.01, one-way ANOVA. 
(C) AMPA receptor endocytosis assay. (C1) Representative double-label images of internalized (green) 
and surface (red) AMPA receptor GluA1 subunit in low density 14 DIV hippocampal neurons in 
indicated experimental groups. (C2) Ratiometric analysis of the intensity of internalized GluA1 to 
surface GluA1 in indicated conditions. Data are shown as mean ± SEM; control: n = 34, Arhgap12 sh#1: 
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n = 20, Arhgap12: n = 15, Arhgap12_R695Q: n = 15, Arhgap12_Δ1-156aa: n = 15; data pooled from 
three independent cultures; *P<0.05, t-test. Scale bars, 10 μm. 
(D, E) Excitatory miniature events recorded from neurons biolistically transfected at 12 DIV with 
indicated constructs. Data are shown as mean ± SEM; GFP: n = 12, Arhgap12: n = 16, Arhgap12_R695Q: 
n = 11, Arhgap12_Δ1-156aa: n = 11; data pooled from three independent experiments; *P<0.05, 
*P<0.01, one-way ANOVA. 
See also Figure S6. 
 
 
Furthermore, based on the minimal interacting sequence (414-428 aa) in CIP4 that we 
obtained from our yeast two-hybrid screening (Figure S7A), we designed a small interfering 
peptide (PepA12-CIP4) to disrupt the ARHGAP12-CIP4 complex. A corresponding scrambled 
peptide was used as a control (Pepctrl). The peptides were conjugated to the cell-membrane 
transduction domain of the HIV-1 TAT protein (TAT), which allowed the peptide to cross the 
membrane of neurons. In HEK293T cells, we found that PepA12-CIP4 disrupted the ARHGAP12-
CIP4 interaction, whereas Pepctrl did not (Figure 7A). Additionally, we observed no effect of 
both Pepctrl and PepA12-CIP4 on surface NMDAr expression and Cdc42-CIP4 interaction (Figure 
S7B, C). Next we examined whether disrupting the ARHGAP12-CIP4 interaction influences 
GluA1 endocytosis. Live-cell antibody feeding experiments were performed in 14 DIV primary 
hippocampal neurons treated with Pepctrl or PepA12-CIP4 for 24 hours. Our results showed that 
PepA12-CIP4 significantly impaired AMPAr GluA1 subunit endocytosis compared to Pepctrl treated 
neurons (Figure 7B). Electrophysiologically, CA1 pyramidal neurons treated with PepA12-CIP4 
exhibited a significantly increased amplitude compared to Pepctrl treated neurons (Figure 7C), 
indicating that disrupting the interaction of ARHGAP12-CIP4 was sufficient to increase the 
amount of AMPArs accumulating at synapses, mimicking the effect of ARHGAP12 knockdown 
on AMPAr mediated transmission. Finally, to further exclude the possibility that the 
ARHGAP12-CIP4 interaction can regulate spine morphology, we imaged dendritic spine 
morphology of neurons treated with Pepctrl or PepA12-CIP4. No significant differences between 
two conditions were observed (Figure 7D). These results suggest that the ARHGAP12-CIP4 
interaction is responsible for controlling AMPA receptor endocytosis, but not for regulating 
spine morphology. 
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Figure 7 Disrupting ARHGAP12-CIP4 interaction impairs AMPAr endocytosis  
(A) HEK293T cells co-transfected with GFP-Arhgap12 and myc-Cip4 constructs were incubated with 
Pepctrl and PepARHGAP12-CIP4 with indicated concentrations for 24 hours. Interaction between ARHGAP12 
and CIP4 were examined using immunoblotting with an anti-ARHGAP12 antibody. n = 3. 
(B) AMPA receptor endocytosis assay. (B1) Representative double-label images of internalized (green) 
and surface (red) AMPA receptor GluA1 subunit in low density 14 DIV hippocampal neurons; (B2) 
Ratiometric analysis of the intensity of internalized GluA1 to surface GluA1 in Pepctrl and PepARHGAP12-
CIP4 conditions. Data are shown as mean ± SEM; Pepctrl: n = 18, PepARHGAP12-CIP4: n = 19; data pooled from 
three independent cultures; *P<0.05, t-test. Scale bar, 10 μm. 
(C) Excitatory miniature events recorded at 14 DIV from organotypic hippocampal slices treated with 
Pepctrl or PepARHGAP12-CIP4 for 24 hours. Data are shown as mean ± SEM; Pepctrl: n = 13, PepARHGAP12-CIP4: n 
= 12; data pooled from three independent experiments; *P<0.05, t-test. 
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(D) Morphological analysis of dendritic spine density and volume of CA1 pyramidal neurons treated 
with 10 μM pepctrl or 10 μM pepARHGAP12-CIP4 for 24 hours. Data shown as mean ± SEM; pepctrl: n = 7, 
pepARHGAP12-CIP4: n = 7 from three independent experiments; t-test. 
See also Figure S7. 
 
 
Together, our findings indicate that ARHGAP12 regulates spine morphology via its GAP 
activity and synaptic strength via its interaction with the F-BAR protein CIP4. 
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Discussion 
The molecular mechanisms that promote excitatory synapse formation and maturation 
have been extensively studied. However, the molecular events preventing precocious 
excitatory synapse development so that synapses form at the correct time and place 
are less well understood. Here we identified ARHGAP12, a previously uncharacterized 
Rac1-GAP in the brain, as a critical coordinator of synaptic structure and function in 
the developing rat hippocampus.  
ARHGAP12-Rac1 signaling in regulating spine morphology 
In the present study, we focused on hippocampal CA3-CA1 synapses, based on the prominent 
expression of ARHGAP12 in CA1 during early development. We found that overexpressing WT 
Arhgap12 resulted in reduced spine density and volume, and an increased percentage of 
immature spines in CA1 pyramidal neurons, whereas overexpressing the Arhgap12 GAP 
mutant failed to generate a similar phenotype. In addition, we showed that downregulation 
of Arhgap12 led to enlarged spine volume and this enlargement was successfully rescued by 
pharmacologically inhibiting overactive Rac1 signaling. These results strongly suggest that 
negatively regulating Rac1 signaling via ARHGAP12’s GAP activity is essential for maintaining 
normal dendritic spine structure at the CA3-CA1 synapse. These data agree with several other 
reports in which downregulation or overexpression of Rac1-GAPs increased or decreased 
spine size and density, respectively 18. For instance, overexpression of the Rac1 GAP, alpha 1-
chimaerin, resulted in a loss of spines by inhibiting the formation of new spines as well as 
promoting the pruning of existing spines 44,45. More recently, mice lacking the Rac-GAP Bcr 
and its relative Abr were shown to exhibit increased spine size and density 46.  
An intriguing aspect of our study is that ARHGAP12 exhibits a unique spatiotemporal 
profile, with an almost exclusive expression in CA1 and DG. Specific spatiotemporal profiles 
have been observed for numerous GEFs and GAPs and are believed to contribute to the 
specificity of Rho signaling in the brain 18. Our study thus unveils a vital role of ARHGAP12 in 
regulating spine structure via Rac1 signaling in CA1 and supports the hypothesis that Rho GEFs 
and GAPs cooperate in complimentary signaling pathways, so to spatially and temporally 
regulate Rho GTPase signaling during synapse remodeling 23  
73
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ARHGAP12-CIP4 interaction in regulating synaptic strength 
In this study, we found that knocking down Arhgap12 potentiated hippocampal CA3-CA1 
synapses, whereas Arhgap12 up-regulation led to a significant synaptic depression. 
Specifically, Arhgap12 knockdown increased AMPAr-mediated EPSCs and the frequency and 
amplitude of mEPSCs, indicating that reducing ARHGAP12 levels promoted synaptic 
expression of AMPArs. Due to the tight correlation between synaptic strength and spine size, 
the increase in synaptic strength could occur as a consequence of the changes in spine size 
47,48. Alternatively, ARHGAP12 could regulate synapse function independently of spine size. 
We found that the F-BAR containing protein CIP4 interacts with ARHGAP12. Similar to 
ARHGAP12, CIP4 is highly expressed during early cortical development, and CIP4 inhibits 
neurite formation by promoting lamellipodial protrusions 37 and restrains synaptic growth at 
the NMJ 41. We demonstrated that the interaction between ARHGAP12 and CIP4 involves the 
N-terminus of ARHGAP12 and is independent of its GAP activity. Importantly, CIP4 is recruited 
in clathrin-coated pits during clathrin-mediated endocytosis 38, implying a function for CIP4 in
this process. We showed that interrupting the ARHGAP12-CIP4 interaction, using a peptide
mimicking the ARHGAP12 binding site on CIP4, resulted in elevated AMPAr-mediated
transmission. In addition, interfering with the ARHGAP12-CIP4 interaction decreased the
endocytosis of GluA1 AMPAr subunits, leading to more synaptic AMPArs. Interestingly, we
found that the interaction between ARHGAP12 and CIP4 was not required for regulating spine 
morphology. This is somewhat different from the function of CIP4 at the NMJ in Drosophila,
where dCIP4 acts downstream of Cdc42 to activate the postsynaptic Wsp–Arp2/3 pathway to
restrain synaptic growth 41. Together these data suggest that by binding to CIP4, ARHGAP12
increases AMPAr endocytosis and thereby reduces synaptic strength. Several studies have
shown that events triggering changes spine morphology and insertion/removal of AMPAr
subunits are distinct. How these two events are kept in check so that changes in spine
morphology correlate with synaptic strength is still unclear. The GluA1 C-tail has been
proposed to play a critical role herein by linking both events 49. Our data unveil an interesting
model in which ARHGAP12 via its GAP activity, regulates spine structure, while by interacting
with CIP4, is able to modulate AMPAr-mediated synaptic transmission in the hippocampus.
Thus neurons might use an elegant mechanism to keep changes in spine morphology and
synaptic strength balanced, where ARHGAP12 signaling controls both actin polymerization
and AMPAr trafficking. Exactly how ARHGAP12 and CIP4 cooperate to increase AMPAr
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endocytosis still remains to be elucidated. It is possible that CIP4, similar to FBP17, affects 
AMPAr endocytosis by recruiting WASP and dynamin for vesicle initiation and scission 38.  
   
Synaptic maturation is restricted by ARHGAP12 during hippocampal development   
A characteristic hallmark of the developing brain is the presence of silent synapses, which 
contain NMDArs but lack AMPArs. Premature or delayed synapse unsilencing has been 
implicated in neurodevelopmental disorders, including ASD 50–52. Since ARHGAP12 is highly 
expressed during early postnatal stages and followed by a gradual decline in CA1, which 
mirrors the trend of robust synaptogenesis, it raises the possibility that the presence of 
ARHGAP12 might impede synaptic development. Our data showed that the potentiation of 
synaptic transmission, as a result of Arhgap12 downregulation, was the strongest at 4 DIV and 
gradually decreased with age. Conversely, when ARHGAP12 was maintained at a high level, 
synaptic development was impeded. We here thus unveil a potentially interesting positive 
feedback mechanism between synaptic activity and ARHGAP12 signaling, in the sense that 
synaptic activity is required for ARHGAP12 repression, and in turn, ARHGAP12 downregulation 
enhances the synaptic efficacy. Such a positive feedback relationship could play a key role 
during critical periods of synapse development, with too little activity preventing synapse 
development. Our data thus support the notion that ARHGAP12 is an intrinsic factor in the 
developmental program of synapses and functions as a synaptic “brake” during hippocampal 
development. Releasing the braking effect of ARHGAP12 at an inappropriate time might result 
in mistimed maturation of glutamatergic synapses and in a disrupted balance between 
excitation and inhibition in the hippocampus.  
Also noteworthy, several genes associated with ASD have now been identified to function 
like synaptic brakes to prevent precocious maturation of excitatory synapses. In particular, 
accelerated maturation of excitatory synapses in an early period of hippocampal development 
has been observed in a mouse model of human SYNGAP1 haploinsuffciency, leading to 
learning deficits 52. Similarly, accelerated maturation of glutamatergic synapse has been seen 
in a KO mouse model for MET receptor tyrosine kinase. HGF signaling through MET receptor 
activation prevents the maturation of silent synapses 53. This is of particular interest since 
ARHGAP12 was initially characterized as a transcriptional target of HGF in epithelial cells 29. In 
addition, MET is highly expressed in CA1 pyramidal neurons during late prenatal and early 
postnatal development 54–56, similar to the expression pattern of ARHGAP12. This raises the 
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intriguing possibility that ARHGAP12 might function downstream of MET signaling, in the 
developing hippocampus. Future experiments will have to determine if and how ARHGAP12 
participates in MET signaling during development.  
 
 
  
74 
 
76
C
h
a
p
te
r 
3
73 
 
74 
 
Experimental Procedures 
Virus production, Western blot, immunofluorescence, yeast two-hybrid and images analysis 
are described in Supplemental Experimental Procedures. 
 
Animals  
Wistar rats were housed per 2 or 3 animals on a 12-h light cycle in a temperature-controlled 
(21 ± 1°C) environment with ad libitum access to food and water. Rats were used at E18 or P6 
for primary neuronal cultures or organotypic hippocampal slices, respectively. All experiments 
involving animals were evaluated and approved by the Committee for Animal Experiments of 
the Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. 
 
Electrophysiology  
Whole-cell recordings in cultured slices were obtained with Multiclamp 700B amplifiers (Axon 
Instruments). To study the effects of ARHGAP12 on synaptic transmission, organotypic 
hippocampal slices were infected with lentiviruses expressing shRNAs on the same day of 
plating and recorded at indicated times after infection (4 DIV, 7 DIV, 13-14 DIV). To 
overexpress ARHGAP12, organotypic hippocampal slices were biolistically transfected at 5 DIV 
(for evoked EPSCs) or 12 DIV (for miniature EPSCs) using a Helios Gene Gun (Bio-Rad) and 
analyzed two days post-transfection. Whole-cell recordings were obtained simultaneously 
from an infected and an adjacent uninfected neuron in the CA1 region under visual guidance, 
using epifluorescence and transmitted light illumination. See Supplemental Experimental 
Procedures for details. 
 
Two-photon laser scanning microscopy  
Imaging was essentially performed as described previously 24.  
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Supplemental Data 
 
 
 
 
 
Figure S1 Localization of ectopic ARHGAP12 in hippocampal neurons (related to Figure 1). Left, 
representative confocal microscopy image of hippocampal neurons (21 DIV) expressing GFP-Arhgap12 
double-stained with synaptic markers Synapsin-I and PSD95. Right, high magnification images of the 
area indicated in the white box on the left panel. White arrows show sites of co-localization of 
ARHGAP12 and PSD95. Scale bars, 10 μm. 
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Figure S2 Evaluation of ARHGAP12 protein levels (related to Figure 2). (A1) Verification of Arhgap12 
shRNAs. Dissociated hippocampal neurons were either non-treated or infected at 1 DIV with pTRIP 
lentiviral vector coexpressing GFP and scrambled shRNA, Arhgap12 sh#1, #2 or #3. Eight days post-
transfection, cell extracts were prepared and analyzed by Western blot with an anti-ARHGAP12 
antibody. Expression of γ-TUBULIN was used as a loading control. (A2) Quantification of ARHGAP12 
expression. Data are shown as mean ± SEM, n = 3, *P<0.05, t-test). (B1) Immunofluorescence of 
ARHGAP12 in organotypic hippocampal slices biolistically transfected at 12 DIV with indicated 
constructs. Immunostaining experiments were performed two days post-transfection. (B2-B3) 
Quantification of immunofluorescence intensity in transfected neurons compared to adjacent non-
transfected neurons. Dashed lines indicate endogenous ARHGAP12. Data are shown as mean ± SEM; 
n = 9 for each group from three independent experiments; *P<0.05, ** P<0.01, *** P<0.001, t-test. 
Scale bar, 10 μm. 
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Figure S3 Effect of neuronal activity on ARHGAP12 expression and function (related to Figure 2). (A-
B) Quantification of spine volume (A) and density (B) for each experimental condition as indicated. 
Data are shown as mean ± SEM; GFP: n = 12, Arhgap12 sh#1: n = 8, MgCl2: n = 6, APV: n = 7; data pooled 
from three independent experiments; *P<0.05, one-way ANOVA. (C1) Developmental expression of 
ARHGAP12 with or without the presence of 100 μM APV. (C2) Quantification of ARHGAP12 expression. 
Data are shown as mean ± SEM; *P<0.05, two-way ANOVA. 
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Figure S4 GFP does not affect excitatory synaptic transmission and Arhgap12 knockdown does not 
alter inhibitory synaptic transmission (related to Figure 3). (A) Average AMPAr- and NMDAr-mediated 
EPSCs recorded simultaneously at 7 DIV from a CA1 pyramidal neuron infected with GFP and an 
adjacent uninfected neuron. Data are shown as mean ± SEM; n = 9 pairs from three independent 
experiments; paired t-test. (B) Normalized GABAr-mediated IPSCs simultaneously recorded from 
neighboring uninfected neurons and Arhgap12 sh#1 infected neurons. Data are shown as mean ± SEM; 
n = 9 pairs from three independent experiments; paired t-test. 
 
 
 
 
 
 
 
 
 
 
85
83 
 
 
Figure S5. Elevated Arhgap12 levels throughout hippocampal development depresses CA3-CA1 
excitatory synapses (related to Figure 4). (A-B) Primary hippocampal neurons were electroporated 
with GFP or GFP-Arhgap12 at 0 DIV. Miniature excitatory events (mEPSC) were recorded from 13 DIV 
control GFP and GFP-Arhgap12 transfected neurons (GFP: n = 22, GFP-Arhgap12: n = 25, from 4 
independent experiments; *P<0.05, t-test). (C1-C2) Immunostaining of PSD95 on GFP and GFP-
Arhgap12 transfected neurons. (C1) Representative images of PSD95 staining. Scale bar, 10 μm. (C2) 
Quantification of PSD95 density. Data are shown as mean ± SEM; n = 16-18 from three independent 
experiments; *P<0.05, t-test. 
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Figure S6 Regulation of ARHGAP12 on Rac1 activity and effect of inactivation of Rac1 signaling on 
GFP and Arhgap12 overexpressing neurons (related to Figure 6). (A) Normalized Rac1 activation signal 
for indicated experimental groups. Data are shown as mean ± SEM; n = 3; **P<0.01, t-test. (B-C) 
Quantification of spine volume (B) and density (C) for each experimental condition as indicated. Data 
are shown as mean ± SEM; GFP: n = 12, NSC23766: n = 9, Arhgap12+NSC23766: n = 8 from two 
independent experiments; *P<0.05, one-way ANOVA. 
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Figure S7 Overview of positive colonies matching CIP4 sequence in yeast two hybrid screening and 
effect of ARHGAP12-CIP4 interfering peptide on surface NMDAr expression and Cdc42-CIP4 
interaction (related to Figure 7). (A) “AA in gene CDS” indicates the amino acids sequence of CIP4 
interacting with ARHGAP12 in each colony; “appeared on day” indicates the days that colonies 
appeared in culture; “α-gal” and “β-gal” indicate the scores of each colony in galactosidase assays. (B1-
B2) Surface labeling of NR1 subunit in 15 DIV non-treated, 10 μM Pepctrl or 10 μM PepA12-CIP4 treated 
hippocampal neurons (B1) and quantification of average fluorescence intensity for indicated groups 
(B2). Data are shown as mean ± SEM, n = 16-18 from three independent experiments; one-way ANOVA. 
(C) Co-immunoprecipitation of Cdc42 and CIP4 in vitro. HEK293T cells co-transfected with GFP-Cdc42 
and myc-Cip4 constructs were treated with 10 μM Pepctrl or 10 μM PepA12-CIP4 for 24 hours. Protein 
extracts were incubated with mouse IgG or an anti-Myc antibody. The immunoprecipitates were 
analyzed by immunoblotting using an anti-Cdc42 antibody.  
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Supplemental Experimental Procedures 
Primary neuronal cultures and organotypic hippocampal slice cultures 
All media and reagents were purchased from Life Technologies. Dissociated hippocampal 
cultures were prepared form gestational day 18 fetal rats (Wistar). Pregnant rats were 
anaesthetized with isoflurane and sacrificed by cervical dislocation. Embryonic brains were 
dissected in ice-cold Hank’s buffer (HBSS without Ca2+ and Mg2+, 100 U/ml penicillin, 100 μg/ml 
streptomycin, 1x glutamax). The hippocampi were separated from the cortices and incubated 
with 0.025% trypsin for 15 min at 37°C. Neurons were mechanically dissociated in NeuroBasal 
medium containing 10% FCS and B27 supplement (Invitrogen) using fire-polished Pasteur 
pipettes. The cell suspension was filtered through a 70 μm cell strainer (BD Falcon) and plated 
on poly-D-lysine (Invitrogen) pre-coated glass coverslips in 12-wells plates at a density of 
50.000 neurons per well. Medium was replaced after 4 hours with Neurobasal medium 
containing B27 supplement, and 1x GlutaMax. Neurons were maintained in a 5% CO2 
humidified 37°C incubator. Half of the medium was refreshed every three to four days. 
Organotypic hippocampal slices were prepared from P6 rats as described previously 1  and 
maintained in a 5 % CO2 humidified 35°C incubator on slice culture medium (pH 7.3, osmolarity 
317-325) consisting of MEM, 20 % horse serum, 1 mM L-Glutamine, 1 mM CaCl2, 2 mM MgSO4, 
0.25 mg Insulin, 1.25 mM Ascorbic acid, 12.87 mM D-Glucose, 5.25 mM NaHCO3 and 30 mM 
Hepes. Medium was refreshed every two days. For knockdown condition, slices were infected 
with Arhgap12 shRNAs at 0 DIV and used for electrophysiology experiments on indicated days. 
To infect hippocampal slice cultures, concentrated viral solution was injected into the CA1 
pyramidal cell layer using a pico-liter injector (Warner instruments). To perform functional 
analysis in Arhgap12 overexpression condition, slices were biolistically transfected at 5 DIV 
(for evoked EPSCs) or 12 DIV (for miniature EPSCs) and recorded two days post-transfection. 
For morphological studies, slices were biolistically transfected at 12 DIV with indicated 
constructs using a Helios Gene Gun (Bio-Rad) and imaged two days post-transfection lively 
with two-photon microscopy (Leica TCS SP5).  
 
DNA constructs, cloning and virus production 
The GFP-Arhgap12 wild type construct was described previously 2 and was a generous gift of 
Dr. M. Furuse. The Arhgap12_R596Q mutant was generated by introducing a point mutation 
(R695Q) into the catalytic domain of ARHGAP12 using the Quick Change system (Stratagene). 
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Arhgap12_ΔSH3 and Arhgap12_Δ1-156aa mutants were generated by PCR-based methods 
from the GFP-Arhgap12 wild type construct. For RNAi knockdown experiments, the pSuper 
system (Oligoengine) was applied to target rat Arhgap12 mRNA using expression of short 
hairpin RNAs (shRNAs) (Arhgap12 sh#1: Forward primer, 5’-
GATCCCCGGACCAGAAGGAGCTTAAATTCAAGAGATTTAAGCTCCTTCTGGTCCTTTTTA-3’; reverse 
primer,  5’-
AGCTTAAAAAGGACCAGAAGGAGCTTAAATCTCTTGAATTTAAGCTCCTTCTGGTCCGGG-3’; 
Arhgap12 sh#2:  Forward primer, 5’-
GATCCCCCCAGTCATATACACTGGATAATTCAAGAGATTATCCAGTGTATATGACTGGTTTTTA-3’; 
reverse primer, 5’-
AGCTTAAAAACCAGTCATATACACTGGATAATCTCTTGAATTATCCAGTGTATATGACTGGGGG-3’). 
Myc-CIP4 construct was a kind gift of Dr. (E. Dent). Lentiviruses were generated by 
cotransfecting HEK-293T cells with FUGW plasmids containing shRNAs, the HIV-1 packaging 
vector Δ8.9, and the VSVG envelope glycoprotein vector, using calcium phosphate co-
precipitation method. HEK293T cells were maintained in a 5% CO2 humidified 37°C incubator 
and the media was replaced 5 hours after cotransfection. Supernatants of culture media were 
collected 48h after transfection and centrifuged at 21.000 RPM to concentrate the virus. 
Viruses were resuspended in HBSS without Ca2+ and Mg2+ (Life technologies). Viral stocks were 
aliquoted and stored at -80°C until use. 
 
Immunofluorenscence  
Immunofluorescence staining of hippocampal slices was conducted according to a previously 
described procedure with modifications 3,4. For staining organotypic slices, indicated 
constructs were biolistically delivered at 12 DIV and fixed at 14 DIV with ice-cold 4% 
paraformaldehyde/ 4% sucrose in PBS. For hippocampal slices from postnatal days 20 rats, 
brains were fixed, embedded in low melting agarose (3%) and then being sectioned into 60 
μm sections using a microtome (Leica VT-1000S). Free-floating sections or fixed organotypic 
slices were incubated overnight with blocking buffer containing 5% normal goat serum 
(Invitrogen), 5% normal donkey serum (Sigma), 5% horse serum (Sigma), 1% glycine (Sigma), 
1% lysine (Sigma) and 0.4% Triton X-100, permeabilized, and incubated overnight with anti-
ARHGAP12 (NBP1-91678, Novus Biologicals), anti-NeuN ( ABN91, Millipore) and anti-MAP2 
(188004, Synaptic system) primary antibodies, followed by incubation with Alexa-488, Alexa-
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568 or Alexa-647 conjugated secondary antibody (Invitrogen) in blocking buffer. Sections were 
mounted onto slides with fluorescence mounting medium containing 406-diamidion-2-
phenylindole (Dako, Carpinteria, California, USA). Dissociated hippocampal neurons 
electroporated with GFP or GFP-Arhgap12 at DIV 0 were fixed in 4% paraformaldehyde 
solution at DIV 21, permeabilized with 0.2% Triton X-100 in PBS, and stained with the following 
primary antibodies: anti-PSD95 (MA1-045, Thermo Scientific) and anti-Synapsin-1 (AB1543P, 
Bio-Connect). Following secondary antibodies were used: Alexa-568 and 647 (Invitrogen). 
Cells were imaged using an LSM 510 confocal laser-scanning microscope (Zeiss) with a 
63x/1.40 Plan-Apochromat objective or imaged with Axio Imager Z1 (Zeiss, Basel, Switzerland) 
equipped with a camera (AxioCam MRm; Zeiss). Images were processed using Axiovision Rel 
(V.4.6) and analysed using ImageJ (NIH, Bethesda, Maryland, USA). For surface labeling NR1 
receptors in peptides treated hippocampal neurons, an anti-NR1 antibody (Biolegend) 
recognizing the extracellular region of NR1 subunit was used to feed 15 DIV neurons at 37°C 
for 1h, followed with fixation, blocking and incubating with an secondary antibody without 
permeabilization. 
 
Western blotting 
Rat hippocampal tissue or cell culture were collected and homogenized in ice-cold RIPA buffer. 
Lysates were then heated at 95°C for 10 min. Equal amounts of protein samples (50 μg) were 
fractionated on 4%-15% precast SDS-PAGE gels (Bio-Rad) then blotted to nitrocellulose 
membrane (Bio-Rad). Membranes were subsequently incubated for 1h at room temperature 
in 5% milk in PBS-Tween to prevent non-specific binding. Primary antibodies used were: anti-
ARHGAP12 (Abvona), anti-PSD95 (Thermo Scientific), or anti- Υ-TUBULIN (Sigma) as loading 
control.  Secondary antibodies used were: goat anti-mouse HRP (Jackson Immuno Research 
Laboratories) and goat anti-rabbit (Invitrogen). Images were acquired with ChemiDocTM 
imaging system (Bio-Rad). 
 
Peptides 
The sequences of pepARHGAP12-CIP4 and pepctrl are: NH2-GRKKRRQRRR-ahx-DSLGRTEEARNSLV-
OH and NH2-GRKKRRQRRR-ahx-EAETRVLSNRGDSL-OH.  The human immunodeficiency virus-
type 1 Tat sequence 5 was fused to the peptides to aid delivery into the cell. Purified peptides 
(>90%) were obtained from Chinapeptides. 
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Electrophysiology 
Whole-cell recordings in organotypic slices and primary hippocampal neurons were obtained 
with Multiclamp 700B amplifiers (Axon Instruments). The recording chamber was perfused 
with artificial cerebrospinal fluid (ACSF) containing 119 mM NaCl, 2.5 mM KCl, 4 mM CaCl2, 4 
mM MgCl2, 26 mM NaHCO3, 1 mM NaH2PO4, 11 mM glucose, 0.1 mM picrotoxin, 4 μM 2-
chloroadenosine (pH 7.4), and gassed with 5% CO2/95% O2. Recordings were made at 30◦C. 
Patch recording pipettes (4–7 MΩ) were filled with intracellular solution containing 115 mM 
cesium methanesulfonate, 20 mM CsCl, 10 mM HEPES, 2.5 mM MgCl2, 4 mM Na2ATP, 0.4 mM 
Na3GTP, 10 mM sodium phosphocreatine, and 0.6 mM EGTA (pH 7.25, Osm 285-295). Evoked 
responses were induced using bipolar electrodes (FHC) placed on Schaffer collateral pathway 
(0.1 Hz). Responses were recorded at both -60 mV (for AMPAr-mediated responses) and +40 
mV (for NMDAr-mediated responses). NMDAr-mediated responses were quantified as the 
mean between 60 and 65 ms after stimulation. Evoked IPSCs were recorded in the presence 
of 6-Cyano-7-nitroquinoxaline-2, 3-dione (CNQX, 5 μM) and D-(-)-2-Amino-5-
phosphonopentanoic acid (D-APV, 100μM). Cells were excluded if the access resistance 
exceeded 25 MΩ. All data are reported as mean ± SEM. Statistical significance was determined 
by the paired Student’s t-test (for paired recordings).  
Miniature post-synaptic excitatory currents (mEPSCs) on primary hippocampal neurons and 
organotypic slices were recorded at -60 mV in ACSF containing 2 mM CaCl2 and 1 mM MgCl2 
at 32°C in the presence of 1 μM TTX and 0.1 mM picrotoxin. 10 min of recordings from each 
cell were acquired at 5 kHz, filtered at 2 kHz and analyzed using Mini Analysis Program 
(Synaptosoft).  
Paired pulse ratio was recorded in the presence of 0.1 mM picrotoxin and calculated as 
Peak2/peak1 after correcting for any residual current at the second pulse. All recordings were 
performed by stimulating two independent synaptic inputs. Results from each pathway were 
averaged and counted as n = 1.  
Failure rate experiments were performed using minimum stimulation. Failure rate was 
calculated as a percentage of failed evoked responses over 50 sweeps at a holding potential 
of -60 and +40 mV. We used the peak amplitudes of individual responses as the criterion for 
defining success or failure. The peak amplitudes of each response were measured in Clampfit 
(Axon). We used a threshold (10 pA for responses at -60 mV and 20 pA for responses at +40 
mV) as a cutoff criterion. Responses with a peak amplitude above the threshold were counted 
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as success. The success trials had a clear response above the baseline and all displayed kinetics 
in line with evoked responses. The percentage of silent synapses was calculated as 1-(LN 
failure rate -60mV)/(LN failure rate +40 mV) 6.  
To record surface AMPAr responses, AMPA (1 μM, Tocris Bioscience) was applied for 10 min 
and holding current (Vhold=-60 mV) was measured every 30s. To assess the composition of 
GluA2-lacking AMPA receptors, rectification indexes were calculated by obtaining the ratio of 
mean evoked AMPAR responses at -60 mV divided by mean responses at +40 mV. 
Yeast two hybrid screening 
The GAL4-based yeast two-hybrid system (HybriZAP, Stratagene, La Jolla, USA) was used for 
identifying protein-interaction partners of ARHGAP12. Full-length human ARHGAP12 and 
several truncations containing different functional domains of ARHGAP12 (Figure 5), fused to 
a DNA-binding domain (GAL4-BD), were used as a bait for screening a human oligo-dT primed 
fetal brain cDNA library. The yeast strain PJ69-4A, which carried the HIS3 (histidine), ADE2 
(adenine), MEL1 (α-galactosidase) and LacZ (β-galactosidase) reporter genes, was used as a 
host. Interactions were analyzed by assessment of reporter gene activation via growth on 
selective media (HIS3 and ADE2 reporter genes), α-galactosidase colorimetric plate assays 
(MEL1 reporter gene), and β-galactosidase colorimetric filter lift assays (LacZ reporter gene). 
Protein interactions were evaluated on the basis of growth on selective media and staining in 
α- and β-galactosidase activity assays.  
Co-immunoprecipitations 
Precleared HEK293T cells lysates co-transfected with Myc-Cip4 and GFP-Arhgap12 WT, 
Arhgap12 mutants or GFP-Cdc42 for 24 hours were incubated with mouse IgG (eBioscience), 
anti-myc (Abcam) or anti-ARHGAP12 (Abvona) antibodies (2.5 μg/ml lysate) at 4°C for 1h. 
Peptides were added on the same day of transfection. Dynabeads® Protein G (50 μl per 
sample, Invitrogen) were then added and incubated for 1h at 4°C under gentle rotation. 
Samples were washed three times with lysis buffer (20 mM Tris, 150 mM NaCl, 2 mM EDTA, 1 
mM DTT and protease inhibitor, pH7.4). Co-immunoprecipitated proteins were detected by 
Western blotting with anti-ARHGAP12 or anti-myc antibodies. 
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AMPA receptor endocytosis assay 
Endocytosis assay was performed as previously described 7,8 with modifications. Briefly, living 
primary hippocampal neurons were first labeled with anti-GluA1 antibody (Millipore). 
Internalization of the labeled GluA1 subunits was then allowed for 2 hours at 37°C. After 
fixation with 4% paraformaldehyde and blocking with 5% BSA, surface-labeled GluA1 subunits 
were exposed to Alexa-568 secondary antibody (Invitrogen). After washing, the remaining 
surface GluA1 subunits were incubated with unlabeled secondary antibody at a concentration 
of 0.13 mg/ml overnight to saturate surface anti-GluA1 antibodies. Neurons were then 
permeabilized and incubated with Alexa-647 secondary antibody to label internalized GluA1 
subunits. GluA1 endocytosis was calculated by dividing the intensity of internalized GluA1 by 
the intensity of surface GluA1 using imageJ (I647/ I568).  
Two-photon laser scanning microscopy 
Hippocampal slices were biolistically transfected at 12 DIV with indicated constructs and 
neurons were imaged 2 days after transfection. Experiments were performed at 30°C in 
physiological ACSF (119 mM NaCl, 26 mM NaHCO3, 1 mM NaH2PO4, 11 mM D-glucose, 2.5 mM 
KCl, 2 mM CaCl2, 1 mM MgCl2, and 1.25 mM NaHPO4) gassed with 5% CO2 and 95% O2.  Before 
TPLSM imaging, transfected/infected CA1 pyramidal neurons were identified by 
epifluorescence illumination. High-resolution three-dimensional image stacks were collected 
on a laser-scanning microscope (Leica TCS SP5). The light source was a mode-locked 
Ti:sapphire laser (Coherent Chameleon, USA) running at 910 nm. We used an Olympus 20X1.0 
numerical aperture objective. Each optical section was resampled three times and was 
captured every 0.5 μm. Images were taken from regions on apical dendrites, which were 
typically about 100 μm away from the soma and covered 150-200 μm in length. A minimum 
of 500 spines were analyzed per condition for all comparative studies, sister cultures were 
used.  
TPLSM Image display 
All images displayed in the manuscript are data from consecutive stacks displayed using a 
maximum value projection. At any given x-y coordinate, the maximum pixel value in that Z- 
column is displayed in the two-dimensional image. Ratio images are displayed for two-channel 
data (green/red; i.e., ARHGAP12/volume) and mapped in pseudocolor with red representing 
92 
94
C
h
a
p
te
r 
3
91 
μ
μ μ
92 
a high ratio and blue a low ratio. Image analysis was conducted on raw data using full Z-stacks 
as discussed below.  
TPLSM Quantitative image analysis 
Images were analyzed as previously described 9. Briefly, spines were analyzed using custom 
software written in MatLab. All analyses were conducted blind to the constructs being 
expressed. For each experiment, projection images of 40-60 consecutive z-series sections 
were generated for each cell or each time point.  
For spine density and volume experiments spines were identified using green 
fluorescence channel and rectangular regions of interest (ROIs) were manually positioned to 
fully cover each spine. Spine density was calculated as the number of manually counted spines 
divided by dendrite segment length. Background-subtracted integrated fluorescence was 
taken as a measure for spine volume after normalizing to mean fluorescence at soma and 
large apical dendrite. No effort was made to analyze spines emerging below or above the 
dendrite, because the TPLSM resolution of these is compromised. It is also possible that many 
small structures were not detected, although point spread function limited structures were 
observed. Spine density and size values were compared using an unpaired two-tailed 
Student’s t- test. Significance was set at p < 0.05.  
For quantifications of ARHGAP12 spine enrichment, spines were identified using the 
dsRed channel and ARHGAP12 signal was identified using the green fluorescence channel. 
Spine ROIs were manually positioned to fully cover each spine, and dendrite ROIs were placed 
at the base of each spine centered on the dendrite with approximately the same area as the 
corresponding spine ROI. Enrichment of ARHGAP12 in spines is defined as (integrated spine 
green/integrated spine red fluorescence)/(mean dendrite green/mean dendrite red 
fluorescence). This approach is used as a relative means of determining enrichment. Thus, our 
“enrichment index” is a measurement of the relative concentration of ARHGAP12 in the spine 
(compared to dendritic regions), and is independent of spine size.  
Rac1 activation assay 
To assay Rac1 activity in cells, we used a luminescence-based G-LISA. Rac1 activation assays 
were executed following the manufacturer's instructions (Cytoskeleton. BK128). Briefly, 
primary hippocampal neurons at 0 DIV were infected with lentivirus expressing GFP control, 
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Arhgap1 sh#1, sh#2 or electroporated with WT Arhgap12 or Arhgap12_R695Q and lysed at 7 
DIV in the provided lysis buffer. Lysates were centrifuged at 13,200 rpm for 15 min at 4°C. The 
supernatants, each containing a total of 25-35 μg of proteins, were transferred into wells of a 
microtiter plate coated with Rac1 binding protein, and equal volumes of ice-cold binding 
buffer were added to each well. The microtiter plate was shaken on a cold orbital microtiter 
plate shaker (300 rpm) for 30 min at 4°C, solution was removed from wells, and the wells were 
incubated with diluted anti-Rac1 primary antibodies followed by secondary antibodies on a 
microtiter plate shaker (300 rpm) at RT for 45 min each. The plate was incubated with an HRP 
detection reagent for 15 min at 37°C, and after addition of an HRP stop buffer, the absorbance 
was immediately recorded at 490 nm.  
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Abstract 
Recently, we marked TRIO for the first time as a candidate gene for intellectual disability (ID). 
Across diverse vertebrate species, TRIO is a well-conserved Rho GTPase regulator that is highly 
expressed in the developing brain. However, little is known about the specific events regulated 
by TRIO during brain development and its clinical impact in humans when mutated. Routine 
clinical diagnostic testing identified an intragenic de novo deletion of TRIO in a boy with ID. 
Targeted sequencing of this gene in over 2,300 individuals with ID, identified three additional 
truncating mutations. All index cases had mild to borderline ID combined with behavioral 
problems consisting of autistic, hyperactive and/or aggressive behavior. Studies in dissociated 
rat hippocampal neurons demonstrated the enhancement of dendritic formation by 
suppressing endogenous TRIO, and similarly decreasing endogenous TRIO in organotypic 
hippocampal brain slices significantly increased synaptic strength by increasing functional 
synapses. Together, our findings provide new mechanistic insight into how genetic deficits in 
TRIO can lead to early neuronal network formation by directly affecting both neurite 
outgrowth and synapse development.  
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Introduction 
Intellectual disability (ID), defined as an IQ of 70 or lower, has an estimated prevalence of 2- 
3% in the population 1. The genetic etiology of ID is highly heterogeneous, with to date 
approximately >700 genes known to be associated with this common disorder 2, the majority 
of which are very rarely mutated. Novel sequencing approaches, such as massive parallel 
sequencing, have proven to be successful in identifying novel genes for Mendelian disorders 
3. Especially family-based whole exome sequencing (WES) in proband and parents has been 
instrumental to identify de novo pathogenic variants in sporadic cases with ID, thereby 
increasing the diagnostic yield in patients with severe ID (IQ<50) to up to 36% 4–10. For mild 
and borderline ID, however, family-based sequencing is more complex as the distinction 
between a normal or a mildly affected parent can be difficult to make. This complicates the 
interpretation of variants from family-based WES as the phenotype can also be the result of 
inherited variants. To determine the role of mutations in candidate ID genes in individuals 
with ID, it is necessary to find additional individuals with a mutation in the same gene and a 
comparable phenotype. Furthermore, interpretation can be supported by functional studies 
to investigate the mutational effect on protein function. Recently, we marked TRIO [MIM 
601893; NM_007118.2] for the first time as one of these candidate genes for ID, based on the 
identification of two potentially pathogenic de novo missense mutations in this gene in 
independent individuals with severe ID 6. Both individuals, however, also carried a second de 
novo mutation in a known ID gene, TCF4 and another candidate ID gene, GFPT2, respectively, 
complicating a straightforward interpretation of the contribution of the TRIO mutation to the 
patients' phenotype 6,11. In a routine diagnostic setting using a genomic microarray, we also 
identified an individual with mild developmental delay carrying an 235 kb intragenic de novo 
deletion, disrupting TRIO 12  (chr5:14160447-14395478 (hg19)). Finally, seven de novo 
mutations were found in TRIO in the context of large scale sequencing projects focused on 
various neurodevelopmental conditions, including ID, epilepsy and autism 8,13,14. Whereas 
these seven de novo mutations were not reported as conclusive cause of disease, they do 
support a possible role for TRIO in the development of ID (Fig. 1B).  
 TRIO is a large protein encoded by 57 coding exons (3097 amino acids) and containing 
several domains, including an N-terminal SEC14 domain, several spectrin repeats, two Dbl-
homology-Pleckstrin-homology (DH-PH) Rho-GEF units, an Ig-like domain, and a C-terminal 
serine/threonine kinase domain (Fig. 1C). The serine/threonine kinase domain is presumed to 
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be active but quite selective; both DH-PH Rho-GEF domains are enzymatically active 15,16. The 
first DH-PH domain has been shown to activate Rac1 and RhoG, whereas the second DH-DP 
domain activates RhoA 17,18. Rho GTPases regulate changes in cell morphology in response to 
many factors including stimulation by extracellular ligands. They are activated by guanine 
exchange factors (GEF) catalyzing GDP dissociation and allowing the binding of GTP 19. 
Interestingly, Rho GTPase signaling pathways have been identified as a major hub-signaling 
pathway in ID, affecting synaptic structure and function 20,21. In Drosophila, TRIO has been 
shown to be involved in axon guidance and dendritic arborisation 22–24 during neuronal 
development. Additionally, TRIO is required for axonal growth in vitro and in vivo 25–27 and 
may contribute to the regulation of cell-cell contact 28,29. Yet, surprisingly little is known about 
the function of TRIO in early dendrite formation and synaptic function in the mammalian 
system 20. 
Here we report the identification of 4 cases with intragenic truncating mutations in TRIO, 
presenting with mild to borderline ID combined with behavioral problems consisting of autistic, 
hyperactive and/or aggressive behavior. Additionally, we show that during early 
neurodevelopment TRIO negatively regulates neurite outgrowth and synaptic strength by 
interfering with AMPAr endocytosis.  
 
Results  
Identification of individuals with mutations in TRIO 
Based on the identification of multiple de novo mutations affecting TRIO, we decided to 
perform targeted sequencing for TRIO in >2300 patients with ID using molecular inversion 
probes (Materials and Methods) 30. Filtering for putative loss-of-function mutations (initiator 
codon; nonsense; frameshift; canonical splice sites), we identified three additional TRIO 
truncating mutations (Fig. 1C), including one de novo nonsense mutation, c.4128G>A, 
predicted to result in p.(Trp1376*), in a 10 year old boy; a de novo frameshift mutation, 
c.3752del, predicted to result in p.(Asp1251Valfs*11) in a 35 year old woman; and a nonsense 
mutation, c.649A>T leading to p.(Arg217*) in a 20 year old male. The latter mutation was 
inherited from a similarly affected father (Supplementary Figure 1). This family also has a 
second child with learning difficulties and behavioral problems, who did not show the 
mutation upon segregation analysis, suggesting that his phenotype may have another (genetic 
or environmental) origin. A third, unaffected brother, did not show the variant either. DNA of 
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a fourth brother, the grandparents, and/or the 13 siblings from the father, was unavailable for 
testing. All these individuals, however, appeared to be normal.  
As also de novo missense mutations have been implicated in ID 6, we subsequently 
selected for rare, possible pathogenic (CADD score ı 20), missense mutations in TRIO 
detected in our cohort. This analysis yielded seven missense variants (supplemental table 1), 
for which three could be tested for segregation in parental samples. Two of them appeared 
inherited from an unaffected parent, whereas the other was also identified in a father with 
borderline ID and behavioral problems, similar to his child. For the remaining four missense 
variants parental samples were not available. As from these data the impact of (de novo) 
missense mutations cannot unambiguously be assessed, we decided to further focus on the 
loss-of-function aspects of TRIO. 
De novo truncating mutations have not been observed in over 2,000 healthy controls 14, 
but 13 different loss-of-function variants are reported in ExAC, a large databases collecting 
NGS variants as proxy for the general population (Supplementary Table 2)( URL: 
http://exac.broadinstitute.org [November 2015]). Notably, only two of 13 have been observed 
more than once (highest minor allele frequency 3.11E-04). These two variants represent a 
single base deletion- and duplication at the same genomic location, in a homopolymer stretch, 
potentially suggesting a sequencing and/or mapping artifact rather than the true nature of the 
reported variant. Comparison of the observed de novo mutation frequency of TRIO in ID to 
the gene specific de novo mutation rate 31 however indicates that we observed more de novo 
mutations in our ID cohort than expected based on chance alone (Exact Poisson Test, 
p<0.005). 
In total, we identified 5 individuals from 4 families with a truncating mutation of TRIO, 
suggestive for loss of TRIO function. The clinical details for these four families are shown in 
Table 1. To avoid reporting inherited familial traits, the father of individual 2, who also had 
learning difficulties and behavior problems, was not included in this table. In summary, all of 
the index cases (age range 7-35 years) showed mild to borderline ID (IQ range 68-81) with 
autistic, hyperactive and aggressive behavioral problems. All individuals attended special 
education and needed special therapy to improve their language and motor development. 
Other observed features were recurrent infections (3/4 individuals), micrognathia (3/4), minor 
hand abnormalities (4/4), microcephaly (2/4), or low normal head circumference (2/4). No 
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congenital abnormalities were observed and only mild facial dysmorphisms were noted (Fig. 
1A).   
 
 
Figure 1 Individuals with loss-of-function TRIO mutations. 
(A) Frontal and lateral photographs of individual 1 with the deletion disrupting TRIO and individuals 2, 
3 and 4 with loss-of-function mutations in TRIO. Only mild facial dysmorphisms were observed.  
(B) Schematic overview of the 235kb de novo deletion on chromosome 5, partially disrupting TRIO in 
individual 1. 
(C) Schematic overview of TRIO, including the known domains (N-terminal SEC14 domain, several 
spectrin repeats, two Dbl-homology-Pleckstrin-homology (DH-PH) Rho-GEF units, Ig-like domain, and 
C-terminal putative serine/threonine kinase domain). The positions of the three identified mutations 
in individuals 2, 3 and 4 (p.Trp1376*, p.Asp1251Valfs*11 and p.(Arg217*) are depicted. 
 
 
Developmental expression of TRIO and its role in neurite outgrowth  
To find supportive evidence for TRIO as underlying cause in the phenotypes observed in our 
individuals, we investigated the neuronal function of TRIO in mammalian cells by examining 
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the expression of TRIO during rat hippocampal development. Western blot analysis of protein 
extracts revealed that full length TRIO is expressed during the early postnatal (P) period, but 
rapidly decreases after postnatal (P) day 11 (Fig. 2A, B). The rapid reduction in TRIO during 
postnatal development was further confirmed by measuring Trio mRNA expression (Fig. 2C). 
This decreased expression of TRIO is consistent with previous results 32 and suggests a role for 
TRIO in early neuronal development.  
To study the function of endogenous TRIO during early neuronal development, we 
designed short hairpin RNAs (shRNAs) targeting the spectrin repeat region of Trio, a region 
that is present in most of the alternately spliced Trio transcripts  33. The efficiency of Trio 
shRNA#1 and #2 was verified by co-expression with a vector encoding myc-TRIO (full length) 
in HEK293 cells (Fig. 2D). Dissociated rat hippocampal neurons were nucleofected at days in 
vitro (DIV) 0 with either a Trio shRNA or a scrambled shRNA control; expression of DsRed, 
which is encoded by the same vector, allowed identification of transfected cells and 
assessment of neuronal morphology. We first evaluated whether TRIO contributes to axon 
specification in early development by immunostaining neurons with a monoclonal antibody 
against Ankyrin G, which localizes to the axon initial segment 34. A single Ankyrin G-positive 
process was identified in the control group and in the Trio knock-down groups at DIV4 and 
DIV7 (Fig. 2E), indicating that axon polarity is not affected by the absence of endogenous TRIO. 
Next, we examined dendritic arbor formation. Compared to control neurons, expression of 
Trio shRNAs significantly increased both the number of primary dendrites and branch points 
observed at DIV4 and at DIV7 (Fig. 2E, F). Similar results were obtained at DIV2 (data not 
shown). These results demonstrate that endogenous TRIO limits dendrite formation, without 
affecting the establishment of axon polarity. Kalirin, a TRIO orthologue with 64% identical 
protein structure, is emerging as a key regulator of structural and functional plasticity. 
Interestingly, Kalirin has been reported to exhibit the opposite effect, stimulating both 
dendritic outgrowth and branching at this stage of neuronal development 35.  
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Figure 2 Developmental expression of TRIO and its role in neurite outgrowth.  
(A) Rat hippocampi were collected at the indicated ages; equal amounts of protein (50 μg) were 
subjected to Western blot analysis and representative blots are shown.  
(B) Quantification of Trio protein levels at different postnatal ages, normalized to the levels at P1 (n=3).  
(C) Quantification of Trio mRNA levels using Q-PCR at different postnatal ages (n=3).  
(D) 293 cells co-transfected with vectors encoding MYC-TRIO and Trio shRNA #1 and #2 were harvested 
after 24 h. Western blot analysis using a MYC antibody demonstrated that both Trio shRNA #1 and #2 
efficiently reduced Trio expression.  
(E) Rat hippocampal neurons nucleofected at the time of plating with a control (scrambled) shRNA or 
Trio shRNA #1 or #2 were fixed and analyzed at the indicated times. shRNA transfected neurons were 
identified by DsRed co-expression; axon initial segments were identified by staining for Ankyrin G; 
representative images at DIV7 are shown. Scale bar, 50 μm.  
(F) Quantification of primary neurites and branch points at DIV4 and DIV7. Neurons expressing Trio 
shRNAs exhibited more primary neurites and more branch points than neurons expressing the control 
shRNA. Five separate experiments were performed; 20-30 neurons per group per experiment were 
counted. **p<0.01 with respect to the control (scramble) shRNA vector.   
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Post-synaptic TRIO regulates synaptic transmission  
Previous proteomics studies of adult tissue have shown that TRIO is present at both the human 
and mouse post-synaptic density (PSD) 36, suggesting that TRIO functions at this site. In 
addition, the major isoform of Kalirin found in the adult nervous system has been shown to 
play a critical role in synaptic transmission, specifically through the regulation of ionotropic 
AMPA receptor (AMPAr) 37 and NMDA receptor (NMDAr) 38 trafficking. Modifications in the 
number and/or function of glutamate receptors is a core mechanism of regulating synaptic 
efficiency 39. We therefore assessed whether TRIO plays a role in synaptic transmission at the 
hippocampal CA3–CA1 pathway.  
 Organotypic hippocampal brain slices were prepared from P6 pups, a time period at which 
dendrites have already formed, allowing us to bypass the effect of TRIO on dendritic 
arborization (Fig. 2). Hippocampal brain slices were biolistically transfected with Trio shRNAs. 
Four days post-transfection, simultaneous recordings of evoked excitatory post-synaptic 
currents (eEPSCs) from a DsRed-labeled, shRNA expressing CA1 pyramidal neuron and an 
adjacent non-transfected neuron were performed (Fig. 3A). We stimulated the Schaffer 
collaterals with two independent bipolar electrodes and measured the evoked response while 
holding CA1 neurons at either -60 mV to measure AMPAr-mediated responses or at +40 mV 
to measure NMDAr-mediated responses. Neurons transfected with either Trio shRNA#1 or 
Trio shRNA#2 showed significantly increased AMPAr-mediated, but not NMDAr-mediated, 
transmission compared to control (Fig. 3A-D). These data indicate that TRIO, at least at 
excitatory CA1 synapses, is specific for AMPARs versus NMDArs. Importantly, we previously 
showed that expressing GFP or a scrambled shRNA by means of biolistics does not affect 
AMPAr-mediated synaptic transmission 40,41. 
The changes in AMPAr-mediated transmission could be a result of either a change of 
synaptic AMPArs at individual synapses, or a change in the number of functional synapses, or 
both. In order to determine the precise mechanism of action of the above possibilities we 
measured spontaneous excitatory postsynaptic currents (sEPSCs). We observed that the 
frequency, but not the amplitude, of the sEPSCs was significantly increased when neurons 
were transfected with Trio shRNA#1 (Fig. 3E, F). Increases in sEPSC frequency could be due to 
either increased intrinsic excitability of the pre-synaptic CA3 neurons, or increased active 
synapse between CA3 and CA1 neurons. Since biolistic transfection resulted in low 
transfection efficiency (a few neurons/slice), the major contribution of knocking down Trio 
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therefore comes from the recorded transfected postsynaptic cells (CA1) of the CA3-CA1 
synapse. Our data thus suggest that depleting endogenous TRIO in CA1 neurons is sufficient 
to increase synaptic strength by increasing the amount of functional synapses.  
 
 
Figure 3 Post-synaptic TRIO regulates synaptic transmission. 
(A, B) Amplitudes of AMPAr (left panel) and NMDAr (right panel) eEPSCs in control, non-transfected 
neurons are plotted against simultaneously recorded neighboring neurons expressing (A) Trio shRNA#1 
(AMPAr n = 25; NMDAr n = 22), (B) Trio shRNA#2 (AMPAr n = 20; NMDAr n = 19). Black symbols 
represent single pairs of recordings; blue symbols show mean amplitudes. Inserts in each panel show 
sample averaged traces; blue traces, transfected neurons; black traces, non-transfected neighboring 
neurons. Scale bars represent 10 ms and 25 pA.   
(C, D) Summary (mean ± SEM) of effects of expressing Trio shRNA#1, on AMPAr- (left) and NMDAr- 
(right) eEPSCs calculated as the averaged ratios obtained from pairs of infected and uninfected 
neighboring neurons. Data are shown as mean ± SEM. *p < 0.05, paired Student’s t-test, Trio shRNA#1 
(AMPAr n = 25; NMDAr n = 22), (B) Trio shRNA#2 (AMPAr n = 20; NMDAr n = 19).  
(E) Representative traces of sEPSC recorded at −60 mV in an individual neuron from untransfected 
(control) or Trio shRNA#1 transfected group. Scale bars represent 100 ms and 5 pA.  
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(F) Quantification of sEPSC frequency (left) and amplitude (right) for control and Trio shRNA#1-
expressing neurons. Data are shown as mean ± SEM. *p < 0.05, paired Student’s t-test, n = 8 pairs. 
 
 
Down-regulation of Trio reduces AMPAr endocytosis  
To further understand the mechanism by which TRIO affects hippocampal glutamatergic 
synapses we tested whether down-regulation of Trio correlated with persistent changes in 
AMPAr internalization rate. Previously, an isoform of Trio has been shown to colocalize with 
Rab5 in endosomes 42 and Rab5 is required for AMPAr endocytosis at excitatory CA1 synapses 
43.  We therefore assessed directly the function of Trio in AMPAr endocytosis. Primary 
hippocampal neurons were transfected with Trio shRNA#1 at DIV 3. At DIV 14 surface AMPAr 
GluA1 subunits were lively labeled with an antibody recognizing the extracellular epitopes of 
GluA1 and allowed AMPArs to internalize at 37°C for 2h. Neurons transfected with Trio 
shRNA#1 showed a marked reduction in endocystosis as assessed by the ratio between 
internalized and extracellular GluA1, suggesting that down-regulation of Trio decreases 
AMPAr endocytosis rate (Fig. 4A, B). Collectively, our results indicate that TRIO-mediated 
signaling controls synaptic function by regulating AMPAr endocytosis at CA1 excitatory 
synapses. 
 
 
Figure 4 Down-regulation of Trio reduces AMPAr endocytosis. 
(A) Representative double-label images of internalized (green) and surface (red) AMPAr GluA1 subunit 
in low-density hippocampal neurons.  
(B) Ratiometric analysis of the intensity of internalized GluA1 to surface GluA1 in indicated conditions. 
Control shRNA: n=15; Trio shRNA#1: n=14; Scale bars, 10 μm; *P<0.05, t-test; Error bars represent 
SEM. 
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Discussion 
Here we show that loss-of-function mutations in TRIO are responsible for a clinical phenotype 
involving mild to borderline ID with behavioral problems, and that TRIO has an important 
function during neurite outgrowth and basal synaptic transmission. Specifically, we 
demonstrated for the first time that endogenous Trio negatively regulates hippocampal 
synaptic strength by specifically affecting AMPAr internalization at CA1 excitatory synapses. 
Large scale reference data sets such as present in ExAC have now catalogued human genetic 
diversity at unprecedented level 44. Whereas the LoF mutations identified in this study are not 
present in ExAC, 13 other truncating variants in TRIO (NM_007118.2) are. Four of these are 
located in the last exon, thereby escaping nonsense mediated mRNA decay. This leaves nine 
different potential loss-of-functions variants, reported to occur in 33 of >60,000 individuals 
represented in ExAC.  Remarkably, ExAC recently reported that only 3,230 human genes 
(~15%) are near-completely depleted from truncating variants. This implicates that for 
the vast majority of genes such truncating variants are observed, and therefore likely, also 
include well-known disease genes causing disease by haploinsufficiency. For instance, 
analysis of ARID1B revealed 16 different LoF variants, identified in 29 of >60,000 
individuals in ExAC (data not shown). Interestingly, however, LoF mutations in ARID1B 
cause autosomal dominant mental retardation type 12 [MIM 614562]. Whereas such 
individuals could go undiagnosed in the general population for which ExAC is a proxy, 
the frequency in which these ARID1B LoF mutations are observed relatively high to 
remain undiagnosed in the general population. In contrast, the aspecific phenotype and 
mild-to-borderline ID observed in patients with truncating variants in TRIO could remain 
undiagnosed in the population. Hence, LoF of TRIO are not unexpected to be present in 
ExAC.  
 The molecular mechanisms that promote excitatory synapse development have been 
extensively studied. However, the molecular events that prevent premature excitatory 
synapse development so that synapses form at the correct time and place are less well 
understood. Here we find that knockdown of Trio, during early development prevents both 
neurite outgrowth and synapse formation. Together with our observation that TRIO is highly 
expressed at early stages of development and that its expression decreases at the time when 
synapses are being formed, our data suggest that TRIO serves as an endogenous break for 
synaptic development. Indeed, downregulation of TRIO in hippocampal brain slices, using two 
independent shRNAs, increased AMPAr-mediated but not NMDAr-mediated transmission. 107 
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This Increased synaptic AMPAr-mediated response, was accompanied by an increase in the 
frequency of spontaneous excitatory currents as well as by a reduction of AMPAr 
internalization. Interestingly, an isoform of Trio (Trio8) has been shown to modulate early-
endosome dynamics in COS-7 cells and to colocalize with Rab5 in neurons, whereas Rab5 
activation drives the specific internalization of synaptic AMPArs in a clathrin-dependent 
manner 42,43. It is therefore plausible that TRIO controls AMPAr endocytosis via a functional 
interaction with Rab5 in hippocampal neurons.  
 It is known that the redistribution of postsynaptic AMPARs plays a key role in 
controlling excitatory synaptic efficacy during early development. Early in development a 
majority of the synapses are silent, referring to the fact that they contain NMDArs but no 
functional AMPArs 45. The proportion of these silent synapses rapidly decreases during the 
first two weeks of post-natal development in the hippocampus, coinciding with the 
maturation process of the synapses 46 and occurs as a result of AMPAr incorporation. Loss of 
TRIO could thus accelerate this unsilencing process. Of interest, premature maturation of 
excitatory synapses has been observed in several models for ASD. For example, accelerated 
maturation of excitatory synapses in an early period of hippocampal development contributes 
to the learning deficits in a mouse model of human SYNGAP1 haploinsuffciency 47. Similarly, 
accelerated maturation of glutamatergic synapses has been seen upon loss of the ID and 
Schizophrenia-associated microRNA, miR-137 48.  
 Kalirin and TRIO belong to the dbl family of RhoGEFs and are unique within this family in 
that they display two GEF domains of distinct specificity. Whereas Kalirin has been extensively 
studied for its synaptic function, very little is known regarding the role of TRIO at the synapse. 
To our surprise we found that TRIO plays an opposing role compared to Kalirin both, at the 
level of neurite outgrowth and synaptic strength. Whereas Kalirin stimulates neurite 
outgrowth 35 we found that knockdown of Trio enhanced neurite outgrowth. Similarly, 
whereas Kalirin is required for activity-dependent spine enlargement and enhancement of 
AMPA-mediated synaptic transmission we found that TRIO negatively regulated AMPAr-
mediated but did not affect NMDAr-mediated transmission 37. The distinct effects of TRIO and 
Kalirin in mammals indicate that these genes contribute to different aspects of neuronal 
development. Their opposing roles could result in the fine balance needed to form complex 
dendritic arbors during development, which are critical for proper synaptogenesis and precise 
cognitive function. In addition, several Trio splicing variants have been identified 33, and the 
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expression of each isoform is regulated in a temporal and spatial-specific manner. These 
isoforms display either one or both GEF domains, suggesting that they could differentially 
regulate Rac1 and RhoA. Loss of TRIO in different brain structures could therefore account for 
different phenotypes. Functions of these isoforms are however largely unknown. Future 
studies will be needed to explore the function of the multiple TRIO domains in dendritic 
arborization and synapse formation and how the actions of the different domains are 
coordinated to regulate neuronal development.   
 In summary, our current data identified TRIO in patients with mild to borderline ID 
combined with behavioral problems and provide novel insight into how genetic deficits in TRIO 
can lead to glutamatergic dysfunction. Over the coming years, we expect many more 
mutations in TRIO to be identified. Therefore, we established a website 
(http://www.triogene.com) to collect detailed phenotypic data of individuals harboring TRIO 
mutations not only to gain insight into the clinical spectrum that these mutations might cause 
but also to obtain fundamental understanding of the pathogenic mechanisms underlying 
TRIO-related ID. 
Materials and Methods 
Identification of additional individuals with TRIO mutations 
We performed targeted sequencing of the coding sequence of candidate ID genes, including 
TRIO, in a cohort of 2326 individuals with unexplained ID, using molecular inversion probes 
(MIPs) as described previously 30. The individuals in this cohort were selected from the in-
house collection of the Department of Human Genetics of Radboud University Medical Center 
(Nijmegen), containing more than 5000 samples from individuals with unexplained ID. DNA 
was extracted from peripheral blood. After confirmation with Sanger sequencing, de novo 
occurrence of the mutation was determined by using parental DNA. This study was approved 
by the institutional review board Commissie Mensgebonden Onderzoek Regio Arnhem-
Nijmegen NL36191.091.11. Written informed consent was obtained from all individuals. 
Cell Culture 
Hippocampal neuron cultures were prepared from embryonic day 18 rats (Sprague-Dawley, 
Charles River) and nucleofected with various Ds-Red vectors as described previously 35. Briefly, 
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hippocampal tissue was separated and meninges were removed carefully with forceps under 
the dissecting microscope. Tissues were digested with 0.25% trypsin (Corning) for 15 min 
before dissociation. Culture media contained 1 μg/ml fungizone (amphotericin B, Gibco) and 
1 μM Ara-C (Sigma) until harvest. Cultures were examined at day in vitro (DIV) 2, 4 and 7, 
enumerating the numbers of primary neurites and branch points in the transfected cells, using 
fluorescence to identify transfected neurons 35. 
Organotypic hippocampal slice cultures were prepared from postnatal day 6 rat pups as 
described 49. Slices were biolistically transfected at 4 DIV using a Helios Gene Gun (Bio-Rad) 41 
and recorded 4 days post-transfection. 
Knockdown Experiments 
To reduce expression of endogenous Trio in the cultures, shRNAs targeted the spectrin repeat 
region, since most of the alternately spliced Trio transcripts contain the spectrin repeats2; the 
effects of shRNAs targeting Trio were compared to a control shRNA (scrambled shRNA), which 
matches nothing in rodent genomes or transcripts. Oligonucleotides were annealed and 
ligated into the RNAi-Ready-pSiren-DNR-DsRed-Express vector (Clontech, Mountain View, CA). 
This vector utilizes the human U6 promoter to control shRNA expression and the CMV 
promoter to control DsRed expression3. The sequences targeted were: Scramble shRNA, 
AATGCACGCTCAGCACAAGC; Trio shRNA #1, TTCTGGCAGAAACAGAGGA; Trio shRNA #2, 
TTCAGACGCAGCACAATCA. All constructs were verified by sequencing. Transfection with 2 μg 
DNA was performed using a NucleofectorTM 2b device (Lonza) at the time of plating and 
2.5x106 neurons for each transfection 35. Neurons were fixed at DIV2, 4 or 7 using 4% 
paraformaldehyde in phosphate buffered saline.  
Immunocytochemistry and Image Acquisition 
Fixed neurons were permeabilized with 0.3% Triton and stained with antisera to Ankyrin G (1: 
1000; mouse, Neuromab). Images were taken using a Zeiss LSM 510 Meta confocal microscope 
and a 40x objective. For each neuron, numbers of primary neurites and branch points were 
measured from the same image. Primary neurites that are longer than one soma diameter 
were counted at all days in vitro indicated. 
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Western Blot Analysis 
For time course studies, hippocampal tissues collected from rats at different ages were 
sonicated into the SDS lysis buffer, heated for 10 min at 95°C and insoluble debris was 
removed by centrifugation. The supernatant protein concentration was determined using the 
bicinchoninic acid assay (Pierce, Rockford, IL) and bovine serum albumin as the standard; 50 
μg of total protein was loaded onto each lane for analysis of Trio expression. Westerns were 
performed with Trio antibody (UltraCruz) at 1:10002. Similar expression patterns were 
observed in a separate set of animals.  
RNA isolation, reverse transcription and Real-Time PCR 
Total RNA from the tissue was isolated using Nucleospin RNA kit (Macherey-Nagel). cDNA was 
synthesized from 0.5–1 mg RNA using iScript™ cDNA Synthesis Kit. For detecting Trio 
expression, Real-time PCR was performed in 7900HT Fast Real-Time PCR System using GoTaq 
qPCR Master mix (Promega). The following primers were used: forward#1, 
GTCACGGAACATGTTGAAGG, reverse#1, CCTGTATCACCTCACGGATG; forward#2, 
TCGAGGAAGTTGCACAGAAC, reverse#2, ATCTCTTCGGGGTCACATTC; forward#3, 
AGTTGGAGAACGGGTACAGG; reverse#3, ACCTCGCTCAATGGGATAAC. Relative Trio expression 
compared to the control was calculated by 2-ΔΔCt. 
Electrophysiology 
Whole-cell recordings were obtained with Multiclamp 700B amplifiers (Axon Instruments). To 
monitor TRIO’s effects on synaptic transmission, slices were biolistically transfected at DIV 4. 
Two days later, whole-cell recordings were obtained simultaneously from a transfected and 
an adjacent non-transfected neuron in the CA1 region under visual guidance using 
epifluorescence (red fluorescence) and transmitted light illumination. The recording chamber 
was perfused with artificial cerebrospinal fluid (ACSF) containing 119 mM NaCl, 2.5 mM KCl, 4 
mM CaCl2, 4 mM MgCl2, 26 mM NaHCO3, 1 mM NaH2PO4, 11 mM glucose, 0.1 mM picrotoxin, 
and 4 μM 2-chloroadenosine (pH 7.4), and gassed with 5% CO2/95% O2. Recordings were made 
at 30°C. Patch recording pipettes (3–5 MΩ) were filled with intracellular solution containing 
115 mM cesium methanesulfonate, 20 mM CsCl, 10 mM HEPES, 2.5 mM MgCl2, 4 mM Na2ATP, 
0.4 mM Na3GTP, 10 mM sodium phosphocreatine, and 0.6 mM EGTA (pH 7.25). Evoked 
responses were induced using bipolar electrodes placed on Schaffer collateral pathway. 
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Responses were recorded at both −60 mV (for AMPAr-mediated responses) and +40 mV (for 
NMDAr-mediated responses). NMDAr-mediated responses were quantified as the mean 
between 60 and 65 msec after stimulation. All recordings were done by stimulating two 
independent synaptic inputs; results from each pathway were averaged and counted as n = 1. 
Spontaneous responses were recorded at −60 mV (sEPSC) in ACSF containing 2.5 mM CaCl2 
and 1.2 mM MgCl2 at 30°C. sEPSCs were recorded in the presence of 0.1 mM picrotoxin. Five 
to 10 min of recordings were analyzed from each cell. Data were acquired at 5 kHz, filtered at 
2 kHz, and analyzed using the Mini Analysis Program (Synaptosoft). All data are reported as 
mean ± SEM. Statistical significance was determined by the paired Student's t-test. 
Significance was set to P < 0.05. 
AMPA receptor endocytosis assay 
Endocytosis assay was performed as previously described (50, 51) with modifications. Briefly, 
living primary hippocampal neurons transfected with indicated constructs were pretreated for 
30 min with 100 μg/ml leupeptin and then labeled with anti-GluA1 antibody (Millipore). 
Internalization of the labeled GluA1 subunits was then allowed for 2 hours at 37 °C. After 
fixation with 4% paraformaldehyde and blocking with 5% BSA, surface-labeled GluA1 subunits 
were exposed to Alexa-488 secondary antibody (Invitrogen). After washing, the remaining 
surface GluA1 subunits were incubated with an unlabeled secondary antibody at a 
concentration of 0.13 mg/ml overnight to saturate surface anti-GluA1 antibodies. Neurons 
were then permeabilized and incubated with Alexa-647 secondary antibody to label 
internalized GluA1 subunits. GluA1 endocytosis was calculated by dividing the intensity of 
internalized GluA1 by the intensity of surface GluA1 using imageJ (I488/ I647).  
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Table 1          Molecular and clinical details of individuals with TRIO mutations 
 Individual 1 Individual 2 Individual 3 Individual 4 
Gender Male Male Female Male 
Age at last visit 7 20 35 10 
Mutations 
Deletion breakpoints Chr5:14160447-
14395478 
- - - 
Deleted genes TRIO - - - 
cDNA change -  c.649A>T c.3752del c.4128G>A  
Amino acid change -  p.Arg217* p.Asp1251Valfs*11 p.Trp1376* 
Chromosome position - 14290933 14387728 14390409 
Growth 
Birth weight 0 SD +0.25 SD -0.75 SD 0 SD 
Height 0 SD -0.75 SD -1.5 SD +1.25 SD 
Weight NR NR +1 SD +3 SD  
Head circumference -1 SD -2.5 SD -2.5 SD -1.5 SD 
Development 
Intellectual disability Borderline (IQ81) Borderline (IQ78) Mild (IQ62)  Mild (IQ68) 
Speech delay + 
7 years: 5-6 words 
NR 
NR 
+ 
3 years: first words 
+ 
NR 
Motor delay + 
Fine motor delay 
+ 
3 years: first steps 
+ 
2 years: first steps 
+ 
Fine motor delay  
Neurological 
Behavioral problems 
 
+ 
PDD-NOS 
+ 
ADHD 
+ 
Autistic-like traits 
+ 
ADHD 
High reflexes - + + - 
Hyperacusis + - + - 
Swallow difficulties - NR + + 
Facial 
Facial asymmetry - + + - 
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Periorbital fullness + - + - 
Full lips - + + - 
High palate - + NR + 
Dental crowding - + + + 
Micrognathia - + + + 
Other facial dysmorphism High forehead, 
large protruding 
ears, short 
philtrum 
- High forehead, 
Full eyebrows, 
Downslanted 
palperbral fissures, 
full nasal tip 
High forehead, 
Long philtrum 
Extremities 
Minor hand abnormalities + 
Short, broad with 
Simian creases 
and volaire pads 
+ 
Broad proximal 
interphalangeal 
joints, 
camptodactyly dig 
V 
+ 
Brachydactyly dig I, 
tapering fingers 
+ 
Tapering fingers 
Other 
Recurrent infections + NR + + 
Kyphosis - - + + 
Fatigue + - + - 
Neonatal feeding difficulties + - NR + 
Other clinical features Anal fistula, 
scapula alatae, 4th 
palmar crease, 
clinodactyly 
digitus 5, sandal 
gap 
 Torsio testis, 
pectus 
excavatum, 
tremor 
Constipation, 
hypercalcemia, 
hypotonia, pes 
planus, varices 
Automutilation  
NR= not reported 
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Supplemental Data 
 
Supplementary Tables 
Supplementary Table 1: Highly conserved missense mutations in 2,326 patients with ID 
 
Genomic position 
cDNA change 
(NM_007118.2) 
Predicted protein 
change 
CADD 
score 
Mutation 
type Segregation 
chr5(GRCh37):g.14366984C>A c.2770C>A p.Arg924Ser 34 missense paternally inherited 
chr5(GRCh37):g.14387688T>C c.3712T>C p.Tyr1238His 27 missense n.a. 
chr5(GRCh37):g.14471427G>A c.5764G>A p.Ala1922Thr 20 missense maternally inherited 
chr5(GRCh37):g.14471479G>A c.5816G>A p.Ser1939Asn 25 missense paternally inherited 
chr5(GRCh37):g.14482826C>G c.6601C>G p.Leu2201Val 24 missense n.a. 
chr5(GRCh37):g.14485261G>C c.6741G>C p.Glu2247Asp 23 missense n.a. 
chr5(GRCh37):g.14498270G>A c.8120G>A p.Arg2707Gln 24 missense n.a. 
 
 
Supplementary Table 2:  Overview of truncating mutations from ExAC for TRIO based on 
NM_007118.2 [November 2015] 
 
dB 
Origin cDNA 
Predicted                     
protein effect 
Individuals   
tested 
Allele 
frequencies 
(mut/wt) 
Genotypes                      
(hmz mut -  het - hmz 
wt) 
Minor Allele     
Frequency 
ExAC c.1708_1709del p.Val570Phefs*41 57,499 1/114,998 0 - 1 - 57,498 0.0000087 
ExAC c.3358G>T p.Glu1120* 51,398 1/102,796 0 - 1 - 51,397 0.0000097 
ExAC c.5032C>T p.Arg1678* 60,427 1/120,854 0 - 1 - 60,426 0.0000083 
ExAC c.6657+1dup p.? 58,349 1/116,698 0 - 1 - 58,348 0.0000086 
ExAC c.7050del p.Val2351Cysfs*62 33,774 21/67,548 0 - 21 - 33,753 0.0003109 
ExAC c.7050dup p.Val2351Argfs*90 33,774 5/67,548 0 - 5 - 33,769 0.0000740 
ExAC c.7448dup p.Ser2484Leufs*41 43,966 1/87,932 0 - 1 - 43,965 0.0000114 
ExAC c.8019+1G>T p.? 60,265 1/120,530 0 - 1 - 60,264 0.0000083 
ExAC c.8665G>T p.Glu2889* 60,296 1/120,592 0 - 1 - 60,295 0.0000083 
ExAC c.8773G>T p.Glu2925* 59,864 1/119,728 0 - 1 - 59,863 0.0000084 
ExAC c.9207_9210del p.Phe3069Leufs*58 59,959 1/119,918 0 - 1 - 59,958 0.0000083 
ExAC c.9209_9210insGG p.Ile3070Metfs*59 59,931 1/119,862 0 - 1 - 59,930 0.0000083 
ExAC c.9268C>T p.Gln3090* 58,469 1/116,938 0 - 1 - 58,468 0.0000086 
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Figure 1 Pedigree of family with dominantly segregating nonsense mutation in TRIO  
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Abstract 
Lowe syndrome (LS) is a developmental disorder caused by mutations in the OCRL1 gene. 
Although one of the major tissues affected in LS is the brain, surprisingly little is known about 
the neuronal function of OCRL1. Here, we report the functional characterization of OCRL1 in 
the rat hippocampus. OCRL1 is present in the hippocampus with constant developmental 
expression. Functionally, OCRL1 regulates both spine density and basal synaptic transmission 
at mature CA3-CA1 synapses. In addition, OCRL1 downregulation causes a “traffic jam” of 
AMPArs on the endocytic-lysosomal trafficking route, indicated by impaired AMPAr 
endocytosis, increased extrasynaptic accumulation of AMPArs and elevated total AMPAr 
levels. Of note, aberrant expression of OCRL1 leads to altered long-term potentiation (LTP). 
Overall, our findings for the first time provide evidence that loss of OCRL1 alters synaptic 
structure and function in the hippocampus, which may explain how mutations in OCRL1 result 
in cognitive impairment in LS.    
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Introduction 
Intellectual disability (ID) consists of a wide range of disorders that are characterized by 
cognitive impairment and reduced adaptive skills. ID affects 2% - 3% of the population and it 
can be resulted from genetic defects as well as environmental causes. To date, over 700 genes 
have been associated with ID 1 and a major challenge has been to uncover the cellular 
mechanisms responsible for declined cognitive function. ID has long been proposed to be “a 
disease of the synapse”. This assumption is supported by the observation that ID genes 
converge to common signaling cascades that impinge on synaptic function. During normal 
brain development and learning and memory, synapses undergo rapid and/or long-lasting 
changes due to the remodeling of synaptic structure (e.g. spine size and density) and function 
(e.g. presynaptic neurotransmitter release, expression of postsynaptic receptors), eventually 
leading to changes in synaptic strength. A number of molecules and signaling pathways have 
been implicated in these processes, including Rho GTPase signaling 2–4, AMPA receptor 
trafficking signaling 5–9 and phospholipid signaling 10–14. It is, therefore, not surprising that the 
vast majority of ID genes, such as OPHN1, BRAG1, ARHGEF6, FMR1 and TSPAN7, are involved 
in these signaling pathways 15–19. 
The gene OCRL1 lies across 24 exons on the X-chromosome encoding the inositol 5-
phosphotase OCRL1. Mutations of OCRL1 result in oculocerebrorenal syndrome of Lowe 
(Lowe Syndrome, LS), a rare X-linked disorder characterized by congenital cataracts, ID and 
renal proximal tubulopathy. Another rare X-linked disorder, type 2 Dent disease, which shows 
selectively renal dysfunction has also been reported to result from OCRL1 mutations 20,21. 
OCRL1 is a multidomain protein containing an N-terminal PH domain, a central inositol 5-
phosphatase domain, a C-terminal ASH and a RhoGAP-like domain, as well as two clathrin 
binding motifs 22 (Figure 1A). Through these domains and motifs, OCRL1 interacts with key 
components of membrane trafficking machineries such as clathrin, clathrin adaptors, Rab and 
Rho GTPases, as well as the endocytic proteins APPL1. Consistently, OCRL1 has been reported 
to display a broad cellular distribution including the plasma membrane, the endosomal 
system, the Golgi complex and clathrin-coated vesicles 23–26. OCRL1 has two splice isoforms 
that differ by a single exon encoding 8 amino acids. The longer isoform a is the only form 
present in the brain, whereas both isoforms are expressed in all other tissues 27. Over 120 
mutations in OCRL1 have been identified in the patients with LS, including premature stop 
codons, frameshift mutations, in-frame deletions, genomic or exon deletions and missense 
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mutations 28–31. These mutations lead to misfolding, loss of stability and interactions, as well 
as loss of catalytic activity of OCRL1 protein, indicating that both structure and catalytic 
activity of OCRL1 are important for normal cell physiology 32. 
 
 
Figure 1 Domain organization of OCRL1 and INPP5B 
(A) OCRL1 contains an N-terminal PH domain, followed by a 5-phosphatase domain, an ASH and a GAP 
domain. Besides, OCRL1 has two clathrin-binding motifs an AP2 binding motif.  
(B) INPP5B has the same domain structure as OCRL1, but lacks the clathrin and AP2 binding motifs. In 
addition, INPP5B contains a CAAX motif at its C-terminus. 
 
Intensive studies have been performed, in non-neuronal cells, regarding the cellular 
function of OCRL1 23,26,33. Phosphoinositides (PIs) are involved in diverse cellular events such 
as signal transduction, exo- and endocytosis, membrane trafficking and regulation of the actin 
cytoskeleton 14,34,35. Reversible phosphorylation of the inositol ring at position 3, 4 and 5 
generates seven PIs each of which has a unique subcellular distribution 36. As one of the ten 
conserved 5-phosphatases, OCRL1 preferentially dephosphorylates PI(4,5)P2 and also 
displays activity toward PI(3,4,5)P3 to a less extent in vitro 37,38. Previous studies have found 
that cell lines derived from LS patients show a reduced 5-phosphatase activity (less than 10% 
compared to unaffected individuals) and elevated PI(4,5)P2 levels 39, suggesting an essential 
role of OCRL1 in controlling PI homeostasis. In addition, OCRL1 has been reported to be 
essential for protein trafficking from endosomes to the trans-Golgi network via its 5-
phosphatase activity 40. Defects in clathrin-mediated endocytosis and recycling of several 
receptors including megalin have been observed in cells lacking OCRL1 41. Interestingly, OCRL1 
has been found to regulate actin cytoskeleton dynamics by modulating PI(4,5)P2 homeostasis 
as well as Rac1 GTPases activity via its GAP domain, although it has been reported to possess 
only a weak GAP activity in some cell lines previously 33. Cells lacking OCRL1 display elevated 
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PI(4,5)P2 levels and produce actin comets from the Golgi apparatus and endosomes in an N-
WASP-dependent manner. Vicinanza et al. further confirmed that OCRL1 regulates 
endosomal actin polymerization via PI(4,5)P2-Arp2/3-N-WASP signaling 40. Together, these 
data strongly indicate that OCRL1 regulates general membrane trafficking and actin dynamics.  
So far, no ideal murine model has been available for studying the mechanisms of LS and 
Dent disease. One reason may lie with the functional redundancy for OCRL1 and INPP5B, an 
OCRL1 homolog with ~45% sequence identity and similar protein structure 42 (Figure 1B). The 
loss of OCRL1 in mice is fully compensated by INPP5B, therefore, no phenotype is detectable 
in Ocrl1 KO mice 44. In human, the degree of compensation is lower compared to that in mice, 
which might due to two reasons: the relative low levels of INPP5B and the different splicing 
of human INPP5B gene leading to a shorter version of INPP5B protein 44. A “humanized” 
mouse line was generated by expressing human INPP5B in Ocrl1/Inpp5b double knockout 
mice. These mice show reduced growth and a renal tubulopathy however do not show any 
ocular or neurological defects 45. In addition, several groups have made use of zebrafish 
models for studying OCRL1 function. A mutant zebrafish in which OCRL1 expression is 
attenuated by insertion of a retrovirus in the promoter has been generated and delayed brain 
and eye development with impaired cell proliferation as well as increased apoptosis have 
been observed in this mutant 46. Other studies used depletion of OCRL1 by injecting antisense 
morpholinos in zebrafish and reported altered ciliogenesis 47.  
Although one of the most debilitating symptoms in LS is intellectual disability, until now 
the function of OCRL1 in the brain remains elusive. In this study, we clarify the role of OCRL1 
in the brain by examining its expression and impact on synapse structure and function in the 
hippocampus, a region that plays a key role in learning and memory. We show that OCRL1 is 
expressed in all hippocampal subregions and the mRNAs of Ocrl1 is stably expressed 
throughout hippocampal development. Elevated Ocrl1 levels significantly increase dendritic 
spine density and mEPSC frequency of mature CA1 pyramidal neurons while depletion of 
Ocrl1 displays opposing effect. In addition, overexpression of Ocrl1 impairs LTP, one of the 
major molecular mechanisms underlying learning and memory, whereas downregulation of 
Ocrl1 enhances LTP magnitude. Of note, Ocrl1 knockdown significantly increases total GluA1 
protein levels and impairs AMPAr endocytosis. We therefore propose a model in which loss 
of OCRL1 causes a “traffic jam” of AMPArs on the endocytic-lysosomal trafficking route, which 
is likely to expand the mobile pool of AMPArs and subsequently facilitate LTP. Overall, our 
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findings for the first time provide evidence of loss of OCRL1 leading to altered spine structure 
and function, which may explain how mutations in OCRL1 result in cognitive impairment in LS.    
 
 
Results 
OCRL1 in the hippocampus 
We initiated the characterization of Ocrl1 by determining its spatiotemporal expression in 
hippocampus. By using quantitative polymerase chain reaction PCR (qPCR), we examined the 
transcriptional expression pattern of Ocrl1 during hippocampal development. Our results 
showed that Ocrl1 levels were constant throughout all developmental stages in the 
hippocampus (chapter 2 and Figure 2A). To determine the spatial distribution of OCRL1 in 
hippocampus, we performed immunostaining experiments on rat brain sections. We found 
that OCRL1 was highly expressed in all hippocampal subregions, with relative higher levels in 
CA3 and dentate gyrus (DG) (Figure 2B). Together, these results reveal a significant presence 
of OCRL1 throughout hippocampal development, implying its contribution in both developing 
and mature hippocampus. 
 
 
Figure 2 Expression and distribution of OCRL1 in the hippocampus  
(A) Expression of Ocrl1 mRNA during hippocampal development. 
(B) Hippocampi sections from a P20 rat double-immunolabled with an anti-OCRL1 antibody (red) and 
an anti-NeuN antibody (green). Scale bars, 50 μm.  
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OCRL1 regulates dendritic spine morphology 
OCRL1 contains several conserved protein domains that have been shown to regulate actin 
cytoskeleton dynamics via distinct signaling pathways, such as a 5-phosphatase domain and 
a RhoGAP-like domain. We speculated that OCRL1 might be important for neuronal structure, 
although whether the GAP-like domain is functional still remains controversial. We therefore 
examined the effects of OCRL1 in regulating dendritic spine morphology of CA1 pyramidal 
neurons by two-photon laser scanning microscopy (TPLSM). We biolistically introduced a GFP-
expressing construct, as a cellular marker, with or without a second construct containing full-
length human Ocrl1 isoform a (Ocrl1_a) into organotypic hippocampal slices at 12 DIV and 
imaged GFP-labeled dendrites and spines from transfected CA1 neurons 48 hours post-
transfection. Compared to neurons expressing GFP alone, Ocrl1_a overexpressing CA1 
pyramidal neurons displayed a significant increase in spine density without changes in spine 
volume (Figure 3A, B). We next examined the function of endogenous OCRL1 by probing the 
effects of Ocrl1 downregulation on dendritic spines of CA1 neurons, using RNAi. We verified 
the efficiencies of shRNAs by performing qPCR experiments. Both Ocrl1 shRNA #1 (Ocrl1 sh#1) 
and #2 (Ocrl1 sh#2) significantly reduced endogenous Ocrl1 mRNA levels with distinct 
efficiencies (sh#1: 51% and sh#2: 82%) in hippocampal neurons, whereas a control shRNA did 
not affect Ocrl1 level (data not shown). We found that both shRNAs significantly reduced 
spine density (Figure 3A, B) without affecting spine volume. These results suggest that OCRL1 
bidirectionally controls dendritic spine density in hippocampal CA1 pyramidal neurons. 
 
 
Figure 3 OCRL1 regulates spine morphology 
Quantification of spine density (A), spine volume (B). A minimum of 500 spines were analyzed per 
condition; *P<0.05, t-test. 
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OCRL1 controls excitatory synaptic transmission  
Due to the tight correlation of dendritic spine morphology with synaptic function, and the 
effects of OCRL1 in spine density, we next sought to determine whether misregulation of 
OCRL1 levels disrupted excitatory synaptic transmission. By recording miniature synaptic 
transmission (often called “minis”), which is caused by spontaneous release of single synaptic 
vesicle from presynaptic neurons acting on a small amount of postsynaptic receptors, we 
began to probe the effect of Ocrl1 overexpression condition. Organotypic hippocampal slices 
were infected with Ocrl1_a containing lentivirus at 0 DIV. The frequency and amplitude of 
miniature excitatory postsynaptic current (mEPSCs) were measured at 13 DIV, a timepoint 
that most neurons reach mature stage. Ocrl1_a significantly increased mEPSC frequency in 
CA1 pyramidal neurons while no difference of the amplitude was detected. We next 
measured minis in Ocrl1 shRNAs infected neurons. Conversely, we found that both Ocrl1 sh#1 
and sh#2 significant decreased the mEPSCs frequency without affecting the amplitude. Since 
altered mEPSCs frequency could be due to either changes of the presynaptic release 
probability or changes of the amount of functional synapses, we further examined the release 
probability by recording the paired-pulse ratio (PPR). We did not detect any differences of 
PPR between control uninfected and Ocrl1 sh#1 infected neurons (data not shown), indicating 
that Ocrl1 knocking down did not cause substantial changes of presynaptic release probability. 
Thus, these results support our findings of OCRL1 bidirectionally controls dendritic spine 
density and suggest that OCRL1 plays an important role in regulating synaptic transmission at 
hippocampal CA3-CA1 synapses. 
To determine whether OCRL1 plays a role in controlling synaptic transmission during 
development, we monitored the changes of synaptic transmission at earlier stages of 
hippocampal development. We first recorded mEPSCs in CA1 neurons infected with Ocrl1 
sh#2 at 11 DIV. Surprisingly, we did not observe any significant changes in the frequency or 
the amplitude of mEPSCs in Ocrl1 downregulated neurons compared to uninfected control 
neurons, suggesting that decreased level of Ocrl1 did not influence synaptic transmission at 
this stage. Next, we evaluated the effects of OCRL1 in regulating synaptic function at 7 DIV. 
Due to extremely low amount of minis at this age, we measured evoked excitatory post-
synaptic currents (eEPSCs) using whole-cell simultaneous recordings. Organotypic 
hippocampal slices were injected with Ocrl1_sh#1 containing lentivirus at 0 DIV and eEPSCs 
were measured simultaneously from an infected CA1 pyramidal neuron and an adjacent 
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control uninfected neuron at 7 DIV. Our results showed that decreased OCRL1 levels did not 
influence eEPSCs mediated by AMPAr (AMPAr-EPSC) or by NMDAr (NMDAr-EPSC). Together, 
these findings indicate that misregulating OCRL1 leads to synaptic dysfunction in mature 
hippocampal CA1 neurons. 
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Figure 4 OCRL1 regulates synaptic transmission  
(A, B) Effects of Ocrl1 overexpression or knockdown in regulating mEPSC at 13 DIV. 
(C, D) Effects of Ocrl1 knockdown in mEPSC at 11 DIV.  
(E, F) Effects of Ocrl1 knockdown in eEPSC at 7 DIV. Blue symbols represent single pairs of 
recordings. Green symbols show mean value. 
Data are shown as mean ± SEM; *P<0.05, t-test. 
 
 
OCRL1 maintains homeostatic AMPAr expression and trafficking 
Due to the presence of OCRL1 in the endocytic pathway and its role of regulating synaptic 
transmission, we hypothesized that OCRL1 might be critical for regulating AMPAr expression 
and trafficking in hippocampal CA1 neurons. To test this hypothesis, we first examined the 
protein levels of AMPAr GluA1 subunit in control uninfected, Ocrl1_a expressing and Ocrl1 
shRNAs expressing hippocampal neurons by performing Western blot analysis. We observed 
130 
 
134
C
h
a
p
te
r 
5
129 
 
130 
 
a significant decrease of GluA1 levels in Ocrl1 overexpressed neurons compared to control 
neurons. On the contrary, we found that reduced Ocrl1 levels led to elevated expression of 
GluA1 (Figure 5). These results suggest that aberrant levels of OCRL1 disrupt homeostatic 
protein expression of AMPArs in the hippocampus.  
 
Figure 5 OCRL1 regulates cellular abundance of GluA1 
Representative results and quantification of total GluA1 expression in Ocrl1 overexpression or 
knockdown condition. Data are shown as mean ± SEM; *P<0.05, t-test. 
 
 
To directly evaluate the endocytic process of GluA1 in Ocrl1 knocking-down condition, we 
performed live-cell antibody feeding experiments on 14 DIV hippocampal neurons which 
were infected with Ocrl1 shRNAs at 2 DIV. Our results showed that GluA1 endocytosis was 
significantly impaired in Ocrl1 sh#2 infected neurons. Ocrl1 sh#1 infected neurons also 
exhibited reduced GluA1 endocytosis, although not statistically significant (Figure 6A). 
Following recycling assay revealed that reduced Ocrl1 levels did not influence AMPAr 
recycling (Figure 6B). In addition, we visualized surface-expressed AMPAr in Ocrl1 
downregulated neurons by using pH-sensitive GFP fused GluA1 (pHluorin-GluA1) construct 48. 
Hippocampal neurons were electroporated with pHluorin-GluA1 at 0 DIV and transfected with 
Ocrl1 siRNA at 18 DIV. Immunostaining of MAP2 on transfected neurons were performed at 
21 DIV. We found that knocking down Ocrl1 resulted in a significant enhancement of GFP 
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signal, indicating increased surface expression of GluA1 AMPAr subunit (Figure 6C). Together, 
these results indicate that OCRL1 plays a critical role in maintaining AMPArs homeostasis and 
endocytosis.  
 
 
Figure 6 OCRL1 is involved in controlling AMPAr trafficking 
(A) AMPA receptor endocytosis assay. Left, representative double-label images of internalized and 
surface AMPA receptor GluA1 subunit in low density 14 DIV hippocampal neurons in indicated 
experimental groups. Right, ratiometric analysis of the intensity of internalized GluA1 to surface GluA1 
in indicated conditions. *P<0.05, t-test. Scale bars, 10 μm. 
(B) Ratiometric analysis of AMPAr recycling assay. The average intensity of surface GluA1 to recycled 
GluA1 in control and Ocrl1 sh#2 neurons are presented.  
(C) Left, representative double-label images of MAP2 (red) and surface GluA1 (green) in low density 
21 DIV hippocampal neurons. Right, quantification of the amount of surface GluA1. *P<0.05, t-test. 
Scale bars, 10 μm. 
 
 
OCRL1 modulates synaptic plasticity in CA1 
Knowing that OCRL1 loss of function results in intellectual disability, one of the symptoms of 
LS, and the involvement of OCRL1 in controlling synaptic structure and transmission, we 
reasoned that OCRL1 might also be important for synaptic plasticity. To this end, LTP was 
induced by using the pairing protocol in organotypic hippocampal slices infected with Ocrl1_a 
or Ocrl1 sh#1 expressing virus at 0 DIV. Simultaneous recordings from an infected neuron and 
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an adjacent non-infected control neuron were performed at 6-7 DIV (Figure 7A). We first 
examined the effect of Ocrl1 overexpression. Our data showed that elevated Ocrl1 levels led 
to reduced magnitude of LTP (Figure 7B). We subsequently examined the effects of Ocrl1 
knocking down on both functional and structural plasticity in hippocampal CA1 neurons. Our 
results revealed a significant increase of LTP magnitude in Ocrl1 downregulated neurons 
compared to control uninfected neurons (Figure 7C). 
 
 
 
Figure 7 OCRL1 modulates synaptic plasticity 
(A) Schematic figure indicating simultaneous recordings of LTP from an infected neuron and an 
adjacent non-infected control neuron. All experiments were performed at 6-7 DIV. 
(B) Impaired LTP in neurons with elevated Ocrl1 levels. 
(C) Enhanced LTP in neurons with reduced Ocrl1 levels. 
(D, E) Sustained spine enlargement in Ocrl1 Knocked down neurons. (D), representative images of 
changes in spine volume during the induction of cLTP. (E), quantification of average spine size during 
cLTP. *P<0.05, t-test. 
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To study the effect of OCRL1 in structural plasticity, we biolistically transfected GFP or 
Ocrl1 sh#1 constructs into 5 DIV hippocampal slices and used a chemical LTP (cLTP) protocol 
as described previously two days post-transfection 49. Changes in spines of GFP and Ocrl1 sh#1 
transfected neurons were monitored by TPLSM. Consistent with previous studies 49, we 
observed a rapid and persistent spine enlargement in GFP control neurons. Also, neurons with 
low Ocrl1 levels displayed similar enlarged spine size after cLTP induction. Interestingly, we 
observed more profound increase of spine size 60 minutes after the induction compared to 
GFP control neurons (Figure 7D, E). 
Collectively, these data indicate that OCRL1 plays an important role in synaptic plasticity in 
the Schaffer collateral-CA1 pathway. 
 
 
Discussion 
Functional characterization of individual genes that are associated with cognitive deficits will 
provide valuable insights into the neuronal basis of cognition. Lots of efforts have be made to 
unravel the biological function of genes that are identified to be linked to ID, such as TSPAN7 
and OPHN1 19,50,51. Lowe Syndrome, a rare monogenic disorder resulting from mutated OCRL1 
gene, affects eyes, kidney and nervous system. Despite being first described more than half a 
century ago, the neurological function of OCRL1 remains unclear. The ubiquitous expression 
pattern, the wide variety of interactors and the functional redundancy with INPP5B for OCRL1 
make it challenging to unravel the molecular mechanisms underlying LS. Here, we report for 
the first time the role of OCRL1 in the brain at the synaptic level in vitro. We have provided 
evidence encompassing following primary points: 1) OCRL1 is present in the hippocampus and 
the transcript levels of Ocrl1 are constant throughout hippocampal development; 2) 
elevated/reduced Ocrl1 levels increases/decreases dendritic spine density and the frequency 
of mEPSCs; 3) OCRL1 modulates functional and structural LTP; 4) loss of OCRL1 impedes 
AMPAr endocytosis and 5) OCRL1 is essential for maintaining cellular abundance of GluA1 
AMPAr subunit. 
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OCRL1 controls dendritic spine morphology 
In the present study, we report that dendritic spine morphology is remarkably impacted by 
aberrant levels of OCRL1. Growing evidence suggests that changes in brain function, both 
normal and pathological, consistently correlate with dynamic changes in neuronal anatomy 
52,53. Focusing on dendritic spines, the highly dynamic sites where most excitatory synapses 
are located, we genetically manipulated Ocrl1 levels and evaluated the effects of OCRL1 in 
CA1 pyramidal neurons. We observed a significant reduction in spine density when knocking 
down Ocrl1 in CA1 neurons. Conversely, elevated Ocrl1 levels led to increased spine density. 
These results suggest that OCRL1 is essential for maintaining normal spine density. 
Abnormalities in spine structure have been well documented in numerous neurological 
disorders including ID and ASD 54,55. Particularly, decreased spine density in several brain 
regions has also been observed in patients and a mouse model of Rett Syndrome, an X-
chromosomal disorder causing severe ID in females 56,57. Therefore, impaired spinogenesis 
might be a primary outcome of pathogenic OCRL1 mutations in LS patients. Subsequent lack 
of sufficient synaptic input on post-synaptic CA1 neurons may compromise synaptic 
connectivity and eventually lead to cognitive deficits in LS.  
Dynamic changes and enduring stabilization of dendritic spines are intimately associated 
with the coordinated regulation of actin cytoskeleton 58. Polymerization of F-actin promotes 
formation of dendritic spines while actin depolymerization results in spine elimination 59,60. 
By interacting with a series of molecular partners, OCRL1 is involved in several signaling 
pathways that control the assembly and disassembly of actin cytoskeleton. Previous studies 
have shown that, despite a low activity, OCRL1 interacts with Rac1 and strongly inhibits Rac-
dependent actin polymerization via its GAP-like domain in cell lines 33. If this is also the case 
in neurons, downregulation of Ocrl1 would promote spinogenesis instead of repressing it. It 
is therefore unlikely that OCRL1 controls dendritic spine density via Rac GTPase signaling. 
Further investigations examining whether and how OCRL1 regulates Rac signaling in neurons 
will test this possibility. An alternative possibility is that OCRL1 controls spine morphogenesis 
by manipulating synaptic lipid homeostasis via its 5-phosphatase catalytic activity. The main 
substrate of OCRL1, PI(4,5)P2, has been reported to facilitate actin polymerization by 
activating N-WASP- and Arp2/3-mediated actin branching and impairing activation of actin-
severing proteins including gelsolin and cofilin/ADF 61. Therefore, reduced spine density in 
Ocrl1 downregulated neurons could be due to accumulated PIP2-induced actin 
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polymerization. If so, restoring PIP2 levels to physiological levels might rescue the phenotype 
in spine density. Inhibiting the production of PIP2 by genetically suppressing the expression 
of PtdIns4P 5-kinase (PIP5K), a major kinase converting PI(4)P to PI(4,5)P2, has been 
successfully used in Ocrl1 depleted cells and a zebrafish model of LS 40,47. More recently, a 
small molecule inhibitor of PIP5K1C, UNC3230, has been identified in a high-throughput 
screen. UNC3230 has been found to lower membrane PIP2 levels in dorsal root ganglia 
neurons and attenuate pain in animal models 62. Thus, it would be interesting to take 
advantage of these genetic and pharmacological tools and examine whether the abnormal 
spine morphology resulting from loss of function of OCRL1 could be rescued by rebalancing 
PIP2 levels at the synapse. This will also provide important clue of searching for effective 
therapeutic targets for LS. 
 
OCRL1 controls synaptic transmission in late hippocampal development 
In line with our observations in spine morphology, we found that knocking down Ocrl1 
significantly reduced the frequencies of mEPSCs at hippocampal CA3-CA1 synapses, whereas 
Ocrl1 overexpression led to the opposing effect at 13 DIV. The amplitudes of mEPSCs in both 
manipulations did not change. These results indicate that altered spine density in Ocrl1 
misregulated CA1 neurons leads to synaptic dysfunction. 
It is worth noting that the deficient synaptic transmission was detectable only in late 
hippocampal development in vitro (13 DIV). One could speculate that a profound reduction 
in excitatory input caused by selective loss of OCRL1 in post-synaptic CA1 neurons might 
trigger a series of machineries, such as enhanced local translation of the OCRL1 homologue 
INPP5B, increased pre-synaptic release probability or downregulated GABAergic system, to 
counterbalance the excitatory dysfunction to a certain extent. These compensations, 
however, are not sufficient to keep correcting miswired network until late developmental 
stages. Future experiments are required to determine the precise mechanisms underlying 
these events. Alternatively, the protein levels of OCRL1 have been found to be low in 
embryonic and early postnatal stages and gradually increases with age (EI Demerdash and 
Fernandez-Monreal, personal communication), despite the constant mRNA levels of Ocrl1 
throughout development observed in our study. This raises the possibility that post-
transcriptional/translational modifications might be involved to ensure precise temporal 
expression of OCRL1 protein in hippocampus. It could also explain our findings in the sense 
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that manipulating Ocrl1 levels when endogenous OCRL1 proteins are expressed at a low level 
might not lead to any functional consequences. It has been unveiled that RhoGTPase signaling 
undergoes post-transcriptional regulations. For example, miR-124 which is enriched in 
developing and adult neurons suppresses Cdc42 and Rac1 expression and regulates axon 
growth 63. P250GAP, a recently identified candidate gene for schizophrenia 64, has also been 
found to be a target of miR-132. The miR-132-p250GAP pathway is reported to be required 
for normal dendritic development and leptin-induced synaptogenesis 65,66. Elucidating 
regulatory mechanisms for the temporal expression of OCRL1 will shed more light on the role 
of OCRL1 in regulating synaptic function. 
 
OCRL1 determines the routes of AMPAr trafficking and regulates LTP 
Involvement of OCRL1 in endocytic machinery has previously been proposed both in cell lines 
and a zebrafish model for LS 47. Here, we specified the role of OCRL1 in controlling AMPAr 
amount and trafficking route in neurons. By performing AMPAr endocytosis and recycling 
assay, we provided direct evidence indicating that Ocrl1 knockdown significantly impaired 
GluA1 endocytosis without affecting recycling process. Making use of pH-sensitive GFP fused 
GluA1 construct, we observed enhanced surface GluA1 signal in Ocrl1 depleted neurons 
compared to control neurons. Together with unaltered amplitude of mEPSCs, these results 
suggest that lacking of Ocrl1 leads to impaired AMPAr endocytosis and subsequent 
accumulation of excess AMPArs at extrasynaptic sites. Moreover, we detected elevated total 
amount of GluA1 protein in Ocrl1 downregulated neurons and decreased GluA1 protein levels 
in neurons overexpressed Ocrl1, suggesting that OCRL1 is critical for neurons to maintain 
proper levels of AMPAr. It has been demonstrated that, after being internalized via clathrin-
mediated endocytosis, AMPArs are either sorted into recycling pathway back to the cell 
surface or transported to late endosomes and retained for degradation in lysosomes 67,68. 
Therefore, our initial findings reveal an interesting scenario, in which loss of OCRL1 causing a 
“traffic jam” on the “membrane-endosome-lysosome” highway results in disrupted dynamic 
equilibrium of AMPArs in neurons.  
Previous studies have shown that OCRL1 directly interacts with the key components of 
endocytosis, clathrin and adaptor protein 2 (AP2) 26, and loss of OCRL1 causes deficits in 
clathrin-mediated endocytosis in fibroblasts of LS patients 41. It is therefore not surprising that 
AMPAr endocytosis, which is largely dependent on clathrin, is impaired in Ocrl1 lacking 
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neurons. Apart from its direct interaction with clathrin and AP2, OCRL1 might impact clathrin-
mediated endocytic process via indirect manipulation of PI(4,5)P2 levels. By binding to 
PI(4,5)P2, AP2 is recruited to the plasma membrane and subsequently initiates formation of 
clathrin-coated pit (CCP). Besides, the release of AP2 from CCP in the uncoating stage of 
clathrin-mediated endocytosis is in a PI(4,5)P2-dependent manner. Consistently, two other 5-
phosphatases, Synaptojanin and SHIP2 have also been reported to control clathrin-mediated 
endocytosis 69,70. Future experiments will have to determine the precise mechanisms of how 
the clathrin-bind boxes and catalytic domain of OCRL1 interact and control clathrin-mediated 
endocytosis in neurons. In general, the ratio of synthesis and degradation eventually 
determines global protein expression. The late-endosomal and lysosomal localization of 
OCRL1 in cell lines highlight the possibility that OCRL1 plays an essential role for proper 
clearance of proteins, including AMPArs in lysosome and for maintenance of optimal protein 
concentrations required for normal cellular function. Accumulation of non-degraded 
molecules resulting from lysosomal dysfunction has been reported to cause lysosomal storage 
diseases, which lead to multisystem manifestation such as bony abnormalities, 
ophthalmologic signs and intellectual disability 71. It would be interesting to examine whether 
general protein homeostasis is disrupted due to misregulated Ocrl1 levels and whether this 
disruption partially accounts for the pathology of LS. 
Another important finding in the present study is that knocking down Ocrl1 increased the 
magnitude of LTP whereas Ocrl1 overexpression exhibited the opposing effect. Although 
remaining controversial, both lateral movement and exocytosis of AMPArs have been shown 
to contribute to LTP 8,72–77. It is likely that lateral diffusion of AMPArs from nonsynaptic sites 
enhances synaptic strength while exocytosis replenishes the extrasynaptic pool of AMPArs 
during LTP 8. In Ocrl1 lacking neurons, on one hand, elevated surface accumulation enlarging 
extrasynaptic AMPAr pool might facilitate lateral diffusion in response to LTP-induction, on 
the other hand, increased AMPArs levels might subsequently increase the size of intracellular 
reserve pool of AMPArs and indirectly promotes LTP. Future experiments will have to 
determine the precise mechanisms of OCRL1 in controlling synaptic plasticity. 
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Materials and Methods 
Animals  
Wistar rats were housed per 2 or 3 animals on a 12-h light cycle in a temperature-controlled 
(21 ± 1°C) environment with ad libitum access to food and water. Rats were sacrificed at E17, 
P3, P10, P17, P24 and P90 (adult). The hippocampus and cortex were dissected out and snap-
frozen in liquid nitrogen. All samples were stored at -80°C for further analysis. All experiments 
involving animals were evaluated and approved by the Committee for Animal Experiments of 
the Radboud university medical center, Nijmegen, the Netherlands. 
 
RNA isolation, reverse transcription and qPCR  
Total RNA from the tissue was isolated using RNeasy Lipid Tissue mini kit (Qiagen). cDNA was 
synthesized from 0.5–1 mg RNA using iScript™ cDNA Synthesis Kit. QPCR experiments were 
subsequently performed in 7900HT Fast Real-Time PCR System using GoTaq qPCR Master mix 
(Promega). 
 
Immunofluorenscence  
For hippocampal slices from postnatal days 20 rats, brains were fixed, embedded in low 
melting agarose (3%) and then being sectioned into 60 μm sections using a microtome (Leica 
VT-1000S). Free-floating sections or fixed organotypic slices were incubated overnight with 
blocking buffer containing 5% normal goat serum (Invitrogen), 5% normal donkey serum 
(Sigma), 5% horse serum (Sigma), 1% glycine (Sigma), 1% lysine (Sigma) and 0.4% Triton X-
100, permeabilized, and incubated overnight with custom anti-OCRL1 and anti-NeuN ( ABN91, 
Millipore) primary antibodies, followed by incubation with Alexa-488 or Alexa-568 conjugated 
secondary antibody (Invitrogen) in blocking buffer. Sections were mounted onto slides with 
fluorescence mounting medium containing 406-diamidion-2-phenylindole (Dako, Carpinteria, 
California, USA).  
 
Western blotting 
Rat hippocampal tissue or cell culture were collected and homogenized in ice-cold RIPA buffer. 
Lysates were then heated at 95°C for 10 min. Equal amounts of protein samples (50 μg) were 
fractionated on 4%-15% precast SDS-PAGE gels (Bio-Rad) then blotted to nitrocellulose 
membrane (Bio-Rad). Membranes were subsequently incubated for 1h at room temperature 
143
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in 5% milk in PBS-Tween to prevent non-specific binding. Primary antibodies used were: anti-
GluA1 (Millipore) or anti- Υ-TUBULIN (Sigma) as loading control.  Secondary antibodies used 
were: goat anti-mouse HRP (Jackson Immuno Research Laboratories) and goat anti-rabbit 
(Invitrogen). Images were acquired with ChemiDocTM imaging system (Bio-Rad). 
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Spines were analyzed using custom software written in MatLab. All analyses were conducted 
blind to the constructs being expressed. For each experiment, projection images of 40-60 
μ
◦
Ω
μ
139 
Υ
Two-photon laser scanning microscopy 
Hippocampal slices were biolistically transfected at 12 DIV with indicated constructs and 
neurons were imaged 2 days after transfection. Experiments were performed at 30°C in 
physiological ACSF (119 mM NaCl, 26 mM NaHCO3, 1 mM NaH2PO4, 11 mM D-glucose, 2.5 
mM KCl, 2 mM CaCl2, 1 mM MgCl2, and 1.25 mM NaHPO4) gassed with 5% CO2 and 95% O2.  
Before TPLSM imaging, transfected/infected CA1 pyramidal neurons were identified by 
epifluorescence illumination. High-resolution three-dimensional image stacks were collected 
on a laser-scanning microscope (Leica TCS SP5). The light source was a mode-locked 
Ti:sapphire laser (Coherent Chameleon, USA) running at 910 nm. We used an Olympus 20X1.0 
numerical aperture objective. Each optical section was resampled three times and was 
captured every 0.5 μm. Images were taken from regions on apical dendrites, which were 
typically about 100 μm away from the soma and covered 150-200 μm in length. A minimum 
of 500 spines were analyzed per condition for all comparative studies, sister cultures were 
used. For the chemical LTP experiments, slices were incubated with Mg2+ free ACSF containing 
forskolin and rolipram. Images were taken at indicated time points for the same regions of 
interest (ROIs). 
TPLSM Image display 
All images displayed are data from consecutive stacks displayed using a maximum value 
projection. At any given x-y coordinate, the maximum pixel value in that Z- column is displayed 
in the two-dimensional image. Image analysis was conducted on raw data using full Z-stacks 
as discussed below.  
TPLSM Quantitative image analysis 
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consecutive z-series sections were generated for each cell or each time point.  
For spine density and volume experiments spines were identified using green 
fluorescence channel and rectangular ROIs were manually positioned to fully cover each spine. 
Spine density was calculated as the number of manually counted spines divided by dendrite 
segment length. Background-subtracted integrated fluorescence was taken as a measure for 
spine volume after normalizing to mean fluorescence at soma and large apical dendrite. No 
effort was made to analyze spines emerging below or above the dendrite, because the TPLSM 
resolution of these is compromised. It is also possible that many small structures were not 
detected, although point spread function limited structures were observed. Spine density and 
size values were compared using an unpaired two-tailed Student’s t- test. Significance was set 
at p < 0.05.  
Electrophysiology 
Whole-cell recordings in organotypic slices were obtained with Multiclamp 700B amplifiers 
(Axon Instruments). The recording chamber was perfused with artificial cerebrospinal fluid 
(ACSF) containing 119 mM NaCl, 2.5 mM KCl, 4 mM CaCl2, 4 mM MgCl2, 26 mM NaHCO3, 1 
mM NaH2PO4, 11 mM glucose, 0.1 mM picrotoxin, 4 μM 2-chloroadenosine (pH 7.4), and 
gassed with 5% CO2/95% O2. Recordings were made at 30◦C. Patch recording pipettes (4–7 
MΩ) were filled with intracellular solution containing 115 mM cesium methanesulfonate, 20 
mM CsCl, 10 mM HEPES, 2.5 mM MgCl2, 4 mM Na2ATP, 0.4 mM Na3GTP, 10 mM sodium 
phosphocreatine, and 0.6 mM EGTA (pH 7.25, Osm 285-295). Evoked responses were induced 
using bipolar electrodes (FHC) placed on Schaffer collateral pathway (0.1 Hz). Responses were 
recorded at both -60 mV (for AMPAr-mediated responses) and +40 mV (for NMDAr-mediated 
responses). NMDAr-mediated responses were quantified as the mean between 60 and 65 ms 
after stimulation. All data are reported as mean ± SEM. Statistical significance was determined 
by the paired Student’s t-test (for paired recordings).  
Miniature post-synaptic excitatory currents (mEPSCs) on organotypic slices were 
recorded at -60 mV in ACSF containing 2 mM CaCl2 and 1 mM MgCl2 at 32°C in the presence 
of 1 μM TTX and 0.1 mM picrotoxin. 10 min of recordings from each cell were acquired at 5 
kHz, filtered at 2 kHz and analyzed using Mini Analysis Program (Synaptosoft). 
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LTP was induced with a pairing protocol: postsynaptic depolarization at 0mV was paired 
with synaptic stimulation (3 Hz for 90 s). Whole-cell recordings were obtained simultaneously 
from an infected and an adjacent uninfected neuron in the CA1 region under visual guidance, 
using epifluorescence and transmitted light illumination. 
AMPA receptor trafficking assay 
For AMPAr endocytosis assay, living primary hippocampal neurons were first labeled with 
anti-GluA1 antibody (Millipore). Internalization of the labeled GluA1 subunits was then 
allowed for 2 hours at 37°C. After fixation with 4% paraformaldehyde and blocking with 5% 
BSA, surface-labeled GluA1 subunits were exposed to Alexa-568 secondary antibody 
(Invitrogen). After washing, the remaining surface GluA1 subunits were incubated with 
unlabeled secondary antibody at a concentration of 0.13 mg/ml overnight to saturate surface 
anti-GluA1 antibodies. Neurons were then permeabilized and incubated with Alexa-647 
secondary antibody to label internalized GluA1 subunits. GluA1 endocytosis was calculated 
by dividing the intensity of internalized GluA1 by the intensity of surface GluA1 using imageJ 
(I647/I568).  
For AMPAr recycling assay, living primary hippocampal neurons were first incubated with 
Leupeptin for 30 min at 37 °C, followed by labelling with anti-GluA1 antibody (Millipore) at 
10°C for 20 min. Neurons were then incubated for 30 min at 37°C to allow internalization. The 
remaining surface GluA1 proteins were saturated with unlabelled secondary antibody. 
Neurons were then incubated for additional 30 min at 37°C to allow recycling of internalized 
GluA1 subunits. After fixation with 4% paraformaldehyde and blocking with 5% BSA, surface-
labeled GluA1 subunits were exposed to Alexa-568 secondary antibody (Invitrogen). Neurons 
were then permeablized and incubated with Alexa-647 secondary antibody to label 
internalized GluA1 subunits. GluA1 recycling was calculated by dividing the intensity of 
surface GluA1 by the intensity of internalized GluA1 using imageJ (I568/I647).   
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Abstract 
Kinesin superfamily (KIF) genes encode motor proteins that have fundamental roles in brain 
functioning, development, survival and plasticity by regulating the transport of cargo along 
microtubules within axons, dendrites and synapses. Mouse knock out studies support these 
important functions in the nervous system. The role of KIF genes in intellectual disability (ID) 
has so far only received limited attention, although previous studies have suggested that 
many ID genes impinge on synaptic function.  
By applying next generation sequencing (NGS) in ID patients, we identified likely 
pathogenic mutations in two members of the KIF gene family, KIF4A and KIF5C, suggesting 
that these genes may be novel players in ID.  
Four males from a single family with a disruptive mutation in the X-linked KIF4A (c.1489-
8_1490delins10; p.?- exon skipping) showed mild to moderate ID and epilepsy, whereas a 
female patient with a de novo missense mutation in KIF5C (c.11465A>C; p.(Glu237Lys)) 
presented with severe ID, epilepsy, microcephaly and cortical malformation. Of interest, very 
recently in a family with Malformations of Cortical Development (MCD) a missense mutation 
in KIF5C was reported, further confirming a role of this gene in brain development. We found 
further supporting evidence for the causality of the present mutations by showing that knock-
down of Kif4a in rat primary hippocampal neurons altered the balance between excitatory 
and inhibitory synaptic transmission, whereas the mutation in Kif5c affected its protein 
function at excitatory synapses. Our results suggest that mutations in KIF4A and KIF5C cause 
ID by tipping the balance between excitatory and inhibitory synaptic excitability. 
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Introduction 
Kinesin superfamily proteins (KIFs) are motor proteins involved in the movement of various 
cargoes along the microtubules, including vesicles, organelles, protein complexes, mRNAs and 
chromosomes 1–4. KIF proteins act together with motor proteins from the dynein and myosin 
superfamilies. These molecular motors are expected to have fundamental roles in several 
processes in the brain, including neuronal functioning, development, survival and plasticity, 
by regulating the anterograde and retrograde transport within the axons, dendrites and 
synapses of neurons 1–4. Studies in mouse models support these essential functions of KIF 
genes in the development and functioning of the nervous system. Mice with homozygous 
knockout mutations in Kif1a, 1b, 2a, 3a, 3b, 4a, 5a and 5b show various neurological 
phenotypes including structural brain anomalies, decreased brain size, loss of neurons, 
reduced rate of neuronal apoptosis and perinatal lethality due to neurological problems 4–12. 
The embryonic lethality of knockout mice for Kif2a, Kif3a and 3b, and Kif5b suggest that these 
Kif genes have an important function in general developmental processes as well 5,7,8,13. 
Overexpression of Kif17 in mice resulted in enhanced spatial learning 14. Conditional knockout 
of KIF5A in mice led to epileptic phenotypes 15. 
Several KIF genes have previously been implicated in the pathogenesis of 
neurodegenerative and neurodevelopmental disorders in humans. (Table 1)  
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Table 1 KIF genes implicated in neurodegenerative and neurodevelopmental diseases in humans. 
KIF gene Disease Inheritance Reference 
KIF1A (MIM 601255) Hereditary spastic paraplegia type 30  
(MIM 610358) 
Hereditary sensory neuropathy, type IIC 
(MIM 614213) 
Non-syndromic ID 
AR 
 
AR 
 
AD  
(4, 16, 17) 
KIF1B (MIM 605995) Charcot-Marie-Tooth disease , type 2A1  
(MIM 118210) 
Multiple Sclerosis (MIM 126200) 
AD 
 
Susceptibility locus 
(11,18) 
KIF2A (MIM 602591) Malformations of Cortical Development (MCD) AD (19) 
KIF5A (MIM 602821)  Hereditary spastic paraplegia type 10  
(MIM 604187) 
AD (4,20) 
KIF5C (MIM 604593) Malformations of Cortical Development (MCD) AD (19) 
KIF7 (MIM 611254) Acrocallosal syndrome (MIM 200990) 
Hydrolethalus syndrome (MIM 614120) 
Joubert syndrome 12 (MIM 200990) 
Syndromic ID 
AR 
AR 
AR 
AR 
(21–23) 
KIF11 (MIM 148760) Microcephaly with or without 
chorioretinopathy, lymphedema, or mental 
retardation (MIM 152950) 
AD (24) 
KIF21A (MIM 608283) Congenital opthalmoplegia  (MIM 135700) AD (25) 
AR: autosomal recessive; AD: autosomal dominant 
 
 
Only a handful of previous reports relate mutations in KIF genes to intellectual disability 
(ID). Putoux et al. identified homozygous mutations in KIF7 (MIM 611254) in patients with 
acrocallosal syndrome (MIM 200990) and hydrolethalus syndrome (MIM 614120) 21 and 
homozygous mutations in the same gene were also found in patients with Joubert syndrome 
12 (MIM 200990) 22. In these ciliary disorders ID is part of the phenotype. Najmabadi et al. 
identified a homozygous missense mutation in KIF7 by targeted sequencing of exons from 
homozygous linkage intervals in a consanguineous family with ID, clubfeet, cataract, hearing 
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loss and midface hypoplasia 23. More recently, the first dominant de novo missense mutation 
in a KIF gene (KIF1A) was found in a patient with non-syndromic ID 17. Very recently, Poirier 
et al. reported the identification of mutations in KIF2A and KIF5C in patients with 
Malformations of Cortical Development (MCD). These patients presented with ID as well 19. 
Here we report the identification of mutations in KIF4A (MIM 300521) and KIF5C (MIM 
604593) in an X-linked ID family, presenting with mild to moderate ID and epilepsy, and in a 
sporadic patient with severe ID, microcephaly, epilepsy and cortical malformation, 
respectively. In addition, we studied the effects on synaptic function of these KIF genes using 
a knockdown system in rat primary neurons.  
 
 
Results 
Clinical description patients 
Family 1 
We searched for the causative mutation in a family (family 1) with five affected males in 
different generations (Fig. 1), suggesting X-linked recessive inheritance. The patients 
presented with mild to moderate ID, were able to speak simple sentences and lived and 
worked in sheltered places. Four of the five individuals had epilepsy that manifested at later 
childhood or adolescent age and comprised complex partial and generalized seizures (both 
absences and tonic-clonic seizures). Head circumferences were small to low-normal (0.6th-
10th centile). Facial dysmorphisms were mild and non-specific. A CT-scan of the brain in two 
of the probands (III:7 at age 53 years and IV:3 at age 7 years) had shown central atrophy of 
both lateral hemispheres and wide posterior horns, respectively. Previous genetic 
investigations in this family included conventional karyotyping, genome-wide array analysis 
by the 2.7M Affymetrix array platform, DNA analysis of FMR1 (MIM 309550) and ARX (MIM 
300382), and a metabolic screen. The results did not provide an explanation for their 
phenotype. Linkage analysis, based on an X-linked recessive inheritance pattern with 
complete penetrance, indicated two intervals with a LOD-score of 1.8 that could contain the 
pathogenic mutation, one of 70 cM on Xp22q13 and the other of 30 cM on Xq23q27.  
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Figure 1 Pedigree of family 1  
X-linked pedigree of family 1 with 5 affected males over 3 generations. The mutation in KIF4A was 
shown to co-segregate in affected males (III:5, III:6, III:7 and IV:3, a DNA sample of II:5 was not 
available) and was not present in two unaffected males (III:3 and III:8). Females II:1, III:1 and IV:2 were 
carriers. 
 
 
Massive parallel sequencing of the X-chromosome specific exons revealed a likely pathogenic 
in-frame mutation, c.1489-8_1490delins10 (NM_012310.4), in KIF4A, which was predicted to 
affect the acceptor splice site of exon 15.(Fig. 2) KIF4A is located in the large Xp22q13 linkage 
interval. No rare deleterious mutations in known X-linked ID genes were identified. Sanger 
sequencing confirmed the presence of the KIF4A mutation and co-segregation analysis 
showed that the mutation segregated with the phenotype in all affected males (a DNA sample 
of the uncle was not available). In addition, three females from three generations were shown 
to be carriers of this mutation and the mutation was absent in two unaffected males.(Fig. 1) 
Further analysis of the mutation at RNA level and sequencing of the cDNA of the PCR product 
showed that exon 15 is spliced out and skipped. (Fig. 3A and B) Figure 4A shows a schematic 
presentation of the KIF4A protein and the relative position of the altered residue.  
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Figure 2 KIF4A sequences  
(A) shows the sequences of affected males, carrier females and non-affected males.  
(B) shows the predicted splice acceptor sites of the reference sequence and the mutated sequence, 
suggesting that the splice acceptor site of the mutated sequence is severely affected.  
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Figure 3 RNA expression studies in cell-lines of patients from family 1 with a mutation in KIF4A and 
control cell-lines, showing effect on splicing 
Panels (A) and (B) confirm that the KIF4 mutation indeed affects the acceptor splice site of exon 15, 
leading to a skip of exon 15 (186 bp in length), as predicted. RNA was isolated from a cell-line from an 
affected family member and a healthy control person. Primers for PCR analysis were designed at exon 
13/14 (primers CTGCGGTGGAGCAAGAAGCC and AATTTGACCCTCCAGCTCCT, product size 340 bp) and 
exon 16/17 (CTGCGGTGGAGCAAGAAGCC and AATTTGACCCTCCAGCTCCT, product size 525 bp) 
bounderies and cDNA was synthesized. (A) Lane 1 shows the band of the patient (mt), which is 185 bp 
shorter in length as compared to the band in a healthy control (c), likely due to skipping of exon 15. 
(B) Sequencing of the PCR product of the patient sample showed that the sequence of exon 14 is 
directly followed by the sequence of exon 16 (upper part) and thus confirmed that exon 15 is skipped. 
The lower part of the figure shows the normal sequence including exon 15 in a control person. 
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Figure 4 Schematic representations of KIF4A and KIF5C proteins with relative positions of the altered 
residues  
Panel (A) shows the KIF4A protein. PRC1= polycomb-group repressive complex 1. 
Panel (B) shows the KIF5C protein. MTBR= microtubule binding region.  
 
 
Patient 2 
Patient 2 was recently described in a large family-based exome sequencing project performed 
by our group in a series of 100 patients with sporadic ID 26. Poirier et al. also refer to this 
patient in their paper in which they report another family with a mutation in this gene 19. In 
short, patient 2 was born after an uncomplicated pregnancy and delivery with normal growth 
parameters. She had a severe developmental delay, did not acquire the ability to speak and 
could only walk with support since the age of 9 -10 years. First seizures manifested at the age 
of 6 months. Her behavior was characterized by severe automutilation. An MRI-scan of the 
brain at age 15 years showed signs of cortical malformation mainly affecting the frontal cortex, 
including a decreased number of gyri, coarse gyri and shallow sulci. (Fig. 5) These 
abnormalities were also seen to a lesser extent at the temporal cortex and insular cortex. 
During clinical evaluation at the age of 12 years she had a normal height (-1 SD), but a very 
dystrophic build and secondary microcephaly (head circumference: 49 cm (< -2.5 SD)). In 
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addition, she had small hands and feet. She had stereotypic hand movements and a slight 
hypertonia. There were no evident facial dysmorphisms. Because of the phenotypic 
similarities to Angelman- and Rett-like syndromes, DNA analysis of MECP2 (MIM 300005), 
FOXG1 (MIM 164874), CDKL5 (MIM 300203), UBE3A (MIM 601623) and 15q11q13 
methylation tests were performed, which were all normal. Subsequent 250k SNP array 
analysis, DNA analysis of ARX, and a metabolic screen revealed no abnormalities either.  
 
 
Figure 5 Cerebral MRI scan in patient 2, showing cortical malformation 
Panels (A) and (B) show signs of cortical malformation, mainly at the frontal cortex, including a 
reduction in the number of gyri, which have a coarse aspect, and shallow sulci (indicated by the 
arrows). 
 
 
Family-based exome sequencing revealed a highly conserved (PhyloP 6.1) de novo 
c.11465A>C mutation in KIF5C (NM 004522.1), predicting a p.(Glu237Lys) substitution. The 
Grantham score of 56 indicated a moderate physicochemical difference. The mutation affects 
the motor domain of the KIF5C protein, and may, in contrast to deletions previously reported 
for this gene 27,28, not lead to haploinsuffiency, but rather suggests a dominant negative effect 
resulting in abnormal heavy chain dimerization. Figure 4B shows a schematic presentation of 
the KIF5C protein and the relative position of the altered residue. 
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Effect of knockdown of Kif4a on miniature excitatory (mEPSC) and inhibitory postsynaptic 
(mIPSC) currents in rat primary hippocampal neurons  
To find further supportive evidence that KIF4A is involved in the ID phenotype in family 1, we 
performed functional studies at the level of synaptic function in primary rat hippocampal 
neurons. This functional assay has previously been successful to show that OPHN1 mediates 
mGluR-dependent long term depression (LTD) through interaction with the endocytic 
machinery 29. Interestingly Kif4a knockdown using validated small interference (si)RNAs, 
resulted in a significant decrease in mEPSC amplitude but an increase in mEPSC frequency 
compared to control siRNA (Kolmogorov Smirnov (KS) test, P<0.001), suggesting that the 
development of excitatory synapses is hampered in neurons lacking Kif4a (Figure 6A-C). Next 
we measured mIPSCs, a response from quantal release of single GABAA vesicles. Down-
regulation of Kif4a decreased mIPSC frequency but not amplitude, indicating that Kif4a affects 
presynaptic GABAA release and /or inhibitory synapse formation without affecting the amount 
GABAA-receptors (GABAARs) at inhibitory synapses (Fig.6A-C, KS-test, P<0.001).  We did not 
observe any changes in the kinetics of mEPSCs or mIPSCs, indicating that the composition 
and/or function of the glutamate receptors and GABAAR subtype mediating the mEPSCs and 
mIPSCs respectively were unchanged (Fig.6D, E).  
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Figure 6 Effect of KIF4A on mEPSC and mIPSC 
(A) Representative whole-cell current traces (mEPSC) of a control neuron or a neuron transfected with 
siRNAs against Kif4a at holding potential of −60 mV. Scale bars: 1.2 s and 20 pA. (B, C) Cumulative 
probability histograms of mEPSC amplitude and inter-event intervals in control (n=39 neurons), Kif4a 
siRNA treated neurons (n=30 neurons).  Differences between the conditions for the displayed mEPSC 
amplitude and inter-event interval cumulative distributions are statistically significant (P < 0.001, using 
Kolmogorov-Smirnov test).  
(D) Representative whole-cell current traces (mIPSC) of a control neuron or a neuron transfected with 
siRNAs against Kif4a at holding potential of −60 mV. Scale bars: 16 s and 25 pA. (E, F) Cumulative 
probability histograms of mIPSC amplitude and inter-event intervals in control (n=7 neurons), Kif4a 
siRNA treated neurons (n=10 neurons). Differences between control and Kif4a siRNA are statistically 
significant for the displayed inter-event interval cumulative distributions but not for the mIPSC 
amplitude (P < 0.001, using Kolmogorov-Smirnov test).  
 
 
Effect of p. Glu237Lys mutation on KIF5C cellular localization and function. 
Since the mutation p.Glu237Lys in KIF5C is predicted to affect the motor domain we first 
determined whether it affected KIF5c movement along dendrites. To this end we transfected 
primary rat hippocampal neurons with Yellow Fluorescent Protein (YFP)-tagged wild-type 
KIF5C (KIF5C-WT) or mutant KIF5C (KIF5C-E237K) construct. KIF5C-WT accumulated in distal 
regions of the dendrites (Fig.7A, C), whereas KIF5C-E237K showed a significant reduction in 
distal localization and a relative increased accumulation throughout the cell body (Fig. 7B, C, 
t-test P<0.05). Next to determine the functional consequence of the missense mutation we 
compared the effect of overexpressing KIF5C-WT versus mutant KIF5C-E237K and control (YFP 
only) on mEPSCs in hippocampal neurons. Overexpressing KIF5C-WT resulted in an increase 
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in mEPSC frequency compared to control transfected neurons (Fig.7D-E, KS-test, P<0.001). 
However overexpressing KIF5C-E237K failed to increase mEPSC frequency, but in contrast led 
to a significant decrease in mEPSC amplitude. Together these data indicate that the missense 
mutation found in KIF5C leads to a non-functional motor domain.  
 
 
Figure 7 Impact of p.Glu237Lys on KIF5C localization and function 
(A, B) Representative images showing the subcellular localization of YFP-tagged KIF5C-WT and KIF5C-
E237K. YFP-tagged constructs of KIF5C were expressed in cultured hippocampal neurons and 
visualized by immunofluorescence staining with an anti-GFP antibody. KIF5C-WT accumulated in the 
distal regions of the dendrites, in contrast to KIF1C-E237K. The neuronal cell bodies and dendrites 
were stained with anti-MAP2 antibody. Scale bars upper image: 20 Pm, lower image: 4 Pm. (C) 
Quantification of dendritic expression of YFP-tagged KIF5C-WT and KIF5C-E237K. Dendritic signal of 
KIF5C-WT and KIF5C-E237K was normalized to its signal in the soma (P <0.05, using t-test, n=6 
neurons). (D, E) Cumulative probability histograms of mEPSC amplitude and inter-event intervals in 
control (n=30 neurons), KIF5C-WT expressing neurons (n=13 neurons) and KIF5C-E237K expressing 
neurons (n=27 neurons). Differences between the conditions for the displayed mEPSC amplitude and 
inter-event interval cumulative distributions are statistically significant (P < 0.001, using Kolmogorov-
Smirnov test).  
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Discussion 
The role of KIF genes in the origin of ID has so far only received limited attention, although a 
growing body of work suggests that many ID genes impinge on synaptic function and as such 
contribute the pathophysiology of the disorder 30. In particular, the balance between 
excitatory and inhibitory synaptic input seems to be disturbed in common 
neurodevelopmental disorders including ID, autism and schizophrenia. 
 Our data show that both KIF4A and KIF5C are important proteins that regulate synapse 
development. In particular KIF4A is a critical protein in controlling the tight balance between 
excitatory and inhibitory inputs during development since knocking down Kif4a resulted in a 
decrease in mIPSCs but an increase in mEPSCs, albeit with a lower amplitude. A disturbed 
balance between excitatory and inhibitory drive could therefore explain the presence of 
epilepsy in the patients. Moreover, we showed that the reported missense mutation in Kif5c 
affects its protein function at excitatory synapses. 
A synaptic function for KIF4A has so far not been explored, whereas KIF5 was recently 
reported to be involved in regulating both glutamatergic and GABAergic synaptic transmission 
in striatal and cortical neurons 31–33. The specific contribution of KIF5C hereto has however 
not been determined.  
KIF4A belongs to the class of the N5-kinesins and is highly expressed in differentiated 
young neurons. It consists of a N-terminal motor domain, a central stalk domain and a C-
terminal C-domain 34. Previous studies showed that KIF4A has various functions and plays a 
role in chromosome condensation and midzone spindle pole formation essential for 
cytokinesis and chromosome segregation during mitosis, as well as in regulation of activity-
dependent neuronal survival and apoptosis, thereby regulating the number of neurons during 
murine brain development 9,35,36. After dissociation from the enzymatic protein poly (ADP-
ribose) polymerase 1 (PARP1), which prevents apoptosis, KIF4A moves into the neurites. Here, 
it possibly transports cargoes essential for neuronal development, such as the adhesion 
molecule L1 which is required for axon formation and synapse development 9,37. Although 
KIF4A was shown by several studies to be involved in spindle pole organization, most studies 
concluded that KIF4A deficient cells show a normal mitotic division. Aneuploidy analysis in 
cultured blood lymphocytes from one of the patients of family 1 showed no increased level 
of aneuploid cells, which is in agreement with the observation in most other studies that 
mitosis is not significantly disturbed 9,35,38. 
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KIF5C, together with KIF5A and KIF5B, belongs to the class of N-1 kinesins and is specifically 
expressed in nervous tissue 1,13,39. Mice with a homozygous knockout of KIF5C are viable and 
do not show gross abnormalities in the nervous system, except from a smaller brain size and 
relative loss of motor neurons to sensory neurons. This mild phenotypic presentation is 
explained by a high similarity between the three KIF5 genes and functional redundancy 13.  
The missense mutation in the family reported by Poirier et al 19 is associated with a severe 
phenotype including severe Malformations of Cortical Development (MCD) and microcephaly, 
which shows remarkable overlap with the phenotype in the present patient 2, who also 
presented with microcephaly and has signs of cortical malformation on her brain MRI as well. 
Interestingly, Poirier et al. showed that expression of the missense variant that they found in 
the family with MCD (p.Glu237Val) in Escheria Coli, results in a complete inability of the 
protein to hydrolyze ATP in a microtubule dependent assay. Of note, this missense variant is 
located at the same position as the here reported variant and affects the microtubule-
interacting domain. In addition they found an altered distribution of the protein. These data 
are in agreement with our results that show that the missense mutation in KIF5C leads to a 
non-functional motor domain, a significant reduction in distal localization of the protein and 
a relative increased accumulation throughout the cell body. 
In summary, these data support the involvement of members of the kinesin superfamily, 
KIF4A and KIF5C, in ID phenotypes. Identification of other patients with mutations in these 
genes should further confirm the role of KIF4A and KIF5C in ID phenotypes and may give 
further insights in the full clinical spectrum. This spectrum likely includes neuronal migration 
defects as was supported by the aberrant cortical formation in patient 2 and the previously 
reported family. 
At the functional level, we found that both KIF4A and KIF5C may contribute to the 
pathophysiology of ID by altering the balance between excitatory and inhibitory synaptic 
efficacy leading to changed neuronal excitability. As such these genes can be added to the 
growing list of ID genes that influence synaptic functioning 30. Together with recently reported 
mutations in similar and other proteins involved in the motor protein complex of the 
microtubule transport pathway, including DYNC1H1, KIF2A and TUBG1 19,40, our findings 
indicate that this pathway may be of great importance to ID, and suggest that other genes 
encoding proteins in this pathway may well be potential candidates for ID phenotypes.   
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Materials and Methods 
Next generation sequencing (NGS) approaches 
Family 1 was included in a larger project involving sequencing of all exons of the X-
chromosome in >200 families with X-linked ID. For each family, DNA from one affected male 
was subjected to targeted enrichment of all X-chromosome specific exons followed by NGS. 
The enriched and sequenced exons encompassed 99.2% of the 7,759 disease-causing X-
chromosomal changes listed in the Human Gene Mutation Database (HGMD, update April 
2011). Variants were filtered against dbSNP135, control populations (185 genomes from the 
1000 Genomes Project Consortium; http://www.1000genomes.org/data, 200 Danish exomes, 
the NHLBI Exome Sequencing Project (ESP, freeze 5400)) as well as an in-house database 
(Kalscheuer et al., personal communication). Variants with a minor allele frequency of ≥ were 
excluded.   
In patient 2 we performed family based whole exome sequencing as previously described 
by de Ligt et al 26. 
Confirmation of mutations and segregation analysis were done by Sanger sequencing.  
 
RNA expression studies in cell-lines of patients from family 1 with a mutation in KIF4A  
RNA was isolated from a cell-line from an affected family member and a healthy control 
person. Primers for PCR analysis were designed at exon 13/14 and exon 16/17 bounderies 
and cDNA was synthesized. Sequencing of the PCR product in an affected family member and 
the healthy control person was performed to confirm skipping of exon 15 in the patients. 
 
siRNAs, DNA constructs, hippocampal neurons and transfection  
The following validated siRNAs were obtained from Sigma Aldrich: Kif4a; 
SASI_Rn02_00290987  5’- CUAAUGACUUCUGUAGCUU-3’;  SASI_Rn02_00290988 5’- 
CAUCUAGAACUGAAACCUA-3’; SASI_Rn02_00290989 5’- CAACCUAGAGGAAACAUUA-3’. Kif5c; 
SASI_Rn02_00231705 5’- GGUUACAAUGGGACAAUUU-3’; SASI_Rn02_00231706; 5’- 
GCUUCUAGCUUCCACCAGA-3’; SASI_Rn02_00231707 5’- CAGAGAACUCCAGACUCUU-3’. The 
BLOCK-iT fluorescent oligo (Invitrogen) that is not homologous to any known genes was used 
as transfection efficiency detector and a negative control. Each siRNA was tested in 
hippocampal neurons and validated using quantitative PCR. Primary hippocampal neurons 
were prepared as described previously 29 and transfected with siRNAs at 6 days in vitro (DIV). 
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Three days later, whole-cell recordings were obtained from transfected neurons. In 
experiments in which we examined the role of KIF5C-WT and KIF5C-E237K on mEPSCs, 
primary hippocampal neurons were electroporated immediately after dissociation using the 
Amaxa Nucleofector device (Amaxa GmbH). 3μg total of GFP, KIF5C-WT and KIF5C-E237K 
plasmids was used per electroporation. Whole-cell recordings were conducted from 
transfected neurons in every group. The YFP-KIF5c (KIF5c-WT) construct was a gift from Dr. A. 
Stephenson. The KIF5C mutant (KIF5C-E237K) was generated by introducing a point mutation 
(E237K) using the Quick Change system (Stratagene).  
 
Measurement of miniature excitatory (mEPSC) and inhibitory postsynaptic currents (mIPSC) in 
rat primary hippocampal neurons. 
Whole-cell voltage-clamp recordings were performed from control neurons or neurons 
transfected with siRNAs against Kif4a or cDNA expressing KIF5C-WT/E237K at holding 
potential of −60 mV in ACSF containing 2.5 mM CaCl2 and 1.2 mM MgCl2 at 30°C. mEPSCs 
were recorded in the presence of 1 μM TTX and 0.1 mM picrotoxin. mIPSCs were recorded in 
the presence of 10 μM CNQX and 100 μM APV. Five to 10 min of recordings were analyzed 
from each cell using the Mini Analysis Program (Synaptosoft). The amplitude of mEPSCs and 
mIPSCs is directly related to the postsynaptic strength, whereas the frequency is correlated 
to the presynaptic release properties and/or the amount of functional synapses.   
 
Immunofluorescence 
To detect the localization of KIF5C-WT and  KIF5C-E237K transfected primary hippocampal 
neurons were fixed at 21 DIV in 4% paraformaldehyde with 4% sucrose solution, 
permeabilized with 0.2% Triton X-100 in PBS, and incubated overnight with following primary 
antibodies: anti-MAP2 (synaptic system) and anti-GFP (Abcam). As secondary antibodies we 
used: Alexa-568 and Alexa-488 donkey anti-rabbit or anti-guinea pig (Invitrogen). 
Immunofluorescence was visualized under a fluorescent microscope (Axio Imager Z1; Zeiss, 
Basle, Switzerland) equipped with a camera (AxioCam MRm; Zeiss). Images were processed 
using Axiovision Rel (version 4.6) and analyzed using ImageJ (NIH, Bethesda). For each 
condition, 3 dendrites per neuron were analyzed (n= 6 neurons/group). Dendritic signal of 
KIF5C-WT and KIF5C-E237K was normalized to its signal in the soma. 
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Chapter 7 
General discussion and future prospects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part of this chapter has been published as a commentary: 
Rho GTPases at the synapse: An embarrassment of choice.  
Small GTPases. 2016 5:1-8. 
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How the brain governs cognitive processes is a fundamental question that attracts numerous 
neuroscientists to dedicate their entire careers for seeking answers. Although considerable 
progress has been made in the past few decades in neuroscience, we are just beginning to 
uncover the mysteries of the human brain. The aim of the research described in this thesis is 
to enrich our knowledge of the cellular and molecular mechanisms underlying learning and 
memory, and therefore to advance our understanding of how cognition in adulthood is 
affected by developmental mechanisms in neurodevelopmental disorders, such as ID and ASD. 
With the main focus on the genes that are involved in Rho GTPase signaling pathways, I have 
contributed to reveal the roles of several previously uncharacterized genes, most of which 
are linked to ID, in neuronal development at the synaptic level (chapters 3-6). Here, I will 
reflect on these results and discuss future prospects in a general framework. 
 
1. Rho GAPs and GEFs in the brain 
1.1 Transcriptional mapping of novel Rho regulators  
Cognitive functions including learning and memory rely on proper performance of the CNS at 
the cellular and molecular level. Rapid remodeling in the shape and the amount of actin-
enriched dendritic spine during development and in response to stimuli has been 
demonstrated to be critical for normal neuronal function and plasticity. As key regulators of 
actin cytoskeleton, Rho GTPases and their regulators act as molecular switches in diverse 
actin-based cellular processes, including modification of spine morphology and synaptic 
efficacy. So far, more than 80 GEFs and more than 70 GAPs exist in the human genome, 1–3 
providing a ratio between the number of Rho GTPases and GEFs/GAPs about 4 to 1. Although 
lots of efforts have been made to unmask the detailed regulatory role of Rho proteins at 
different developmental stages in CNS, the field still lacks a complete picture of why and how 
the brain utilizes “overabundant” molecules involved in Rho GTPase signaling to achieve a 
precise regulation of synaptic strength during development and cognition. One hypothesis is 
that excess GEFs and GAPs enable neurons to temporally and spatially restrict their responses 
to local extracellular cues and further ensure proper connectivity for learning and memory 
(reviewed in refs. 4, 5). A detailed description of spatial-temporal expression pattern of 
previously uncharacterized Rho proteins may further help us to appreciate the logic behind 
the complexity of Rho GTPases and their regulators, and eventually their function in the brain.  
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In this thesis, I have contributed to generate a transcriptional developmental map of Rho 
GTPases and their regulators in the hippocampus and the cortex, two core regions govern 
learning and memory (chapter 2). The results revealed, at least in part, the diverse and unique 
expression patterns of individual genes encoding Rho GTPases and their regulators during 
hippocampal and cortical development, supporting the hypothesis that the cellular specificity 
of Rho regulatory proteins determines the functional specificity of Rho GTPase signaling 
pathways in the brain. For example, I found that Arhgap12 and Arhgap15, two closely related 
members of the RhoGAP subfamily 6, exhibit complimentary expression patterns. Arhgap12 
was found to be highly expressed in early development whereas the level of Arhgap15 rapidly 
increases after birth and reaches a peak level in adulthood. Thus, it is likely that Arhgap12 and 
Arhgap15 govern Rho GTPase signaling pathways and subsequent cellular events at 
complementary developmental stages. Based on the information provided in this map, I 
further performed in depth investigations on several interesting Rho regulators including 
Arhgap12, Trio and Ocrl1 (chapters 3-5). Future experiments identifying gene expression 
profiles for other uncharacterized Rho regulators will be necessary for completing the 
transcriptional mapping of Rho regulators and providing an overview of how the brain 
manipulates these proteins to control synaptic development.  
Previous studies have indicated that several transcriptional factors including p53 and Myc 
can regulate gene expression of some Rho GTPases7. However, full characterization of the 
regulation of developmental expression of Rho regulatory proteins remains elusive. Future 
experiments will determine the transcriptional mechanisms that control gene expression of 
Rho proteins during development under physiological and pathophysiological settings. Of 
note, besides the transcriptional control, levels of Rho GEFs and GAPs can also be fine-tuned 
at the translational level. For example, microRNAs including miR-21 and miR-138 have been 
found to regulate Rho GTPase gene expression in non-neuronal cells at the post-
transcriptional level 8,9. Therefore the mRNA levels might not precisely reflect protein levels 
of Rho regulators. It would be interesting to evaluate how the translational machinery 
contributes to maintain the homeostasis of Rho regulatory proteins at both whole-cell and 
single synapse levels for normal neuronal function.  
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1.2 Synaptic functions of novel Rho regulators  
One major aim of this PhD thesis was to uncover the functions of novel Rho GEFs and GAPs 
during brain development at the synaptic level. Focusing on the Schaffer collateral pathway, 
the most-studied and best-characterized synapses, I have shown detailed functional analysis 
of three important Rho regulatory proteins: the RacGAP ARHGAP12 (chapter 3), the ID 
associated RacGEF TRIO (chapter 4) and the Lowe syndrome protein OCRL1 (chapter 5). Here, 
based on the results and the previous findings, I propose three possible approaches, in 
addition to previously summarized regulatory manners (reviewed in ref. 5), for neurons to 
accurately control synaptic strength via Rho GTPase signaling pathways during development. 
 
a. Using individual multifunctional GEFs/GAPs at synapses 
In chapter 3 of this thesis, I uncovered a dual function for the previously uncharacterized 
RhoGAP, ARHGAP12, specifically at hippocampal excitatory synapses during development 10 
(Fig. 1A). ARHGAP12 is able to orchestrate synaptic efficacy by modulating both spine 
morphology and surface AMPAr levels at the post-synaptic compartment. Overexpression of 
ARHGAP12 reduced both spine density and volume while knocking down ARHGAP12 resulted 
in increased spine volume without affecting spine density. Functionally, elevated levels of 
ARHGAP12 significantly depressed CA3-CA1 synapses, and on the contrary, potentiated 
excitatory synaptic transmission was observed in ARHGAP12 downregulated neurons. The 
data further showed that ARHGAP12 is able to actively regulate excitatory AMPAr endocytosis. 
More importantly, I demonstrated that two distinct pathways are engaged to mediate 
structural and functional alterations respectively. On one hand, the GAP activity of ARHGAP12 
allows it to regulate the activity of its target Rac1 GTPase and subsequently modulate the 
morphology of dendritic spines. On the other hand, by interacting with the F-BAR protein CIP4, 
ARHGAP12 is involved in the endocytic machinery and further regulates AMPAr endocytosis. 
A similar mechanism has been observed in studies of OPHN1, whose mutations have been 
associated with ID. 11 OPHN1 regulates spine structure through its RhoGAP activity and 
maintains normal AMPAr recycling via interacting with Homer1b/c. 12,13 Moreover, via 
interactions with endophilin A2/3, OPHN1 also mediates persistent decreases in surface 
AMPArs in mGluR-LTD. 14 Together, these findings strongly indicate that neurons can optimize 
synaptic efficacy by making use of individual multifunctional proteins involved in Rho GTPase 
signaling at synapses (Fig. 3A). It is not hard to imagine that several advantages may come 
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from this approach. Firstly, using one protein to regulate cellular events that alter synaptic 
structure and function in the same direction would greatly reinforce and ensure desired 
synaptic modifications in response to experience and/or development to occur correctly. 
Secondly, it enables neurons to respond to external cues more rapidly since one signal might 
already be sufficient to trigger structural and functional modifications simultaneously. Lastly, 
it provides an optimal energetic setting at synapses in the CNS. It has been shown that the 
largest component of brain energy is used at synapses and disruptions thereof have been 
found to present pathological effects (reviewed in ref. 15). Using multifunctional Rho GTPases 
and their regulators may contribute to turning on an energy-saving mode at synapses and 
maximize energy supply for normal cognitive processes. 
In line with the spatiotemporal specificity of ARHGAP12, namely its unique expression 
pattern in excitatory neurons of CA1 subregion at early developmental stages, my results 
suggest that ARHGAP12 functions as a synaptic “brake” during hippocampal development by 
limiting silent synapses converting to active synapses (Fig. 1B). Additionally, I also observed a 
positive feedback loop between synaptic activity and ARHGAP12 mediated signaling pathway, 
in the sense that synaptic activity is required for ARHGAP12 repression, and in turn, 
ARHGAP12 downregulation enhances synaptic efficacy. Overall, these results indicate that by 
regulating the levels of individual multifunctional molecules involved in Rho GTPase signaling, 
neurons may adjust to environmental stimuli and developmental changes, and consequently 
maintain synaptic strength and connectivity in an optimal range.  
Notably, Arhgap12 mRNA was recently identified as a potential target of FMRP, an RNA 
binding protein that represses translation 16 and loss of function mutations in FMRP gene 
result in Fragile X Syndrome (FXS). A form of protein synthesis-dependent synaptic plasticity, 
mGluR-LTD, has been demonstrated to be exaggerated in a mouse model of FXS (Fmr1 KO 
mice), due to the absence of FMRP mediated repression of “LTD” proteins. Several 
mechanisms including PICK1-GluA2 interaction, 17,18 OPHN1-endophilin interaction, 14 PKC-
dependent phosphorylation of GluA2, and activation of the Rac1-LimK-cofilin signaling 
pathway 17–20 have been implied in the regulation of mGluR-LTD. Based on these reports and 
our observation of ARHGAP12 being a repressor of spine morphology and synaptic strength, 
we speculate that ARHGAP12 could be perfectly situated to act as a coordinator to structurally 
and functionally weaken synapses during plasticity. Moreover, it could also serve as a 
potential target to reverse the exaggerated mGluR-LTD phenotype observed in FXS. One of 
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the current focuses in our group is to seek direct experimental evidence to evaluate this 
hypothesis. Experiments combining electrophysiological, molecular biological and behavioral 
approaches in Arhgap12 knockout animals will provide novel insight of how ARHGAP12 is 
involved in mGluR-LTD and how neurons command multifunctional GEFs and GAPs to 
precisely regulate cognitive processes. 
 
Figure 1 Synaptic function of ARHGAP12 during hippocampal development. (A) ARHGAP12 is almost 
exclusively expressed in CA1 excitatory neurons. Overexpression of ARHGAP12 significantly reduces 
both spine density and volume while downregulation leads to increased spine size without affecting 
the density. Electrophysiologically, elevated ARHGAP12 levels depress both AMPAr- and NMDAr-
mediated synaptic transmission whereas reduced ARHGAP12 levels specifically enhance AMPAr-
mediated transmission. In addition, knocking down ARHGAP12 promotes silent synapses converting 
to functional synapses. (B) ARHGAP12 acts as a synaptic “brake” during hippocampal development. In 
rodent, rapid synaptogenesis in the hippocampus occurs between the second and the third postnatal 
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week followed by a selective pruning in adolescence and maintenance in adulthood. The expression 
of ARHGAP12 protein in CA1 subregion gradually declines in the first three postnatal weeks and 
sustains low levels throughout hippocampal development, which releases the “brake” and allows for 
synaptogenesis. 
 
 
b. Using homologs displaying opposing effects 
Many of the GAPs and GEFs are highly identical in terms of their structure. As it has been 
proposed, the spatiotemporal expression pattern could explain the functional divergence. A 
typical example is α-chimaerin, a RhoGAP possessing GAP activity towards Rac1 and to a lesser 
extend to Cdc42. There are two isoforms of α-chimaerin, α1- and α2- chimaerin, which both 
contain C1 and RhoGAP domains but differ in that the α2-chimaerin contains an N-terminal 
SH2 domain that is absent from α1. 21 Interestingly, both isoforms strongly differ in their 
temporal expression. Whereas α2-chimaerin is strongly expressed early in development, the 
expression of α1-chimaerin coincides with synaptogenesis, resulting in a high expression in 
mature neurons. In concordance, both isoforms have been found to have very distinct 
functions. Αlpha2-chimaerin has been found important for axon guidance and neuron 
migration, 22–24 whereas α1-chimaerin has a specific role in spine pruning in the hippocampus 
and cerebellum. 25,26 
In addition to the discoveries above, homologs involved in Rho GTPase signaling may also 
target common cellular processes during development in a counterproductive manner. A 
striking example occurs along the functional characterization of Trio and its ortholog Kalirin. 
Initial studies indicated that Trio full-knockout mice display embryonic lethality 27. Moreover, 
disrupted cerebellum development, such as abnormal neurite growth and granule cell 
migration, has been observed in conditional knockout mice of Trio. 28 Recently, we identified 
TRIO as a responsible gene for mild to borderline ID and further revealed its contribution 
during neurite outgrowth and basal synaptic transmission (chapter 4). 29 Our results showed 
that reduced Trio levels promote neurite outgrowth and specifically enhance AMPAr-
mediated transmission, indicating that the endogenous TRIO restricts these two critical 
cellular events (Fig. 2). Surprisingly, although sharing more than 80% of the sequence, the 
effect exhibited by TRIO is opposing to that displayed by Kalirin, which stimulates neurites 
outgrowth and is required for activity-dependent spine enlargement and enhancement of 
AMPAr-mediated transmission. This scenario is of particular interest since it represents 
another approach of neurons accurately regulating multiple critical events of neuronal 
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development. By choosing structural identical homologs displaying opposite synaptic function, 
neurons may achieve a fine balance that is required for all neuronal events including 
migration and synaptogenesis and accurately steer brain development in the proper direction 
(Fig. 3B). Of note, a recent study reported that neurons with elevated levels of a specific 
isoform of TRIO, TRIO-9, displayed increased AMPAr-mediated synaptic transmission. 30 Also, 
knocking down endogenous TRIO at 1 day in vitro (1 DIV) when Trio is the most profoundly 
expressed led to a deficit in synaptic transmission, 30 an opposite effect of reducing TRIO levels 
at a later time point, 4 DIV. These findings imply that variants of GEFs and GAPs might exhibit 
distinct function and aberrations in their levels occurring at different stages of development 
may result in diverse, even completely opposing impact at synapses. Future experiments are 
needed to test this idea. 
 
 
Figure 2 Synaptic function of TRIO in the hippocampus. Reduced expression of TRIO increases 
dendritic complexity and enhances synaptic transmission at CA3-CA1 synapses.  
 
 
c. Recruiting multiple GEFs/GAPs to target common cellular events 
A recent study reported the contribution of ARHGAP12 in regulating phagocytosis, 31 an 
important event responsible for eliminating particles in diverse cell types. A common feature 
of the phagocytic process, regardless of the type of receptor bound or the size of the target 
particles, is the involvement of actin cytoskeleton remodeling. 32 Interestingly, other studies 
showed that both phagocytosis and excitatory synaptogenesis require Rac1 activation 
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downstream of BAI1. 33,34 Schlam et al. have demonstrated that ARHGAP12 acts synergistically 
with two other GAPs, SH3BP1 and ARHGAP25, to disassemble actin, a critical step underlying 
phagosome maturation for completing the internalization of large targets. Sustained Rac or 
Cdc42 activities resulted from silencing one of the three Rho GAPs can compromise 
phagocytic efficiency. 31 These findings, in RAW 264.7 cell lines, may provide a hint of why and 
how multiple Rho regulators are required in CNS. Instead of being functionally redundant, 
multiple Rho regulators, with overlapping functions, might be engaged in the same neuronal 
event to ensure it takes place flawlessly (Fig. 3C). Given that both endogenous ARHGAP12 and 
TRIO are the most abundant at early developmental stages in the hippocampus and that both 
are present at synapses and limit synaptic transmission, it stands to reason that ARHGAP12 
and TRIO may serve as GEF-GAP partners and restrict synaptic strength collaboratively in 
order to keep neuronal connectivity optimal. Future experiments are required to evaluate 
this possibility, clarify respective contributions of ARHGAP12 and TRIO and further identify 
more pivotal GEFs and/or GAPs partners in controlling normal synaptic function.  
 
 
Figure 3 Three approaches utilized by neurons to precisely regulate synaptic efficacy. (A) Using 
individual multifunctional RhoGTPase regulatory proteins. (B) Using homologs displaying opposing 
effects. (C) Recruiting multiple GEFs/GAPs to target common cellular event.  
 
179
175 
 
2. AMPAr dysregulation in ID 
ID is a prevalent global disorder which is characterized by substantial limitation in both 
adaptive behavior and intellectual abilities. Apart from environmental factors such as fetal 
alcohol syndrome, exposure to neurotoxic compounds and extreme malnutrition, genetics is 
considered to play an important role in the etiology of ID. To date, more than 700 genes have 
been identified to be associated with ID and the number of ID genes is still increasing 35. By 
closely collaborating with geneticists, we combined a top-down approach, namely using 
genetic techniques and human phenotypes to identify novel ID associated genes, with a 
bottom-up strategy applying molecular biology, electrophysiology and imaging techniques in 
cellular models to uncover their functions at the synaptic level and contribute to identify 
novel therapeutic targets.   
With a major focus on the genes involved in Rho GTPase signaling, I have performed 
functional analysis on four ID associated genes which are presented in this thesis: TRIO 
(chapter 4), OCRL1 (chapter 5), KIF4A (chapter 6) and KIF5C (chapter 6). Interestingly, in 
addition to the ability of modulating dendritic spine structure, all four genes appear to directly 
affect AMPArs, one of the most important receptors mediating fast excitatory transmission in 
the CNS. For instance, loss of Trio impairs AMPAr endocytosis while down-regulation of Ocrl1 
significantly reduces AMPAr endocytosis as well as elevates cellular abundance of AMPArs. 
Also, in line with previous studies highlighting the role of KIF family members in transporting 
AMPArs along microtubule tracks in dendrites 36, knocking down Kif4a or overexpressing Kif5c 
results in an increased in AMPAr-mediated mEPSCs frequency. Although previous evidence 
shows that spine geometry is tightly correlated with AMPAr content at synapses, these 
findings indicate that proteins encoded by ID genes may also target AMPArs directly and 
contribute to multiple regulatory processes of AMPAr dynamics, such as synthesis, trafficking 
and degradation, during normal development and cognition. Consistently, studies on other ID 
proteins support their roles in the direct modulation of AMPArs. For example, RAB39B, whose 
encoded gene is linked to ID and ASD, has been recently found to interact with protein 
interacting with C-kinase 1 (PICK1), control surface expression of GluA2 subunit of AMPArs 
and subsequently synaptic transmission 37. These findings may raise another interesting 
question: how are multiple AMPAr modulating proteins organized under physiological 
conditions? A recent study applying high-content protein analysis identified SorCS1 as a 
master regulator of synaptic AMPAr trafficking 38. Linking to major sorting pathways, SorCS1 
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acts as a hub in controlling receptor surface expression including AMPArs in neurons. This 
discovery may initiate an interesting concept of studying synapses at a global level. Besides 
SorCS1, other proteins or machineries might co-exist and function as an intracellular 
“distribution center” for proteins that possess the ability of direct regulation of AMPArs. 
Precise and effective sorting and delivery of AMPAr modulating molecules including 
ARHGAP12, TRIO, OCRL1, KIF4A and KIF5C are required for normal development and 
cognition. Any misdelivery at improper time and location or delivery of “wrong” products will 
hamper synaptic transmission and lead to neurological disorders including ID. It would be 
interesting to test this possibility and identify master molecules of integrating multiple AMPAr 
regulators. The outcome may provide valuable information of novel therapeutic targets which 
is efficacious in treating ID. 
Although we still have a long way to go before we are able to achieve effective 
interventions of various neurological disorders, current knowledge may point AMPAr as a 
potential target for the treatment. Not only are AMPArs critical for basal synaptic 
transmission and plasticity, but also their activity plays an important role in the maintenance 
of dendritic spines 39. Hence, in theory, interventions targeting AMPArs might be beneficial 
for restoring both structural and functional deficits and, eventually, alleviate or reverse the 
symptoms in neurodevelopmental disorders including ID 40. In fact, several AMPAr 
antagonists have been used in treating epilepsy in spite of the tolerance. It is worth noting 
that although some positive AMPAr modulators have been shown to improve cognition in 
health and elderly volunteers 41,42, they have not been advanced into phase II trials due to the 
low potency or toxicity. It implies that direct regulations of AMPArs might result in dramatic 
consequences which makes this strategy unsuitable for clinical use. New medications or 
treatments targeting AMPArs indirectly via AMPAr regulatory molecules such as ARHGAP12 
and TRIO may be considered. Furthermore, recent studies have presented encouraging 
results in treating neurodevelopmental disorders 43,44. For instance, turning on SHANK3, an 
ASD associated gene, in the adult mice reverses both neuronal structure and function in 
striatum as well as obsessive grooming behavior 44. Thus, selectively switching on and off of 
AMPAr modulators in specific brain regions at certain developmental stages by applying novel 
genetic and engineering technology may provide promising therapeutic intervention. Future 
experiments will have to test this possibility. 
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3. Rho GTPases and sleep disturbances in ID 
Although being one of the most burdensome symptoms of ID, sleep disturbances have 
received surprisingly limited attention in research. In fact, sleep problems have been 
observed not only in ID, but also in many other neurodevelopmental disorders such as ASD, 
attention deficit hyperactivity disorders (ADHD) and epilepsy. Sleep disturbances are now 
included in the diagnostic criteria for several neurodevelopmental disorders. Previous studies 
have shown that the estimated prevalence of sleep problems in people with ID is as high as 
86% 45. Due to lacking of mechanistic insights, ID patients with sleep disturbances are far from 
certain to receive effective and personalized treatments. Sustained sleep difficulties, on one 
hand, negatively influence the behavior of ID patients, on the other hand, significantly 
increase the parenting burden and family distress. Therefore, there is an urgent need to clarify 
the underlying mechanisms of sleep disturbances in ID. Based on the frequent correlation 
between ID and sleep disturbances, two fundamental questions may be asked: 1) Do the 
processes of sleep and learning/memory share common signaling pathways or neuronal 
circuitries? 2) Do Rho GTPases and their regulators, whose mutations often lead to ID, play a 
role in regulating sleep?  
Despite that the detailed mechanisms underlying both sleep and learning/memory still 
remain elusive, we could appreciate and get inspired by previously reported observations. 
Two major aspects in the field of sleep neurophysiology received the most attention: the 
biological function of sleep and the regulatory mechanisms of sleep. One dominant 
hypothesis regarding the function of sleep is the “synaptic homeostasis hypothesis” (SHY) 
proposed by Cirelli and Tononi 46, which indicates that the fundamental function of sleep is to 
restore synaptic homeostasis. This hypothesis is supported by direct experimental evidence 
at the cellular and molecular level. It has been shown that dendritic spine formation and 
pruning are affected by sleep/wake cycles, in which waking causes a net increase in cortical 
spines while sleep leads to net spine loss in adult cortex 47. Also, enhanced synaptic strength 
has been detected during wakefulness whereas sleep results in an opposing effect 48. 
Consistently, 30%-40% reduction of AMPArs as well as removal of synaptic AMPArs have been 
observed during or after sleep in rats 49,50. Due to the previous discoveries and the results 
presented in this thesis, which highlight the importance of Rho GTPase signaling in regulating 
synaptic structure and function in developing and mature brains, I believe that it is worth to 
examine whether Rho GTPases and their regulatory proteins could sense the distinct 
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extracellular cues (e.g. different expression levels of adenosine due to different neuronal 
activities during sleep and wakefulness), transfer the information and eventually control 
synaptic homeostasis during sleep/wake states. Interestingly, my preliminary data revealed 
fluctuations in the protein level of ARHGAP12 at different time during a day (data not shown). 
It would be interesting to test whether this fluctuations contribute to modifying dendritic 
spine structure and synaptic transmission during sleep. 
Moreover, one influential two-process model of sleep regulation suggests that the 
interaction of circadian rhythm and sleep pressure (or internal sleep drive) determines the 
sleep/wake status. OPHN1, a Rho GAP encoded by an ID associated gene OPHN1, has be 
reported to interact with Rev-erbα, a nuclear receptor that represses circadian oscillators in 
the hippocampus and this interaction is required for normal oscillation. Also, synaptic activity 
which requires OPHN1 leads to relocation of Rev-erbα into dendritic spines 51. These 
discoveries suggest that a communication between biological clocks and neuronal activity 
which is mediated by Rho proteins exists to maintain both processes balanced. Interestingly, 
a recent study reported a gene encoding a Rho GAP, crossveinless-c (cv-c) governs internal 
sleep drive which is independent on circadian rhythms in Drosophila 52. Cv-c mutants fail to 
show homeostatic rebound sleep upon sleep deprivation and exhibit impaired memory. It 
would be interesting to identify whether the impairment of memory is directly caused by 
mutated Cv-v or just a secondary effect of lacking of sleep in general. Together, these 
discoveries imply that Rho GTPase signaling pathways may play pivotal roles in generating 
and maintaining normal sleep. Future experiments will identify novel Rho proteins that are 
involved in regulating sleep as well as neuronal circuitries responsible for sleep regulation, 
which would help us to comprehend the occurring of sleep disturbances in 
neurodevelopmental disorders. 
 
 
Conclusion  
Overall, the research reported in the thesis revealed novel functions of several previously 
uncharacterized Rho GTPase regulators and provides mechanistic insight into how the normal 
brain regulates cognition and how neurodevelopmental disorders may occur. In addition to 
the continuous investigation of unraveling the neuronal function of individual GEFs and GAPs, 
future experiments might also aim for generating an expression profile of Rho regulators at 
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the single cell, perhaps even at single synapse level. Indeed, novel imaging techniques 
combined with reporter molecules allow to investigate Rho GTPase signaling at single synapse 
level. 53 Different cell types in different brain regions may possess their unique identities as 
reflected by distinct compositions of GEFs and GAPs, which might ultimately determine their 
responses and contributions in cognitive processes.   
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Summary 
The aim of this thesis was to provide mechanistic insights into how the brain regulates 
learning and memory in both health and disease. Specifically, I revealed the neuronal function 
of several novel genes involved in Rho GTPase signaling, most of which are found mutated in 
ID patients, at the synaptic level. 
 Chapter 2 of this thesis presented the spatiotemporal transcriptional pattern of 22 genes 
encoding Rho GTPases and their regulators during development. Based on the output of this 
study, following in-depth investigations on three important Rho regulators were performed. 
Chapter 3 described the novel synaptic function of a previously unstudied RhoGAP, 
ARHGAP12. I show that ARHGAP12 is almost exclusively expressed in the CA1 subregion of 
the hippocampus, a well-studied brain region responsible for spatial learning and navigation. 
I demonstrate that ARHGAP12 functions as a “structural-functional” coordinator at CA3-CA1 
excitatory synapses during development. Specifically, ARHGAP12 negatively controls spine 
size via its RhoGAP activity and promotes, by interacting with CIP4, postsynaptic AMPAr 
endocytosis. Knocking down Arhgap12 leads to precocious maturation of excitatory synapses, 
as indicated by a reduction in the proportion of silent synapses. In Chapter 4, we identified 
TRIO, a gene encoding a RhoGEF, as a responsible gene for mild to borderline ID. TRIO is 
abundantly expressed during early hippocampal development. Physiologically, TRIO 
suppresses dendritic formation without affecting the establishment of axon polarity. 
Consistently, depleting endogenous TRIO significantly enhances synaptic strength of 
hippocampal CA3-CA1 synapses. In Chapter 5, I described the functional characterizations of 
Ocrl1, a gene associated with Lowe Syndrome and type 2 Dent Disease. I show that OCRL1 
bidirectionally controls dendritic spine density, miniature excitatory synaptic transmission 
and LTP. In addition, OCRL1 is involved in the regulation of AMPAr endocytosis and the 
homeostasis of cellular AMPAr abundance in primary hippocampal neurons. Chapter 6 
described that identification of mutations in KIF4A and KIF5C in patients with ID. Functional 
analysis reveals emerging roles of KIF4A and KIF5C in maintaining the balance between 
excitation and inhibition.  
In conclusion, the research presented in this thesis highlights the importance of Rho 
GTPase signaling in maintaining normal development and cognition. 
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Samenvatting 
Het doel van deze thesis was om inzicht te verschaffen in de mechanismen waarmee het brein 
leren en geheugen reguleert in zowel het gezonde als het zieke brein. Ik beschrijf de 
neuronale functies van meerdere nieuw-geïdentificeerde genen die betrokken zijn bij Rho 
GTPase signalering, op het niveau van de synaps. Voor de meeste van deze genen zijn 
mutaties beschreven in patiënten met verstandelijke beperkingen. 
Hoofdstuk 2 van deze thesis beschrijft het spatio-temporele patroon tijdens de 
ontwikkeling van het brein van de transcriptie van 22 kandidaat-genen die coderen voor Rho 
GTPases en hun regulatoren. Gebaseerd op de resultaten van deze studie zijn diepgaande 
vervolgstudies uitgevoerd voor drie belangrijke Rho-regulatoren. Hoofdstuk 3 beschrijft de 
synaptische functie van een tot nu toe onbekende RhoGAP, ARHGAP12. Ik toon aan dat 
ARHGAP12 vrijwel enkel tot expressie komt in het CA1 sub-gebied van de hippocampus, een 
goed bestudeerde hersengebied met een belangrijke functie in ruimtelijk leren en navigatie. 
Ik heb aangetoond dat ARHGAP12 functioneert als een “functie/structuur” coördinator in de 
CA3-CA1 synaps tijdens de ontwikkeling van het brein. Meer specifiek, via het RhoGAP domein 
reguleert ARHGAP12 de grootte van dendritische spines negatief, en stimuleert het 
postsynaptische AMPAr endocytose via interactie met CIP4. Knock-down van Arhgap12 leidt 
tot premature maturatie van excitatoire synapsen, zoals is af te leiden van de afname van het 
aandeel van niet actieve synapsen. In hoofdstuk 4 identificeren we TRIO, een gen dat codeert 
voor een RhoGEF, als een gen dat verantwoordelijk is voor lichte tot milde verstandelijke 
beperking. TRIO komt hoog tot expressie tijdens de vroege ontwikkeling van de hippocampus. 
TRIO onderdrukt de formatie van dendrieten, maar heeft geen effect op de vorming van de 
polariteit van het axon. Als gevolg hiervan versterkt depletie van TRIO CA3-CA1 synapsen in 
de hippocampus. In hoofdstuk 5 beschrijf ik de functionele rol van OCRL1, een gen dat 
verband houdt met Lowe Syndroom. Ik toon aan dat OCRL1 spine dichtheid, excitatoire 
synaptische transmissie en plasticiteit bidirectioneel reguleert. Daarnaast is OCRL1 betrokken 
bij de regulatie van AMPAr endocytose en de homeostase van de hoeveelheid cellulaire 
AMPAren in primaire hippocampale culturen. Hoofdstuk 6 beschrijft de identificatie van 
mutaties in KIF4A en KIF5C in patienten met verstandelijke beperkingen. Functionele analyse 
toont de rol van KIF4A en KIF5C in het behouden van de balans tussen excitatie en inhibitie 
aan. 
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Het bovenstaande onderzoek benadrukt het belang van Rho GTPase signalering voor 
normale hersenontwikkeling en cognitie. 
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